Datasets:
ChatDOC
/
OCRFlux-pubtabnet-cross

Dataset card Data Studio Files Community
1
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
table_fragment_1
stringlengths
43
8.42k
table_fragment_2
stringlengths
39
8.21k
4bbe442954ab7528ec14558ce4cce88c936bf64d593478e140df4af314982427.png
simple
<table><tr><td>Amino Acid</td><td>mg/g Crude Protein</td><td>FAO Report mg/g Protein <sup>a</sup></td><td>AAS</td></tr><tr><td>histidine</td><td>38.6 &#177; 2.3</td><td>16</td><td>2.41</td></tr><tr><td>isoleucine</td><td>54.5 &#177; 0.0</td><td>30</td><td>1.82</td></tr><tr><td>leucine</td><td>102.1 &#177; 0.1</td><td>61</td><td>1.67</td></tr><tr><td>lysine</td><td>80.2 &#177; 5.2</td><td>48</td><td>1.67</td></tr><tr><td>threonine</td><td>44.3 &#177; 3.2</td><td>25</td><td>1.77</td></tr><tr><td>tryptophan</td><td>6.0 &#177; 0.0</td><td>6.6</td><td>0.91</td></tr><tr><td>valine</td><td>62.4 &#177; 2.3</td><td>40</td><td>1.56</td></tr><tr><td>methionine</td><td>6.4 &#177; 0.1</td><td>-</td><td>-</td></tr><tr><td>cysteine</td><td>24.1 &#177; 0.0</td><td>-</td><td>-</td></tr><tr><td>SAA</td><td>30.5</td><td>23</td><td>1.33</td></tr><tr><td>tyrosine</td><td>31.3 &#177; 1.3</td><td>-</td><td>-</td></tr><tr><td>phenylalanine</td><td>76.9 &#177; 2.0</td><td>-</td><td>-</td></tr><tr><td>AAA</td><td>108.2</td><td>41</td><td>1.88</td></tr><tr><td>aspartic acid</td><td>146.1 &#177; 5.1</td><td>-</td><td>-</td></tr><tr><td>serine</td><td>68.5 &#177; 3.5</td><td>-</td><td>-</td></tr><tr><td>glutamic acid</td><td>209.5 &#177; 4.3</td><td>-</td><td>-</td></tr><tr><td>proline</td><td>53.6 &#177; 1.7</td><td>-</td><td>-</td></tr><tr><td>glycine</td><td>46.5 &#177; 3.4</td><td>-</td><td>-</td></tr><tr><td>alanine</td><td>51.4 &#177; 1.4</td><td>-</td><td>-</td></tr><tr><td>arginine</td><td>74.8 &#177; 6.0</td><td>-</td><td>-</td></tr><tr><td>AAS</td><td>0.91</td><td>-</td><td>-</td></tr><tr><td>Limiting amino acid</td><td>tryptophan</td><td>-</td><td>-</td></tr></table>
<table><tr><td>Amino Acid</td><td>mg/g Crude Protein</td></tr><tr><td>histidine</td><td>38.6 ± 2.3</td></tr><tr><td>isoleucine</td><td>54.5 ± 0.0</td></tr><tr><td>leucine</td><td>102.1 ± 0.1</td></tr><tr><td>lysine</td><td>80.2 ± 5.2</td></tr><tr><td>threonine</td><td>44.3 ± 3.2</td></tr><tr><td>tryptophan</td><td>6.0 ± 0.0</td></tr><tr><td>valine</td><td>62.4 ± 2.3</td></tr><tr><td>methionine</td><td>6.4 ± 0.1</td></tr><tr><td>cysteine</td><td>24.1 ± 0.0</td></tr><tr><td>SAA</td><td>30.5</td></tr><tr><td>tyrosine</td><td>31.3 ± 1.3</td></tr><tr><td>phenylalanine</td><td>76.9 ± 2.0</td></tr><tr><td>AAA</td><td>108.2</td></tr><tr><td>aspartic acid</td><td>146.1 ± 5.1</td></tr><tr><td>serine</td><td>68.5 ± 3.5</td></tr><tr><td>glutamic acid</td><td>209.5 ± 4.3</td></tr><tr><td>proline</td><td>53.6 ± 1.7</td></tr><tr><td>glycine</td><td>46.5 ± 3.4</td></tr><tr><td>alanine</td><td>51.4 ± 1.4</td></tr><tr><td>arginine</td><td>74.8 ± 6.0</td></tr><tr><td>AAS</td><td>0.91</td></tr><tr><td>Limiting amino acid</td><td>tryptophan</td></tr></table>
<table><tr><td>FAO Report mg/g Protein a</td><td>AAS</td></tr><tr><td>16</td><td>2.41</td></tr><tr><td>30</td><td>1.82</td></tr><tr><td>61</td><td>1.67</td></tr><tr><td>48</td><td>1.67</td></tr><tr><td>25</td><td>1.77</td></tr><tr><td>6.6</td><td>0.91</td></tr><tr><td>40</td><td>1.56</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>23</td><td>1.33</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>41</td><td>1.88</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr><tr><td>-</td><td>-</td></tr></table>
d39466004cbf68fad9f51f7f9c56163f0ba8fdbcd6ba9ae578e74c97d1366fd9.png
simple
<table><tr><td>Name</td><td>Company</td><td>Catalog number</td><td>Antibody concentration</td></tr><tr><td>DAB2IP</td><td>Abcam</td><td>ab87811</td><td>1 : 1000 or 1 : 200</td></tr><tr><td>E-cadherin</td><td>Cell Signaling Technology</td><td>3195</td><td>1 : 500</td></tr><tr><td>Vimentin</td><td>Cell Signaling Technology</td><td>5741</td><td>1 : 500</td></tr><tr><td>p-ERK1/2</td><td>Cell Signaling Technology</td><td>4370</td><td>1 : 1000</td></tr><tr><td>ERK1/2</td><td>Cell Signaling Technology</td><td>4695</td><td>1 : 1000</td></tr><tr><td>GAPDH</td><td>Beyotime</td><td>AG019</td><td>1 : 2000</td></tr><tr><td><i>&#945;</i>-tubulin</td><td>Sigma-Aldrich</td><td>T6199</td><td>1 : 2000</td></tr></table>
<table><tr><td>Name</td></tr><tr><td>DAB2IP</td></tr><tr><td>E-cadherin</td></tr><tr><td>Vimentin</td></tr><tr><td>p-ERK1/2</td></tr><tr><td>ERK1/2</td></tr><tr><td>GAPDH</td></tr><tr><td>α-tubulin</td></tr></table>
<table><tr><td>Company</td><td>Catalog number</td><td>Antibody concentration</td></tr><tr><td>Abcam</td><td>ab87811</td><td>1 : 1000 or 1 : 200</td></tr><tr><td>Cell Signaling Technology</td><td>3195</td><td>1 : 500</td></tr><tr><td>Cell Signaling Technology</td><td>5741</td><td>1 : 500</td></tr><tr><td>Cell Signaling Technology</td><td>4370</td><td>1 : 1000</td></tr><tr><td>Cell Signaling Technology</td><td>4695</td><td>1 : 1000</td></tr><tr><td>Beyotime</td><td>AG019</td><td>1 : 2000</td></tr><tr><td>Sigma-Aldrich</td><td>T6199</td><td>1 : 2000</td></tr></table>
2d9f6a615a3891c84134293f3cd9bd08be23abf8cd2fb1d13926374221b22c8d.png
complex
<table><tr><td rowspan="2">Intentions *</td><td colspan="5">Male (<i>n</i>)</td><td colspan="6">Female (<i>n</i>)</td></tr><tr><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td><i>p</i></td></tr><tr><td>After the delivery, I would not try to establish breastfeeding. I would bottle-feed my child with formula milk.</td><td>0</td><td>1</td><td>4</td><td>13</td><td>25</td><td>0</td><td>3</td><td>5</td><td>18</td><td>85</td><td>/</td></tr><tr><td>I would breastfeed my child even if the child&#8217;s father does not support my decision to breastfeed.</td><td>17</td><td>19</td><td>5</td><td>1</td><td>1</td><td>67</td><td>26</td><td>10</td><td>6</td><td>2</td><td>/</td></tr><tr><td>I would not breastfeed in public, for example in a restaurant or in a park.</td><td>9</td><td>11</td><td>9</td><td>8</td><td>6</td><td>27</td><td>26</td><td>29</td><td>19</td><td>10</td><td>/</td></tr><tr><td>A child&#8217;s mother and father should make a joint decision about breastfeeding.</td><td>17</td><td>15</td><td>7</td><td>3</td><td>1</td><td>11</td><td>30</td><td>33</td><td>20</td><td>17</td><td>0.000</td></tr><tr><td>Returning to work would not make me stop breastfeeding.</td><td>9</td><td>9</td><td>23</td><td>1</td><td>1</td><td>40</td><td>38</td><td>25</td><td>5</td><td>3</td><td>0.002</td></tr><tr><td>I find it acceptable to breastfeed after a child turns one if a child so desires.</td><td>9</td><td>11</td><td>11</td><td>9</td><td>3</td><td>17</td><td>30</td><td>27</td><td>24</td><td>13</td><td>/</td></tr><tr><td>I would breastfeed my child in accordance with doctors&#8217; recommendations, regardless of close family members&#8217; opinions.</td><td>19</td><td>18</td><td>5</td><td>0</td><td>1</td><td>38</td><td>42</td><td>21</td><td>8</td><td>2</td><td>/</td></tr><tr><td>I would not breastfeed my child after he/she turns two.</td><td>12</td><td>13</td><td>13</td><td>2</td><td>3</td><td>44</td><td>30</td><td>27</td><td>6</td><td>4</td><td>/</td></tr></table>
<table><tr><td rowspan="2">Intentions *</td><td colspan="5">Male (n)</td><td colspan="6">Female (n)</td></tr><tr><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>p</td></tr><tr><td>After the delivery, I would not try to establish breastfeeding. I would bottle-feed my child with formula milk.</td><td>0</td><td>1</td><td>4</td><td>13</td><td>25</td><td>0</td><td>3</td><td>5</td><td>18</td><td>85</td><td>/</td></tr><tr><td>I would breastfeed my child even if the child’s father does not support my decision to breastfeed.</td><td>17</td><td>19</td><td>5</td><td>1</td><td>1</td><td>67</td><td>26</td><td>10</td><td>6</td><td>2</td><td>/</td></tr><tr><td>I would not breastfeed in public, for example in a restaurant or in a park.</td><td>9</td><td>11</td><td>9</td><td>8</td><td>6</td><td>27</td><td>26</td><td>29</td><td>19</td><td>10</td><td>/</td></tr><tr><td>A child’s mother and father should make a joint decision about breastfeeding.</td><td>17</td><td>15</td><td>7</td><td>3</td><td>1</td><td>11</td><td>30</td><td>33</td><td>20</td><td>17</td><td>0.000</td></tr><tr><td>Returning to work would not make me stop breastfeeding.</td><td>9</td><td>9</td><td>23</td><td>1</td><td>1</td><td>40</td><td>38</td><td>25</td><td>5</td><td>3</td><td>0.002</td></tr><tr><td>I find it acceptable to breastfeed after a child turns one if a child so desires.</td><td>9</td><td>11</td><td>11</td><td>9</td><td>3</td><td>17</td><td>30</td><td>27</td><td>24</td><td>13</td><td>/</td></tr></table>
<table><tr><td rowspan="2">Intentions *</td><td colspan="5">Male (n)</td><td colspan="6">Female (n)</td></tr><tr><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>p</td></tr><tr><td>I would breastfeed my child in accordance with doctors’ recommendations, regardless of close family members’ opinions.</td><td>19</td><td>18</td><td>5</td><td>0</td><td>1</td><td>38</td><td>42</td><td>21</td><td>8</td><td>2</td><td>/</td></tr><tr><td>I would not breastfeed my child after he/she turns two.</td><td>12</td><td>13</td><td>13</td><td>2</td><td>3</td><td>44</td><td>30</td><td>27</td><td>6</td><td>4</td><td>/</td></tr></table>
8c23bcdced3b9cd33018063ec840857cd2c629205b4a9ae5f3fe41856c29b144.png
simple
<table><tr><td></td><td>Estimate</td><td>Standard Error</td><td>Chi-Square (df = 1) or t-value</td><td>Odds Ratio</td><td>95% Confidence Interval</td><td>p-value</td></tr><tr><td>W1 drinking predicting stroke</td><td>-0.31</td><td>0.10</td><td>10.8</td><td>0.73</td><td>0.61&#8211;0.88</td><td>0.001</td></tr><tr><td>W1 drinking predicting heart disease</td><td>-0.2</td><td>0.08</td><td>5.8</td><td>0.82</td><td>0.69&#8211;0.96</td><td>0.02</td></tr><tr><td>W1 drinking predicting diabetes</td><td>-0.30</td><td>0.13</td><td>5.4</td><td>0.74</td><td>0.57&#8211;0.95</td><td>0.02</td></tr><tr><td>W1 drinking predicting falls</td><td>-0.09</td><td>0.06</td><td>2.5</td><td>0.91</td><td>0.81&#8211;1.02</td><td>0.12</td></tr><tr><td>W1 drinking predicting hip fracture</td><td>-0.42</td><td>0.17</td><td>5.8</td><td>0.66</td><td>0.47&#8211;0.92</td><td>0.02</td></tr><tr><td>W1 Drinking predicting % any ADL</td><td>-0.22</td><td>0.05</td><td>19.9</td><td>0.80</td><td>0.73&#8211;0.88</td><td>0.0001</td></tr><tr><td>W1 Drinking predicting % any IADL</td><td>-0.18</td><td>0.04</td><td>17.3</td><td>0.83</td><td>0.77&#8211;0.91</td><td>0.0001</td></tr><tr><td>W1 drinking predicting total # Chronic Illnesses</td><td>-0.03</td><td>0.01</td><td>-2.6</td><td>---</td><td>---</td><td>0.01</td></tr><tr><td>W1 drinking predicting CES-D</td><td>-0.1</td><td>0.03</td><td>-3.0</td><td>---</td><td>---</td><td>0.01</td></tr><tr><td>W1 drinking predicting TICS-R</td><td>0.17</td><td>0.08</td><td>2.14</td><td>---</td><td>---</td><td>0.03</td></tr></table>
<table><tr><td></td><td>Estimate</td><td>Standard Error</td><td>Chi-Square (df = 1) or t-value</td><td>Odds Ratio</td><td>95% Confidence Interval</td><td>p-value</td></tr><tr><td>W1 drinking predicting stroke</td><td>-0.31</td><td>0.10</td><td>10.8</td><td>0.73</td><td>0.61–0.88</td><td>0.001</td></tr><tr><td>W1 drinking predicting heart disease</td><td>-0.2</td><td>0.08</td><td>5.8</td><td>0.82</td><td>0.69–0.96</td><td>0.02</td></tr></table>
<table><tr><td>W1 drinking predicting diabetes</td><td>-0.30</td><td>0.13</td><td>5.4</td><td>0.74</td><td>0.57–0.95</td><td>0.02</td></tr><tr><td>W1 drinking predicting falls</td><td>-0.09</td><td>0.06</td><td>2.5</td><td>0.91</td><td>0.81–1.02</td><td>0.12</td></tr><tr><td>W1 drinking predicting hip fracture</td><td>-0.42</td><td>0.17</td><td>5.8</td><td>0.66</td><td>0.47–0.92</td><td>0.02</td></tr><tr><td>W1 Drinking predicting % any ADL</td><td>-0.22</td><td>0.05</td><td>19.9</td><td>0.80</td><td>0.73–0.88</td><td>0.0001</td></tr><tr><td>W1 Drinking predicting % any IADL</td><td>-0.18</td><td>0.04</td><td>17.3</td><td>0.83</td><td>0.77–0.91</td><td>0.0001</td></tr><tr><td>W1 drinking predicting total # Chronic Illnesses</td><td>-0.03</td><td>0.01</td><td>-2.6</td><td>---</td><td>---</td><td>0.01</td></tr><tr><td>W1 drinking predicting CES-D</td><td>-0.1</td><td>0.03</td><td>-3.0</td><td>---</td><td>---</td><td>0.01</td></tr><tr><td>W1 drinking predicting TICS-R</td><td>0.17</td><td>0.08</td><td>2.14</td><td>---</td><td>---</td><td>0.03</td></tr></table>
1460ce6985beef2d512ce7a02207eab4ea5d969effb6920e73cc4d09e91b2a85.png
complex
<table><tr><td colspan="4">WNV-L vs. E</td><td colspan="4">CHIKV-L vs. E</td></tr><tr><td>Symbol</td><td>Entrez gene name</td><td>Log<sub>2</sub> fold change</td><td><i>P</i>-value</td><td>Symbol</td><td>Entrez gene name</td><td>Log<sub>2</sub> fold change</td><td><i>P</i>-value</td></tr><tr><td>Lcn2</td><td>Lipocalin 2</td><td>4.87</td><td>6.81E-10</td><td>Cxcl10</td><td>Chemokine (C-X-C motif) ligand 10</td><td>5.09</td><td>4.38E-13</td></tr><tr><td>Cxcl9</td><td>Chemokine (C-X-C motif) ligand 9</td><td>4.80</td><td>4.46E-11</td><td>Lcn2</td><td>Lipocalin 2</td><td>4.73</td><td>4.48E-09</td></tr><tr><td>Ubd</td><td>Ubiquitin D</td><td>4.76</td><td>2.59E-17</td><td>Ccl5</td><td>C-C motif chemokine ligand 5</td><td>4.19</td><td>4.22E-10</td></tr><tr><td>Tnfaip2</td><td>TNF alpha induced protein 2</td><td>4.71</td><td>4.00E-13</td><td>Ifi204</td><td>Interferon activated gene 204</td><td>4.18</td><td>5.19E-11</td></tr><tr><td>Ccl5</td><td>C-C motif chemokine ligand 5</td><td>4.43</td><td>3.01E-11</td><td>Gbp2</td><td>Guanylate binding protein 2</td><td>4.13</td><td>1.34E-13</td></tr><tr><td>Gzmb</td><td>Granzyme B</td><td>4.39</td><td>4.20E-15</td><td>Lilrb4</td><td>Leukocyte immunoglobulin like receptor 4</td><td>4.12</td><td>5.84E-11</td></tr><tr><td>Slfn12l</td><td>Schlafen family member 12 like</td><td>4.07</td><td>1.39E-08</td><td>Acod1</td><td>Aconitate decarboxylase 1</td><td>4.08</td><td>6.77E-12</td></tr><tr><td>Ifnb1</td><td>Interferon beta 1</td><td>3.89</td><td>9.13E-16</td><td>Cxcl9</td><td>Chemokine (C-X-C motif) ligand 9</td><td>4.02</td><td>6.94E-09</td></tr><tr><td>Ccl13</td><td>C-C motif chemokine ligand 13</td><td>3.89</td><td>1.92E-13</td><td>Ms4a4b</td><td>Membrane-spanning 4-domains, subfamily A, member 4B</td><td>3.99</td><td>3.74E-08</td></tr><tr><td>Lilrb4</td><td>Leukocyte immunoglobulin like receptor B4</td><td>3.89</td><td>6.82E-11</td><td>Tnfaip2</td><td>TNF alpha induced protein 2</td><td>3.89</td><td>1.48E-10</td></tr></table>
<table><tr><td colspan="4">WNV-L vs. E</td><td colspan="2">CHIKV-L vs. E</td></tr><tr><td>Symbol</td><td>Entrez gene name</td><td>Log2 fold change</td><td>P-value</td><td>Symbol</td><td>Entrez gene name</td></tr><tr><td>Lcn2</td><td>Lipocalin 2</td><td>4.87</td><td>6.81E-10</td><td>Cxcl10</td><td>Chemokine (C-X-C motif) ligand 10</td></tr><tr><td>Cxcl9</td><td>Chemokine (C-X-C motif) ligand 9</td><td>4.80</td><td>4.46E-11</td><td>Lcn2</td><td>Lipocalin 2</td></tr><tr><td>Ubd</td><td>Ubiquitin D</td><td>4.76</td><td>2.59E-17</td><td>Ccl5</td><td>C-C motif chemokine ligand 5</td></tr><tr><td>Tnfaip2</td><td>TNF alpha induced protein 2</td><td>4.71</td><td>4.00E-13</td><td>Ifi204</td><td>Interferon activated gene 204</td></tr><tr><td>Ccl5</td><td>C-C motif chemokine ligand 5</td><td>4.43</td><td>3.01E-11</td><td>Gbp2</td><td>Guanylate binding protein 2</td></tr><tr><td>Gzmb</td><td>Granzyme B</td><td>4.39</td><td>4.20E-15</td><td>Lilrb4</td><td>Leukocyte immunoglobulin like receptor 4</td></tr><tr><td>Slfn12l</td><td>Schlafen family member 12 like</td><td>4.07</td><td>1.39E-08</td><td>Acod1</td><td>Aconitate decarboxylase 1</td></tr><tr><td>Ifnb1</td><td>Interferon beta 1</td><td>3.89</td><td>9.13E-16</td><td>Cxcl9</td><td>Chemokine (C-X-C motif) ligand 9</td></tr><tr><td>Ccl13</td><td>C-C motif chemokine ligand 13</td><td>3.89</td><td>1.92E-13</td><td>Ms4a4b</td><td>Membrane-spanning 4-domains, subfamily A, member 4B</td></tr><tr><td>Lilrb4</td><td>Leukocyte immunoglobulin like receptor B4</td><td>3.89</td><td>6.82E-11</td><td>Tnfaip2</td><td>TNF alpha induced protein 2</td></tr></table>
<table><tr><td colspan="2">CHIKV-L vs. E</td></tr><tr><td>Log2 fold change</td><td>P-value</td></tr><tr><td>5.09</td><td>4.38E-13</td></tr><tr><td>4.73</td><td>4.48E-09</td></tr><tr><td>4.19</td><td>4.22E-10</td></tr><tr><td>4.18</td><td>5.19E-11</td></tr><tr><td>4.13</td><td>1.34E-13</td></tr><tr><td>4.12</td><td>5.84E-11</td></tr><tr><td>4.08</td><td>6.77E-12</td></tr><tr><td>4.02</td><td>6.94E-09</td></tr><tr><td>3.99</td><td>3.74E-08</td></tr><tr><td>3.89</td><td>1.48E-10</td></tr></table>
e8931ba2069a2e9c61ffe2a5bd335d08a0e50c4792904dec98cd8bdf41133020.png
complex
<table><tr><td></td><td colspan="10"><i>Pol</i> subtype</td></tr><tr><td><i>Env</i> subtype</td><td>A</td><td>B</td><td>C</td><td>D</td><td>F</td><td>G</td><td>H</td><td>01_AE</td><td>02_AG</td><td>UA</td></tr><tr><td>A-like</td><td>59</td><td></td><td></td><td>3</td><td>1</td><td>3</td><td></td><td>1</td><td>71</td><td>16</td></tr><tr><td>B</td><td>3</td><td>1</td><td></td><td></td><td></td><td>4</td><td></td><td></td><td>2</td><td>2</td></tr><tr><td>C</td><td>1</td><td></td><td>62</td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>D</td><td></td><td></td><td></td><td>5</td><td></td><td></td><td></td><td></td><td>1</td><td></td></tr><tr><td>F</td><td></td><td></td><td></td><td></td><td>6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>G</td><td>1</td><td></td><td></td><td></td><td></td><td>12</td><td></td><td></td><td>5</td><td>5</td></tr><tr><td>H</td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td></tr><tr><td>CRF01AE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>57</td><td></td><td></td></tr><tr><td>UA</td><td></td><td></td><td></td><td></td><td></td><td>2</td><td></td><td></td><td>2</td><td>8</td></tr></table>
<table><tr><td></td><td colspan="10">Pol subtype</td></tr><tr><td>Env subtype</td><td>A</td><td>B</td><td>C</td><td>D</td><td>F</td><td>G</td><td>H</td><td>01_AE</td><td>02_AG</td><td>UA</td></tr></table>
<table><tr><td>A-like</td><td>59</td><td></td><td></td><td>3</td><td>1</td><td>3</td><td></td><td>1</td><td>71</td><td>16</td></tr><tr><td>B</td><td>3</td><td>1</td><td></td><td></td><td></td><td>4</td><td></td><td></td><td>2</td><td>2</td></tr><tr><td>C</td><td>1</td><td></td><td>62</td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td>D</td><td></td><td></td><td></td><td>5</td><td></td><td></td><td></td><td></td><td>1</td><td></td></tr><tr><td>F</td><td></td><td></td><td></td><td></td><td>6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>G</td><td>1</td><td></td><td></td><td></td><td></td><td>12</td><td></td><td></td><td>5</td><td>5</td></tr><tr><td>H</td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td></td><td></td><td></td></tr><tr><td>CRF01AE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>57</td><td></td><td></td></tr><tr><td>UA</td><td></td><td></td><td></td><td></td><td></td><td>2</td><td></td><td></td><td>2</td><td>8</td></tr></table>
5535753c8bc884bdd0efc400bc2badc105fd444c3f2d715fb6b6f69af12b8ef2.png
simple
<table><tr><td></td><td>Range</td><td>Mean (SD)</td></tr><tr><td>Temperature, centigrade</td><td>36&#8211;38</td><td>37 &#177; 0.5</td></tr><tr><td>Systolic blood pressure, mmHg</td><td>100&#8211;190</td><td>140 &#177; 24</td></tr><tr><td>Diastolic blood pressure, mmHg</td><td>60&#8211;140</td><td>86 &#177; 22</td></tr><tr><td>Heart rate</td><td>66&#8211;100</td><td>84 &#177; 11</td></tr><tr><td>Respiratory rate</td><td>14&#8211;26</td><td>18 &#177; 3</td></tr></table>
<table><tr><td></td><td>Range</td><td>Mean (SD)</td></tr><tr><td>Temperature, centigrade</td><td>36–38</td><td>37 ± 0.5</td></tr><tr><td>Systolic blood pressure, mmHg</td><td>100–190</td><td>140 ± 24</td></tr><tr><td>Diastolic blood pressure, mmHg</td><td>60–140</td><td>86 ± 22</td></tr></table>
<table><tr><td>Heart rate</td><td>66–100</td><td>84 ± 11</td></tr><tr><td>Respiratory rate</td><td>14–26</td><td>18 ± 3</td></tr></table>
6435b7e0a3f2a0e5ac455ce8459047c8fe760d2696e67b5cfe1d0c6a17e846c8.png
complex
<table><tr><td colspan="3"><i>FRR</i> (%)</td></tr><tr><td>User</td><td>EEG</td><td>Multi-Task</td></tr><tr><td>1</td><td>6.00</td><td>2.00</td></tr><tr><td>2</td><td>0.00</td><td>0.00</td></tr><tr><td>3</td><td>2.00</td><td>0.00</td></tr><tr><td>4</td><td>12.00</td><td>16.00</td></tr><tr><td>5</td><td>16.00</td><td>8.00</td></tr><tr><td>6</td><td>2.00</td><td>6.00</td></tr><tr><td>7</td><td>10.00</td><td>6.00</td></tr><tr><td>8</td><td>14.00</td><td>0.00</td></tr><tr><td>9</td><td>8.00</td><td>6.00</td></tr><tr><td>10</td><td>4.00</td><td>4.00</td></tr><tr><td>11</td><td>2.00</td><td>2.00</td></tr><tr><td>12</td><td>2.00</td><td>4.00</td></tr><tr><td>13</td><td>10.00</td><td>2.00</td></tr><tr><td>14</td><td>10.00</td><td>0.00</td></tr><tr><td>15</td><td>8.00</td><td>2.00</td></tr><tr><td>Mean (std)</td><td>7.07 (4.95)</td><td>3.87 (4.24)</td></tr></table>
<table><tr><td colspan="3">FRR (%)</td></tr><tr><td>User</td><td>EEG</td><td>Multi-Task</td></tr><tr><td>1</td><td>6.00</td><td>2.00</td></tr><tr><td>2</td><td>0.00</td><td>0.00</td></tr><tr><td>3</td><td>2.00</td><td>0.00</td></tr><tr><td>4</td><td>12.00</td><td>16.00</td></tr><tr><td>5</td><td>16.00</td><td>8.00</td></tr></table>
<table><tr><td colspan="3">FRR (%)</td></tr><tr><td>User</td><td>EEG</td><td>Multi-Task</td></tr><tr><td>6</td><td>2.00</td><td>6.00</td></tr><tr><td>7</td><td>10.00</td><td>6.00</td></tr><tr><td>8</td><td>14.00</td><td>0.00</td></tr><tr><td>9</td><td>8.00</td><td>6.00</td></tr><tr><td>10</td><td>4.00</td><td>4.00</td></tr><tr><td>11</td><td>2.00</td><td>2.00</td></tr><tr><td>12</td><td>2.00</td><td>4.00</td></tr><tr><td>13</td><td>10.00</td><td>2.00</td></tr><tr><td>14</td><td>10.00</td><td>0.00</td></tr><tr><td>15</td><td>8.00</td><td>2.00</td></tr><tr><td>Mean (std)</td><td>7.07 (4.95)</td><td>3.87 (4.24)</td></tr></table>
066a25e7107fba79e621716a8dc8d073bb5408bda2874828f40d48de53316ffa.png
complex
<table><tr><td rowspan="3">Variables</td><td colspan="5">HOMA-IR quartiles</td></tr><tr><td>Q1</td><td>Q2</td><td>Q3</td><td>Q4</td><td><i>p</i> for linear</td></tr><tr><td>(&lt;1.13)</td><td>(1.13&#8211;1.65)</td><td>(1.65&#8211;2.65)</td><td>(&gt;2.65)</td><td>trend</td></tr><tr><td><i>Age (years)</i></td><td>10.3 &#177; 1.9</td><td>10.3 &#177; 1.8</td><td>10.8 &#177; 1.6</td><td>11.4 &#177; 1.3</td><td>&lt;0.001</td></tr><tr><td><i>Body composition</i></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> BMI (kg/m<sup>2</sup>)</td><td>17.3 &#177; 2.6</td><td>18.4 &#177; 2.8</td><td>19.6 &#177; 3.2</td><td>21.4 &#177; 3.6</td><td>&lt;0.001</td></tr><tr><td> Body fat (%)</td><td>7.9 &#177; 6.5</td><td>8.6 &#177; 6.4</td><td>10.1 &#177; 6.4</td><td>16.5 &#177; 8.2</td><td>&lt;0.001</td></tr><tr><td> WC (cm)</td><td>62.5 &#177; 10.2</td><td>64.9 &#177; 10.3</td><td>69.2 &#177; 10.6</td><td>74.5 &#177; 10.1</td><td>&lt;0.001</td></tr><tr><td><i>Blood pressure</i></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> SBP (mmHg)</td><td>104.2 &#177; 14.8</td><td>106.1 &#177; 13.0</td><td>107.4 &#177; 13.7</td><td>110.8 &#177; 15.2</td><td>&lt;0.001</td></tr><tr><td> DBP (mmHg)</td><td>63.8 &#177; 11.0</td><td>64.1 &#177; 8.8</td><td>65.1 &#177; 8.9</td><td>66.7 &#177; 11.8</td><td>&lt;0.001</td></tr><tr><td><i>Metabolic profiles</i></td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> TG (mg/dL)</td><td>70.0 &#177; 29.9</td><td>77.9 &#177; 41.1</td><td>95.5 &#177; 50.1</td><td>110.8 &#177; 55.2</td><td>&lt;0.001</td></tr><tr><td> TC (mg/dL)</td><td>169.3 &#177; 29.5</td><td>171.3 &#177; 29.5</td><td>173.3 &#177; 27.8</td><td>182.7 &#177; 39.1</td><td>&lt;0.001</td></tr><tr><td> HDL-C (mg/dL)</td><td>61.3 &#177; 13.5</td><td>58.7 &#177; 12.6</td><td>53.8 &#177; 12.8</td><td>50.3 &#177; 11.9</td><td>&lt;0.001</td></tr><tr><td> Glucose (mg/dL)</td><td>86.2 &#177; 8.2</td><td>90.9 &#177; 8.6</td><td>91.6 &#177; 8.1</td><td>95.5 &#177; 10.7</td><td>&lt;0.001</td></tr><tr><td> Insulin (<i>&#956;</i>U/mL)</td><td>3.8 &#177; 1.1</td><td>6.2 &#177; 0.9</td><td>9.3 &#177; 1.5</td><td>17.0 &#177; 6.3</td><td>&lt;0.001</td></tr></table>
<table><tr><td rowspan="3">Variables</td><td>HOMA-IR quartiles</td></tr><tr><td>Q1</td></tr><tr><td>(<1.13)</td></tr><tr><td>Age (years)</td><td>10.3 ± 1.9</td></tr><tr><td>Body composition</td><td></td></tr><tr><td>BMI (kg/m2)</td><td>17.3 ± 2.6</td></tr><tr><td>Body fat (%)</td><td>7.9 ± 6.5</td></tr><tr><td>WC (cm)</td><td>62.5 ± 10.2</td></tr><tr><td>Blood pressure</td><td></td></tr><tr><td>SBP (mmHg)</td><td>104.2 ± 14.8</td></tr><tr><td>DBP (mmHg)</td><td>63.8 ± 11.0</td></tr><tr><td>Metabolic profiles</td><td></td></tr><tr><td>TG (mg/dL)</td><td>70.0 ± 29.9</td></tr><tr><td>TC (mg/dL)</td><td>169.3 ± 29.5</td></tr><tr><td>HDL-C (mg/dL)</td><td>61.3 ± 13.5</td></tr><tr><td>Glucose (mg/dL)</td><td>86.2 ± 8.2</td></tr><tr><td>Insulin (μU/mL)</td><td>3.8 ± 1.1</td></tr></table>
<table><tr><td colspan="4">HOMA-IR quartiles</td></tr><tr><td>Q2</td><td>Q3</td><td>Q4</td><td>p for linear</td></tr><tr><td>(1.13–1.65)</td><td>(1.65–2.65)</td><td>(>2.65)</td><td>trend</td></tr><tr><td>10.3 ± 1.8</td><td>10.8 ± 1.6</td><td>11.4 ± 1.3</td><td><0.001</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>18.4 ± 2.8</td><td>19.6 ± 3.2</td><td>21.4 ± 3.6</td><td><0.001</td></tr><tr><td>8.6 ± 6.4</td><td>10.1 ± 6.4</td><td>16.5 ± 8.2</td><td><0.001</td></tr><tr><td>64.9 ± 10.3</td><td>69.2 ± 10.6</td><td>74.5 ± 10.1</td><td><0.001</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>106.1 ± 13.0</td><td>107.4 ± 13.7</td><td>110.8 ± 15.2</td><td><0.001</td></tr><tr><td>64.1 ± 8.8</td><td>65.1 ± 8.9</td><td>66.7 ± 11.8</td><td><0.001</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>77.9 ± 41.1</td><td>95.5 ± 50.1</td><td>110.8 ± 55.2</td><td><0.001</td></tr><tr><td>171.3 ± 29.5</td><td>173.3 ± 27.8</td><td>182.7 ± 39.1</td><td><0.001</td></tr><tr><td>58.7 ± 12.6</td><td>53.8 ± 12.8</td><td>50.3 ± 11.9</td><td><0.001</td></tr><tr><td>90.9 ± 8.6</td><td>91.6 ± 8.1</td><td>95.5 ± 10.7</td><td><0.001</td></tr><tr><td>6.2 ± 0.9</td><td>9.3 ± 1.5</td><td>17.0 ± 6.3</td><td><0.001</td></tr></table>
032738550710d1c7a84243d90d6a84f04c43ccc2c68b95dba351ae5071aecbe1.png
simple
<table><tr><td>Breeds</td><td>MAF &#177; s.d.</td><td>Ho &#177; s.d.</td><td>He &#177; s.d.</td><td><i>F</i>&#177; s.d.</td><td>N<sub>e</sub></td></tr><tr><td>Valle del Belice</td><td>0.290 &#177; 0.003</td><td>0.364 &#177; 0.126</td><td>0.379 &#177; 0.155</td><td>0.055 &#177; 0.150</td><td>369</td></tr><tr><td>Comisana</td><td>0.294 &#177; 0.004</td><td>0.382 &#177; 0.129</td><td>0.382 &#177; 0.114</td><td>0.025 &#177; 0.031</td><td>400</td></tr><tr><td>Pinzirita</td><td>0.301 &#177; 0.005</td><td>0.388 &#177; 0.122</td><td>0.390 &#177; 0.108</td><td>0.016 &#177; 0.042</td><td>685</td></tr></table>
<table><tr><td>Breeds</td><td>MAF ± s.d.</td><td>Ho ± s.d.</td><td>He ± s.d.</td><td>F± s.d.</td><td>Ne</td></tr><tr><td>Valle del Belice</td><td>0.290 ± 0.003</td><td>0.364 ± 0.126</td><td>0.379 ± 0.155</td><td>0.055 ± 0.150</td><td>369</td></tr><tr><td>Comisana</td><td>0.294 ± 0.004</td><td>0.382 ± 0.129</td><td>0.382 ± 0.114</td><td>0.025 ± 0.031</td><td>400</td></tr></table>
<table><tr><td>Pinzirita</td><td>0.301 ± 0.005</td><td>0.388 ± 0.122</td><td>0.390 ± 0.108</td><td>0.016 ± 0.042</td><td>685</td></tr></table>
a077e393df89a339c5e3ef2229589523e044b9ff4ead8ae04652772b11158847.png
simple
<table><tr><td><i>Peg</i></td><td><i>Coupled Score</i></td><td><i>Abstract Coupling Score</i></td><td><i>Function</i></td></tr><tr><td>fig|243277.1.peg.316</td><td>6</td><td>0.38</td><td>Translation elongation factor Tu</td></tr><tr><td>fig|243277.1.peg.318</td><td>39</td><td>0.65</td><td>Transcription antitermination protein NusG</td></tr><tr><td>fig|243277.1.peg.319</td><td>24</td><td>0.61</td><td>LSU ribosomal protein L11p (L12e)</td></tr><tr><td>fig|243277.1.peg.320</td><td>36</td><td>0.64</td><td>LSU ribosomal protein L1p (L10Ae)</td></tr><tr><td>fig|243277.1.peg.321</td><td>11</td><td>0.58</td><td>LSU ribosomal protein L10p (P0)</td></tr><tr><td>fig|243277.1.peg.322</td><td>25</td><td>0.67</td><td>LSU ribosomal protein L7/L12 (L23e)</td></tr><tr><td>fig|243277.1.peg.324</td><td>34</td><td>0.64</td><td>DNA-directed RNA polymerase beta' subunit</td></tr><tr><td>fig|243277.1.peg.354</td><td>-<sup>1</sup></td><td>0.42</td><td>SSU ribosomal protein S12p (S23e)</td></tr><tr><td>fig|243277.1.peg.355</td><td>-</td><td>0.5</td><td>SSU ribosomal protein S7p (S5e)</td></tr><tr><td>fig|243277.1.peg.4033</td><td>-</td><td>0.35</td><td>Preprotein translocase subunit SecE</td></tr><tr><td>fig|243277.1.peg.356</td><td>-</td><td>0.27</td><td>Translation elongation factor G</td></tr></table>
<table><tr><td>Peg</td><td>Coupled Score</td><td>Abstract Coupling Score</td><td>Function</td></tr><tr><td>fig|243277.1.peg.316</td><td>6</td><td>0.38</td><td>Translation elongation factor Tu</td></tr></table>
<table><tr><td>Peg</td><td>Coupled Score</td><td>Abstract Coupling Score</td><td>Function</td></tr><tr><td>fig|243277.1.peg.318</td><td>39</td><td>0.65</td><td>Transcription antitermination protein NusG</td></tr><tr><td>fig|243277.1.peg.319</td><td>24</td><td>0.61</td><td>LSU ribosomal protein L11p (L12e)</td></tr><tr><td>fig|243277.1.peg.320</td><td>36</td><td>0.64</td><td>LSU ribosomal protein L1p (L10Ae)</td></tr><tr><td>fig|243277.1.peg.321</td><td>11</td><td>0.58</td><td>LSU ribosomal protein L10p (P0)</td></tr><tr><td>fig|243277.1.peg.322</td><td>25</td><td>0.67</td><td>LSU ribosomal protein L7/L12 (L23e)</td></tr><tr><td>fig|243277.1.peg.324</td><td>34</td><td>0.64</td><td>DNA-directed RNA polymerase beta' subunit</td></tr><tr><td>fig|243277.1.peg.354</td><td>-1</td><td>0.42</td><td>SSU ribosomal protein S12p (S23e)</td></tr><tr><td>fig|243277.1.peg.355</td><td>-</td><td>0.5</td><td>SSU ribosomal protein S7p (S5e)</td></tr><tr><td>fig|243277.1.peg.4033</td><td>-</td><td>0.35</td><td>Preprotein translocase subunit SecE</td></tr><tr><td>fig|243277.1.peg.356</td><td>-</td><td>0.27</td><td>Translation elongation factor G</td></tr></table>
905e6b01552394c651df9a617c8a19203fe57d963faeceefac903b06534fcebc.png
simple
<table><tr><td>Component score</td><td>SOFA</td><td>MOD</td></tr><tr><td>Cardiovascular</td><td>56%</td><td>18%</td></tr><tr><td>Respiratory</td><td>43%</td><td>23%</td></tr><tr><td>Coagulation</td><td>6%</td><td>4%</td></tr><tr><td>Renal</td><td>0.5%</td><td>0.5%</td></tr><tr><td>Hepatic</td><td>1%</td><td>0%</td></tr></table>
<table><tr><td>Component score</td><td>SOFA</td><td>MOD</td></tr><tr><td>Cardiovascular</td><td>56%</td><td>18%</td></tr><tr><td>Respiratory</td><td>43%</td><td>23%</td></tr><tr><td>Coagulation</td><td>6%</td><td>4%</td></tr><tr><td>Renal</td><td>0.5%</td><td>0.5%</td></tr></table>
<table><tr><td>Hepatic</td><td>1%</td><td>0%</td></tr></table>
f4739a4ef2cc53858da1b212d2de0d0dbf07789092d873e05011f35bea5509cf.png
complex
<table><tr><td rowspan="2">Specimens ID</td><td colspan="4">Multiplex</td><td colspan="4">WHO</td></tr><tr><td>Flu A</td><td>H7</td><td>N9</td><td>RP</td><td>Flu A</td><td>H7</td><td>N9</td><td>RP</td></tr><tr><td>20130405-5</td><td>24.26 &#177; 0.35<sup>a</sup></td><td>24.45 &#177; 0.21</td><td>25.03 &#177; 0.3</td><td>20.83 &#177; 0.3</td><td>24.77 &#177; 0.31</td><td>25.07 &#177; 0.15</td><td>24.85 &#177; 0.5</td><td>21.03 &#177; 0.3</td></tr><tr><td>20130406-32</td><td>26.43 &#177; 0.21</td><td>26.32 &#177; 0.31</td><td>26.23 &#177; 0.36</td><td>22.48 &#177; 0.35</td><td>26.43 &#177; 0.26</td><td>25.98 &#177; 0.15</td><td>26.52 &#177; 0.26</td><td>22.23 &#177; 0.15</td></tr><tr><td>20130407-69</td><td>20.15 &#177; 0.3</td><td>20.37 &#177; 0.32</td><td>20.7 &#177; 0.4</td><td>24.23 &#177; 0.32</td><td>19.78 &#177; 0.35</td><td>20.68 &#177; 0.36</td><td>20.07 &#177; 0.21</td><td>23.66 &#177; 0.31</td></tr><tr><td>20130409-92</td><td>31.33 &#177; 0.26</td><td>30.65 &#177; 0.36</td><td>31.23 &#177; 0.32</td><td>26.72 &#177; 0.4</td><td>30.85 &#177; 0.31</td><td>31.04 &#177; 0.5</td><td>31.2 &#177; 0.32</td><td>26.17 &#177; 0.25</td></tr></table>
<table><tr><td rowspan="2">Specimens ID</td><td>Multiplex</td></tr><tr><td>Flu A</td></tr><tr><td>20130405-5</td><td>24.26 ± 0.35a</td></tr><tr><td>20130406-32</td><td>26.43 ± 0.21</td></tr><tr><td>20130407-69</td><td>20.15 ± 0.3</td></tr><tr><td>20130409-92</td><td>31.33 ± 0.26</td></tr></table>
<table><tr><td colspan="3">Multiplex</td><td colspan="4">WHO</td></tr><tr><td>H7</td><td>N9</td><td>RP</td><td>Flu A</td><td>H7</td><td>N9</td><td>RP</td></tr><tr><td>24.45 ± 0.21</td><td>25.03 ± 0.3</td><td>20.83 ± 0.3</td><td>24.77 ± 0.31</td><td>25.07 ± 0.15</td><td>24.85 ± 0.5</td><td>21.03 ± 0.3</td></tr><tr><td>26.32 ± 0.31</td><td>26.23 ± 0.36</td><td>22.48 ± 0.35</td><td>26.43 ± 0.26</td><td>25.98 ± 0.15</td><td>26.52 ± 0.26</td><td>22.23 ± 0.15</td></tr><tr><td>20.37 ± 0.32</td><td>20.7 ± 0.4</td><td>24.23 ± 0.32</td><td>19.78 ± 0.35</td><td>20.68 ± 0.36</td><td>20.07 ± 0.21</td><td>23.66 ± 0.31</td></tr><tr><td>30.65 ± 0.36</td><td>31.23 ± 0.32</td><td>26.72 ± 0.4</td><td>30.85 ± 0.31</td><td>31.04 ± 0.5</td><td>31.2 ± 0.32</td><td>26.17 ± 0.25</td></tr></table>
297a37acc88ca8ca520e5de801e031f1817a5409fb2a7333880efadc59113587.png
complex
<table><tr><td></td><td colspan="2">Full study population</td><td colspan="5">Nested case-control samples for different case-control ratios</td></tr><tr><td></td><td>DVT +</td><td>DVT-</td><td>Cases</td><td colspan="4">Controls</td></tr><tr><td>Test results</td><td>n = 289</td><td>n = 1006</td><td>n = 289</td><td>1:1n = 289</td><td>1:2n = 578</td><td>1:3n = 867</td><td>1:4n = 1156</td></tr><tr><td>D-dimer test abnormal</td><td>271 (94)</td><td>621 (62)</td><td>271 (94)</td><td>178 (61)</td><td>357 (62)</td><td>535 (62)</td><td>713 (62)</td></tr><tr><td>Calf difference, cm*</td><td>3.2 (1.7)</td><td>2.1 (1.6)</td><td>3.2 (1.7)</td><td>2.1 (1.6)</td><td>2.1 (1.6)</td><td>2.1 (1.6)</td><td>2.1 (1.6)</td></tr><tr><td>Age, years*</td><td>61.9 (16.8)</td><td>59.4 (17.7)</td><td>61.9 (16.8)</td><td>59.4 (17.8)</td><td>59.5 (17.8)</td><td>59.4 (17.8)</td><td>59.4 (17.7)</td></tr><tr><td>Male gender</td><td>137 (47)</td><td>330 (33)</td><td>137 (47)</td><td>94 (33)</td><td>190 (33)</td><td>282 (33)</td><td>380 (33)</td></tr></table>
<table><tr><td></td><td colspan="2">Full study population</td><td colspan="5">Nested case-control samples for different case-control ratios</td></tr><tr><td></td><td>DVT +</td><td>DVT-</td><td>Cases</td><td colspan="4">Controls</td></tr><tr><td>Test results</td><td>n = 289</td><td>n = 1006</td><td>n = 289</td><td>1:1n = 289</td><td>1:2n = 578</td><td>1:3n = 867</td><td>1:4n = 1156</td></tr><tr><td>D-dimer test abnormal</td><td>271 (94)</td><td>621 (62)</td><td>271 (94)</td><td>178 (61)</td><td>357 (62)</td><td>535 (62)</td><td>713 (62)</td></tr><tr><td>Calf difference, cm*</td><td>3.2 (1.7)</td><td>2.1 (1.6)</td><td>3.2 (1.7)</td><td>2.1 (1.6)</td><td>2.1 (1.6)</td><td>2.1 (1.6)</td><td>2.1 (1.6)</td></tr><tr><td>Age, years*</td><td>61.9 (16.8)</td><td>59.4 (17.7)</td><td>61.9 (16.8)</td><td>59.4 (17.8)</td><td>59.5 (17.8)</td><td>59.4 (17.8)</td><td>59.4 (17.7)</td></tr></table>
<table><tr><td></td><td colspan="2">Full study population</td><td colspan="5">Nested case-control samples for different case-control ratios</td></tr><tr><td></td><td>DVT +</td><td>DVT-</td><td>Cases</td><td colspan="4">Controls</td></tr><tr><td>Test results</td><td>n = 289</td><td>n = 1006</td><td>n = 289</td><td>1:1n = 289</td><td>1:2n = 578</td><td>1:3n = 867</td><td>1:4n = 1156</td></tr><tr><td>Male gender</td><td>137 (47)</td><td>330 (33)</td><td>137 (47)</td><td>94 (33)</td><td>190 (33)</td><td>282 (33)</td><td>380 (33)</td></tr></table>
6509683cc84c1b92dd9f729bb2b6a876d41698311d0781521b7fe0e333c830e5.png
complex
<table><tr><td><i>Plan</i></td><td><i>Plane</i></td><td><i>6 MV Gamma Passing Rate (%)</i></td><td><i>Plane</i></td><td><i>18 MV Gamma Passing Rate (%)</i></td></tr><tr><td>I1 Multitarget</td><td>Isocenter</td><td>93.9</td><td>Isocenter</td><td>95.9</td></tr><tr><td>I2 Mock Prostate</td><td>Isocenter</td><td>91.7</td><td>Isocenter</td><td>91.9</td></tr><tr><td>I3 Mock H&amp;N</td><td>Isocenter</td><td>94.0</td><td>Isocenter</td><td>95.0</td></tr><tr><td>I4 Easy C&#8208;Shape</td><td>Isocenter</td><td>95.5</td><td>Isocenter</td><td>89.3</td></tr><tr><td></td><td>6 MV Mean</td><td>93.8</td><td>18 MV Mean</td><td>93.3</td></tr><tr><td></td><td>6 MV SD</td><td>1.6</td><td>18 MV SD</td><td>3.0</td></tr><tr><td></td><td>6 MV CL</td><td>9.3</td><td>18 MV CL</td><td>12.9</td></tr><tr><td></td><td colspan="2">Overall (6 &amp; 18 MV) Mean</td><td colspan="2">93.4</td></tr><tr><td></td><td colspan="2">Overall Standard Deviation</td><td colspan="2">2.3</td></tr><tr><td></td><td colspan="2">Overall Confidence Limit</td><td colspan="2">11.0</td></tr></table>
<table><tr><td>Plan</td><td>Plane</td><td>6 MV Gamma Passing Rate (%)</td><td>Plane</td><td>18 MV Gamma Passing Rate (%)</td></tr><tr><td>I1 Multitarget</td><td>Isocenter</td><td>93.9</td><td>Isocenter</td><td>95.9</td></tr><tr><td>I2 Mock Prostate</td><td>Isocenter</td><td>91.7</td><td>Isocenter</td><td>91.9</td></tr><tr><td>I3 Mock H&N</td><td>Isocenter</td><td>94.0</td><td>Isocenter</td><td>95.0</td></tr><tr><td>I4 Easy C‐Shape</td><td>Isocenter</td><td>95.5</td><td>Isocenter</td><td>89.3</td></tr><tr><td></td><td>6 MV Mean</td><td>93.8</td><td>18 MV Mean</td><td>93.3</td></tr><tr><td></td><td>6 MV SD</td><td>1.6</td><td>18 MV SD</td><td>3.0</td></tr><tr><td></td><td>6 MV CL</td><td>9.3</td><td>18 MV CL</td><td>12.9</td></tr><tr><td></td><td colspan="2">Overall (6 & 18 MV) Mean</td><td colspan="2">93.4</td></tr></table>
<table><tr><td>Plane</td><td>6 MV Gamma Passing Rate (%)</td><td>Plane</td><td>18 MV Gamma Passing Rate (%)</td></tr><tr><td colspan="2">Overall Standard Deviation</td><td colspan="2">2.3</td></tr><tr><td colspan="2">Overall Confidence Limit</td><td colspan="2">11.0</td></tr></table>
4ae25d2a65dc77f41d628dbfa418a0a56761a22c0ae3a20cb0c5922d767e74a3.png
complex
<table><tr><td>Transcription factor family</td><td colspan="2">L1 vs. L2 (transcript) Up-or down-regulated</td><td colspan="2">L1 vs. L3 (transcript) Up-or down-regulated</td><td colspan="2">L2 vs. L3 (transcript) Up-or down-regulated</td></tr><tr><td></td><td>Up</td><td>Down</td><td>Up</td><td>Down</td><td>Up</td><td>Down</td></tr><tr><td>AP2</td><td>1</td><td>13</td><td>14</td><td>0</td><td>4</td><td>10</td></tr><tr><td>ARF</td><td>12</td><td>11</td><td>15</td><td>10</td><td>17</td><td>8</td></tr><tr><td>ARR</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>B-ARR</td><td>12</td><td>12</td><td>9</td><td>15</td><td>8</td><td>16</td></tr><tr><td>A-ARR</td><td>11</td><td>1</td><td>10</td><td>2</td><td>4</td><td>8</td></tr><tr><td>AUX/IAA</td><td>6</td><td>38</td><td>3</td><td>41</td><td>18</td><td>15</td></tr><tr><td>B3</td><td>4</td><td>1</td><td>3</td><td>2</td><td>1</td><td>4</td></tr><tr><td>bHLH</td><td>13</td><td>20</td><td>11</td><td>12</td><td>11</td><td>20</td></tr><tr><td>bZIP</td><td>3</td><td>7</td><td>1</td><td>8</td><td>3</td><td>7</td></tr><tr><td>BEE</td><td>0</td><td>3</td><td>0</td><td>3</td><td>0</td><td>3</td></tr><tr><td>Zinc finger</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>C2H2-type</td><td>3</td><td>11</td><td>5</td><td>9</td><td>7</td><td>7</td></tr><tr><td>C3HC4-type</td><td>7</td><td>6</td><td>7</td><td>6</td><td>9</td><td>3</td></tr><tr><td>CCCH-type</td><td>3</td><td>5</td><td>4</td><td>4</td><td>4</td><td>4</td></tr><tr><td>B-box-type</td><td>1</td><td>4</td><td>4</td><td>1</td><td>4</td><td>1</td></tr><tr><td>C3H4 type</td><td>2</td><td>10</td><td>2</td><td>10</td><td>12</td><td>0</td></tr><tr><td>CAMTA</td><td>15</td><td>5</td><td>15</td><td>5</td><td>13</td><td>7</td></tr><tr><td>ERF</td><td>17</td><td>30</td><td>15</td><td>32</td><td>16</td><td>30</td></tr><tr><td>GATA</td><td>0</td><td>9</td><td>1</td><td>8</td><td>4</td><td>5</td></tr><tr><td>GRAS</td><td>5</td><td>13</td><td>8</td><td>10</td><td>9</td><td>8</td></tr><tr><td>MADS</td><td>2</td><td>5</td><td>5</td><td>2</td><td>6</td><td>1</td></tr><tr><td>MYB</td><td>18</td><td>27</td><td>16</td><td>29</td><td>18</td><td>23</td></tr><tr><td>HSP</td><td>3</td><td>10</td><td>6</td><td>9</td><td>9</td><td>5</td></tr><tr><td>NAC</td><td>16</td><td>21</td><td>9</td><td>28</td><td>16</td><td>18</td></tr><tr><td>NF-YA</td><td>3</td><td>1</td><td>4</td><td>0</td><td>2</td><td>2</td></tr><tr><td>NF-YB</td><td>0</td><td>4</td><td>1</td><td>3</td><td>4</td><td>0</td></tr><tr><td>R2R3-MYB</td><td>0</td><td>8</td><td>0</td><td>8</td><td>5</td><td>3</td></tr><tr><td>SPL</td><td>4</td><td>1</td><td>4</td><td>1</td><td>2</td><td>3</td></tr><tr><td>TCP</td><td>4</td><td>10</td><td>1</td><td>13</td><td>1</td><td>13</td></tr><tr><td>TGA</td><td>1</td><td>3</td><td>1</td><td>3</td><td>3</td><td>1</td></tr><tr><td>WRKY</td><td>8</td><td>28</td><td>9</td><td>27</td><td>16</td><td>19</td></tr></table>
<table><tr><td>Transcription factor family</td><td colspan="2">L1 vs. L2 (transcript) Up-or down-regulated</td><td>L1 vs. L3 (transcript) Up-or down-regulated</td></tr><tr><td></td><td>Up</td><td>Down</td><td>Up</td></tr><tr><td>AP2</td><td>1</td><td>13</td><td>14</td></tr><tr><td>ARF</td><td>12</td><td>11</td><td>15</td></tr><tr><td>ARR</td><td></td><td></td><td></td></tr><tr><td>B-ARR</td><td>12</td><td>12</td><td>9</td></tr><tr><td>A-ARR</td><td>11</td><td>1</td><td>10</td></tr><tr><td>AUX/IAA</td><td>6</td><td>38</td><td>3</td></tr><tr><td>B3</td><td>4</td><td>1</td><td>3</td></tr><tr><td>bHLH</td><td>13</td><td>20</td><td>11</td></tr><tr><td>bZIP</td><td>3</td><td>7</td><td>1</td></tr><tr><td>BEE</td><td>0</td><td>3</td><td>0</td></tr><tr><td>Zinc finger</td><td></td><td></td><td></td></tr><tr><td>C2H2-type</td><td>3</td><td>11</td><td>5</td></tr><tr><td>C3HC4-type</td><td>7</td><td>6</td><td>7</td></tr><tr><td>CCCH-type</td><td>3</td><td>5</td><td>4</td></tr><tr><td>B-box-type</td><td>1</td><td>4</td><td>4</td></tr><tr><td>C3H4 type</td><td>2</td><td>10</td><td>2</td></tr><tr><td>CAMTA</td><td>15</td><td>5</td><td>15</td></tr><tr><td>ERF</td><td>17</td><td>30</td><td>15</td></tr><tr><td>GATA</td><td>0</td><td>9</td><td>1</td></tr><tr><td>GRAS</td><td>5</td><td>13</td><td>8</td></tr><tr><td>MADS</td><td>2</td><td>5</td><td>5</td></tr><tr><td>MYB</td><td>18</td><td>27</td><td>16</td></tr><tr><td>HSP</td><td>3</td><td>10</td><td>6</td></tr><tr><td>NAC</td><td>16</td><td>21</td><td>9</td></tr><tr><td>NF-YA</td><td>3</td><td>1</td><td>4</td></tr><tr><td>NF-YB</td><td>0</td><td>4</td><td>1</td></tr><tr><td>R2R3-MYB</td><td>0</td><td>8</td><td>0</td></tr><tr><td>SPL</td><td>4</td><td>1</td><td>4</td></tr><tr><td>TCP</td><td>4</td><td>10</td><td>1</td></tr><tr><td>TGA</td><td>1</td><td>3</td><td>1</td></tr><tr><td>WRKY</td><td>8</td><td>28</td><td>9</td></tr></table>
<table><tr><td>L1 vs. L3 (transcript) Up-or down-regulated</td><td colspan="2">L2 vs. L3 (transcript) Up-or down-regulated</td></tr><tr><td>Down</td><td>Up</td><td>Down</td></tr><tr><td>0</td><td>4</td><td>10</td></tr><tr><td>10</td><td>17</td><td>8</td></tr><tr><td></td><td></td><td></td></tr><tr><td>15</td><td>8</td><td>16</td></tr><tr><td>2</td><td>4</td><td>8</td></tr><tr><td>41</td><td>18</td><td>15</td></tr><tr><td>2</td><td>1</td><td>4</td></tr><tr><td>12</td><td>11</td><td>20</td></tr><tr><td>8</td><td>3</td><td>7</td></tr><tr><td>3</td><td>0</td><td>3</td></tr><tr><td></td><td></td><td></td></tr><tr><td>9</td><td>7</td><td>7</td></tr><tr><td>6</td><td>9</td><td>3</td></tr><tr><td>4</td><td>4</td><td>4</td></tr><tr><td>1</td><td>4</td><td>1</td></tr><tr><td>10</td><td>12</td><td>0</td></tr><tr><td>5</td><td>13</td><td>7</td></tr><tr><td>32</td><td>16</td><td>30</td></tr><tr><td>8</td><td>4</td><td>5</td></tr><tr><td>10</td><td>9</td><td>8</td></tr><tr><td>2</td><td>6</td><td>1</td></tr><tr><td>29</td><td>18</td><td>23</td></tr><tr><td>9</td><td>9</td><td>5</td></tr><tr><td>28</td><td>16</td><td>18</td></tr><tr><td>0</td><td>2</td><td>2</td></tr><tr><td>3</td><td>4</td><td>0</td></tr><tr><td>8</td><td>5</td><td>3</td></tr><tr><td>1</td><td>2</td><td>3</td></tr><tr><td>13</td><td>1</td><td>13</td></tr><tr><td>3</td><td>3</td><td>1</td></tr><tr><td>27</td><td>16</td><td>19</td></tr></table>
101cdfdc69501b7e1b6f6787c807b5a7c325f14fa11db990f1a7a04702214b50.png
complex
<table><tr><td>RDQ Scale</td><td colspan="2">Effect size</td><td colspan="2">Standardized response mean</td></tr><tr><td></td><td>Esomeprazole</td><td>Placebo</td><td>Esomeprazole</td><td>Placebo</td></tr><tr><td>Heartburn</td><td>2.05</td><td>0.85</td><td>1.52</td><td>0.74</td></tr><tr><td>Regurgitation</td><td>1.36</td><td>0.63</td><td>1.31</td><td>0.60</td></tr><tr><td>Dyspepsia</td><td>1.05</td><td>0.56</td><td>0.99</td><td>0.57</td></tr><tr><td>GERD<sup>a</sup></td><td>2.13</td><td>0.93</td><td>1.68</td><td>0.79</td></tr></table>
<table><tr><td>RDQ Scale</td><td colspan="2">Effect size</td><td colspan="2">Standardized response mean</td></tr><tr><td></td><td>Esomeprazole</td><td>Placebo</td><td>Esomeprazole</td><td>Placebo</td></tr><tr><td>Heartburn</td><td>2.05</td><td>0.85</td><td>1.52</td><td>0.74</td></tr></table>
<table><tr><td>RDQ Scale</td><td colspan="2">Effect size</td><td colspan="2">Standardized response mean</td></tr><tr><td></td><td>Esomeprazole</td><td>Placebo</td><td>Esomeprazole</td><td>Placebo</td></tr><tr><td>Regurgitation</td><td>1.36</td><td>0.63</td><td>1.31</td><td>0.60</td></tr><tr><td>Dyspepsia</td><td>1.05</td><td>0.56</td><td>0.99</td><td>0.57</td></tr><tr><td>GERDa</td><td>2.13</td><td>0.93</td><td>1.68</td><td>0.79</td></tr></table>
162d54cd39327270a11d6cb62707a919cfb212e6072f6cf309b9a330859f37d5.png
complex
<table><tr><td></td><td colspan="3">Median $ (IQR)</td></tr><tr><td></td><td>MostPopular1</td><td>First-linequality-assured ACT</td><td>Oral Artemisinin Monotherapy</td></tr><tr><td>Benin<sup>2</sup></td><td>0.65 <sup>a </sup>(0.43, 1.08) N = 462</td><td>3.24 <sup>b </sup>(1.94, 5.77) N = 216</td><td>8.10 (8.07, 10.45) N = 56</td></tr><tr><td>DRC</td><td>0.39 <sup>a </sup>(0.26, 0.52) N = 1, 258</td><td>1.86 <sup>b </sup>(1.03, 3.61) N = 252</td><td>3.23 (2.45, 4.13) N = 956</td></tr><tr><td>Madagascar</td><td>0.36 <sup>a </sup>(0.36, 0.36) N = 1, 847</td><td>0.14 <sup>b </sup>(0.10, 0.57) N = 302</td><td>(0 and 7.33) N = 2</td></tr><tr><td>Nigeria<sup>3</sup></td><td>0.54 <sup>a </sup>(0.40, 0.81) N = 4, 061</td><td>6.40 <sup>b </sup>(5.05, 6.74) N = 372</td><td>3.24 (2.70, 3.77) N = 1, 438</td></tr><tr><td>Uganda<sup>4</sup></td><td>0.50 <sup>a </sup>(0.30, 0.75) N = 653</td><td>4.48 <sup>b </sup>(2.49, 5.97) N = 81</td><td>9.55 (7.96, 11.94) N = 229</td></tr><tr><td>Zambia</td><td>0.40 <sup>a </sup>(0.30, 0.61) N = 261</td><td>9.63 <sup>b </sup>(3.01, 11.04) N = 83</td><td>6.74 (5.72, 6.74) N = 16</td></tr></table>
<table><tr><td></td><td>Median $ (IQR)</td></tr><tr><td></td><td>MostPopular1</td></tr><tr><td>Benin2</td><td>0.65 a (0.43, 1.08) N = 462</td></tr><tr><td>DRC</td><td>0.39 a (0.26, 0.52) N = 1, 258</td></tr><tr><td>Madagascar</td><td>0.36 a (0.36, 0.36) N = 1, 847</td></tr><tr><td>Nigeria3</td><td>0.54 a (0.40, 0.81) N = 4, 061</td></tr><tr><td>Uganda4</td><td>0.50 a (0.30, 0.75) N = 653</td></tr><tr><td>Zambia</td><td>0.40 a (0.30, 0.61) N = 261</td></tr></table>
<table><tr><td colspan="2">Median $ (IQR)</td></tr><tr><td>First-linequality-assured ACT</td><td>Oral Artemisinin Monotherapy</td></tr><tr><td>3.24 b (1.94, 5.77) N = 216</td><td>8.10 (8.07, 10.45) N = 56</td></tr><tr><td>1.86 b (1.03, 3.61) N = 252</td><td>3.23 (2.45, 4.13) N = 956</td></tr><tr><td>0.14 b (0.10, 0.57) N = 302</td><td>(0 and 7.33) N = 2</td></tr><tr><td>6.40 b (5.05, 6.74) N = 372</td><td>3.24 (2.70, 3.77) N = 1, 438</td></tr><tr><td>4.48 b (2.49, 5.97) N = 81</td><td>9.55 (7.96, 11.94) N = 229</td></tr><tr><td>9.63 b (3.01, 11.04) N = 83</td><td>6.74 (5.72, 6.74) N = 16</td></tr></table>
7dd7c8a9a8daf28191c26ea351d402572713e3081378160d0afc4d6dbd16cbac.png
complex
<table><tr><td>Subtypes of epilepsy</td><td>T. gondiin (%)</td><td>Pvalue</td><td>Toxocaran (%)</td><td>Pvalue</td></tr><tr><td>Idiopathic</td><td>16/117 (13.67)</td><td rowspan="3">0.8</td><td>25/117(21.36)</td><td rowspan="3">0.2</td></tr><tr><td>Febrile seizure(Special syndrome)</td><td>2/10 (20)</td><td>0/10(0)</td></tr><tr><td>Generalized</td><td>2/14 (14.28)</td><td>3/14 (21.42)</td></tr></table>
<table><tr><td>Subtypes of epilepsy</td></tr><tr><td>Idiopathic</td></tr><tr><td>Febrile seizure(Special syndrome)</td></tr><tr><td>Generalized</td></tr></table>
<table><tr><td>T. gondiin (%)</td><td>Pvalue</td><td>Toxocaran (%)</td><td>Pvalue</td></tr><tr><td>16/117 (13.67)</td><td rowspan="3">0.8</td><td>25/117(21.36)</td><td rowspan="3">0.2</td></tr><tr><td>2/10 (20)</td><td>0/10(0)</td></tr><tr><td>2/14 (14.28)</td><td>3/14 (21.42)</td></tr></table>
910c31ed505cf4e16b15020417cd62a7e975c5b42d96660564fad4b3fd0fcd83.png
simple
<table><tr><td>Anamnestic and clinicalFeatures of red flags</td><td>Sign and symptoms ofSpecific shoulder pain</td></tr><tr><td>Fever, shivering, changes in body temperature overnight, diaphoresis, nausea, unexplainable sweating overnight, vomiting, sphincteric complaints, diarrhoea, paleness, fatigue, lurching, fainting, exhaustion, excessive and unexplainable weakness, not linked to any physical effort, unexplainable loss of weight, skin rash, unexplainable multiple hematoma, lumps over the body, deformities, inability to lay supine in bed, marked muscle weakness, marked restriction of movement, limb atrophy, local pain and pain during load when age is less than 20 years old and more than 50.</td><td>Recent trauma of the shoulder complex, high reactivity of symptoms, pain during the night, limitation of flexion (&lt; 90&#176; both passive and active), apprehension, fear of movement and/or weakness during humeral external rotation.</td></tr></table>
<table><tr><td>Anamnestic and clinicalFeatures of red flags</td><td>Sign and symptoms ofSpecific shoulder pain</td></tr></table>
<table><tr><td>Fever, shivering, changes in body temperature overnight, diaphoresis, nausea, unexplainable sweating overnight, vomiting, sphincteric complaints, diarrhoea, paleness, fatigue, lurching, fainting, exhaustion, excessive and unexplainable weakness, not linked to any physical effort, unexplainable loss of weight, skin rash, unexplainable multiple hematoma, lumps over the body, deformities, inability to lay supine in bed, marked muscle weakness, marked restriction of movement, limb atrophy, local pain and pain during load when age is less than 20 years old and more than 50.</td><td>Recent trauma of the shoulder complex, high reactivity of symptoms, pain during the night, limitation of flexion (< 90° both passive and active), apprehension, fear of movement and/or weakness during humeral external rotation.</td></tr></table>
8e11f27ded25eb4e1e5470e2262445211cc049fdc8c5026ccdf655c7aadc0f11.png
simple
<table><tr><td>Measure(n=)</td><td>HIF-1&#945;H-scoreMean(&#177; sd)</td><td>GLUT-1H-scoreMean(&#177; sd)</td><td>CA-IXH-scoreMean(&#177; sd)</td><td>MVDfrequencyhigh(%)</td><td>CK 5/6frequencypositive(%)</td><td>VEGF-Apg/mlMean(&#177; sd)</td><td>IGF-1ng/mlMean(&#177; sd)</td></tr><tr><td>Nodal status<sup>1</sup></td><td>0.073</td><td>0.22</td><td>0.0068</td><td>0.65</td><td>0.10</td><td>0.40</td><td>0.77</td></tr><tr><td>N0 (12)</td><td>44.38(&#177; 27.08)</td><td>107.08(&#177; 43.47)</td><td>63.65(&#177; 24.79)</td><td>1/12(8.33%)</td><td>1/12(8.33%)</td><td>323.39(&#177; 167.41)</td><td>103.2(&#177; 22.27)</td></tr><tr><td>N1 (12)</td><td>100.21(&#177; 67.46)</td><td>131.88(&#177; 46.19)</td><td>64.17(&#177; 67.78)</td><td>8/12(66.7%)</td><td>4/12(33.33%)</td><td>370.00(&#177; 189.65)</td><td>109.93(&#177; 35.57)</td></tr><tr><td>N2 (4)</td><td>93.75(&#177; 47.72)</td><td>99.38(&#177; 42.93)</td><td>38.75(&#177; 7.77)</td><td>2/4(50%)</td><td>0/4(0.0%)</td><td>230.13(&#177; 50.22)</td><td>114.67(&#177; 32.40)</td></tr><tr><td>Grade<sup>1</sup></td><td>0.0064</td><td>0.013</td><td>0.075</td><td>0.0009</td><td>0.0069</td><td>0.15</td><td>0.29</td></tr><tr><td>1 (5)</td><td>41.5(&#177; 19.57)</td><td>108.50(&#177; 31.60)</td><td>72.5(&#177; 19.04)</td><td>0/5(0.0%)</td><td>0/5(0.0%)</td><td>348.75(&#177; 126.36)</td><td>102.03(&#177; 21.77)</td></tr><tr><td>2 (13)</td><td>50.96(&#177; 36.29)</td><td>94.23(&#177; 37.63)</td><td>42.31(&#177; 16.09)</td><td>2/13(15.38%)</td><td>0/13(0.0%)</td><td>401.92(&#177; 209.77)</td><td>119.19(&#177; 34.50)</td></tr><tr><td>3 (10)</td><td>124.0(&#177; 58.47)</td><td>149.75(&#177; 42.22)</td><td>77.63(&#177; 72.38)</td><td>9/10(90.0%)</td><td>5/10(50%)</td><td>236.67(&#177; 89.36)</td><td>97.92(&#177; 22.48)</td></tr><tr><td>ER status<sup>1</sup></td><td>0.18</td><td>0.046</td><td>0.052</td><td>0.038</td><td>0.18</td><td>0.14</td><td>0.075</td></tr><tr><td>Negative (5)</td><td>131.50(&#177; 70.83)</td><td>142.0(&#177; 53.19)</td><td>120.50(&#177; 73.56)</td><td>5/5(100%)</td><td>2/5(40%)</td><td>245.98(&#177; 109.29)</td><td>87.49(&#177; 17.57)</td></tr><tr><td>Positive (23)</td><td>63.15(&#177; 45.72)</td><td>111.09(&#177; 42.43)</td><td>47.23(&#177; 26.94)</td><td>6/23(26.09%)</td><td>3/23(13.04%)</td><td>354.38(&#177; 176.18)</td><td>113.46(&#177; 28.75)</td></tr><tr><td>PR status<sup>1</sup></td><td>0.15</td><td>0.024</td><td>0.018</td><td>0.013</td><td>0.059</td><td>0.069</td><td>0.074</td></tr><tr><td>Negative (6)</td><td>122.08(&#177; 67.42)</td><td>151.25(&#177; 52.70)</td><td>118.13(&#177; 66.05)</td><td>6/6(100%)</td><td>3/6(50%)</td><td>237.44(&#177; 99.96)</td><td>90.77(&#177; 17.66)</td></tr><tr><td>Positive (22)</td><td>62.61(&#177; 46.72)</td><td>107.16(&#177; 38.92)</td><td>44.54(&#177; 24.22)</td><td>5/22(22.73%)</td><td>2/22(9.09%)</td><td>364.36(&#177; 176.92)</td><td>113.85(&#177; 29.64)</td></tr></table>
<table><tr><td>Measure(n=)</td><td>HIF-1αH-scoreMean(± sd)</td><td>GLUT-1H-scoreMean(± sd)</td><td>CA-IXH-scoreMean(± sd)</td><td>MVDfrequencyhigh(%)</td><td>CK 5/6frequencypositive(%)</td><td>VEGF-Apg/mlMean(± sd)</td><td>IGF-1ng/mlMean(± sd)</td></tr><tr><td>Nodal status1</td><td>0.073</td><td>0.22</td><td>0.0068</td><td>0.65</td><td>0.10</td><td>0.40</td><td>0.77</td></tr><tr><td>N0 (12)</td><td>44.38(± 27.08)</td><td>107.08(± 43.47)</td><td>63.65(± 24.79)</td><td>1/12(8.33%)</td><td>1/12(8.33%)</td><td>323.39(± 167.41)</td><td>103.2(± 22.27)</td></tr><tr><td>N1 (12)</td><td>100.21(± 67.46)</td><td>131.88(± 46.19)</td><td>64.17(± 67.78)</td><td>8/12(66.7%)</td><td>4/12(33.33%)</td><td>370.00(± 189.65)</td><td>109.93(± 35.57)</td></tr><tr><td>N2 (4)</td><td>93.75(± 47.72)</td><td>99.38(± 42.93)</td><td>38.75(± 7.77)</td><td>2/4(50%)</td><td>0/4(0.0%)</td><td>230.13(± 50.22)</td><td>114.67(± 32.40)</td></tr><tr><td>Grade1</td><td>0.0064</td><td>0.013</td><td>0.075</td><td>0.0009</td><td>0.0069</td><td>0.15</td><td>0.29</td></tr><tr><td>1 (5)</td><td>41.5(± 19.57)</td><td>108.50(± 31.60)</td><td>72.5(± 19.04)</td><td>0/5(0.0%)</td><td>0/5(0.0%)</td><td>348.75(± 126.36)</td><td>102.03(± 21.77)</td></tr><tr><td>2 (13)</td><td>50.96(± 36.29)</td><td>94.23(± 37.63)</td><td>42.31(± 16.09)</td><td>2/13(15.38%)</td><td>0/13(0.0%)</td><td>401.92(± 209.77)</td><td>119.19(± 34.50)</td></tr><tr><td>3 (10)</td><td>124.0(± 58.47)</td><td>149.75(± 42.22)</td><td>77.63(± 72.38)</td><td>9/10(90.0%)</td><td>5/10(50%)</td><td>236.67(± 89.36)</td><td>97.92(± 22.48)</td></tr><tr><td>ER status1</td><td>0.18</td><td>0.046</td><td>0.052</td><td>0.038</td><td>0.18</td><td>0.14</td><td>0.075</td></tr><tr><td>Negative (5)</td><td>131.50(± 70.83)</td><td>142.0(± 53.19)</td><td>120.50(± 73.56)</td><td>5/5(100%)</td><td>2/5(40%)</td><td>245.98(± 109.29)</td><td>87.49(± 17.57)</td></tr><tr><td>Positive (23)</td><td>63.15(± 45.72)</td><td>111.09(± 42.43)</td><td>47.23(± 26.94)</td><td>6/23(26.09%)</td><td>3/23(13.04%)</td><td>354.38(± 176.18)</td><td>113.46(± 28.75)</td></tr><tr><td>PR status1</td><td>0.15</td><td>0.024</td><td>0.018</td><td>0.013</td><td>0.059</td><td>0.069</td><td>0.074</td></tr><tr><td>Negative (6)</td><td>122.08(± 67.42)</td><td>151.25(± 52.70)</td><td>118.13(± 66.05)</td><td>6/6(100%)</td><td>3/6(50%)</td><td>237.44(± 99.96)</td><td>90.77(± 17.66)</td></tr></table>
<table><tr><td>Positive (22)</td><td>62.61(± 46.72)</td><td>107.16(± 38.92)</td><td>44.54(± 24.22)</td><td>5/22(22.73%)</td><td>2/22(9.09%)</td><td>364.36(± 176.92)</td><td>113.85(± 29.64)</td></tr></table>
80e89249b75fa7745b3b92fd472f41e4dbb724d387c781189364459c8128479a.png
simple
<table><tr><td></td><td>&#961;</td><td>&#961;-partial</td></tr><tr><td>Baseline disability</td><td>0.46<sup>&#8225;</sup></td><td></td></tr><tr><td>Age</td><td>0.26<sup>&#8225;</sup></td><td>0.28<sup>&#8225;</sup></td></tr><tr><td>Somatization</td><td>0.40<sup>&#8225;</sup></td><td>0.23<sup>&#8225;</sup></td></tr><tr><td>Depression</td><td>0.35<sup>&#8225;</sup></td><td>0.25<sup>&#8225;</sup></td></tr><tr><td>Time since onset of pain</td><td>0.14<sup>&#8224;</sup></td><td>0.13<sup>&#8224;</sup></td></tr><tr><td>Coping resources</td><td>&#8722;0.15<sup>&#8224;</sup></td><td>&#8722;0.12<sup>*</sup></td></tr><tr><td>Resilience</td><td>&#8722;0.21<sup>&#8225;</sup></td><td>&#8722;0.18<sup>&#8225;</sup></td></tr><tr><td>Gender</td><td>0.02</td><td>0.08</td></tr></table>
<table><tr><td></td></tr><tr><td>Baseline disability</td></tr><tr><td>Age</td></tr><tr><td>Somatization</td></tr><tr><td>Depression</td></tr><tr><td>Time since onset of pain</td></tr><tr><td>Coping resources</td></tr><tr><td>Resilience</td></tr><tr><td>Gender</td></tr></table>
<table><tr><td>ρ</td><td>ρ-partial</td></tr><tr><td>0.46‡</td><td></td></tr><tr><td>0.26‡</td><td>0.28‡</td></tr><tr><td>0.40‡</td><td>0.23‡</td></tr><tr><td>0.35‡</td><td>0.25‡</td></tr><tr><td>0.14†</td><td>0.13†</td></tr><tr><td>−0.15†</td><td>−0.12*</td></tr><tr><td>−0.21‡</td><td>−0.18‡</td></tr><tr><td>0.02</td><td>0.08</td></tr></table>
67d9a122fa2b71c585df3d4900d1f0200a91d695f0234379bc11c688900c40cd.png
simple
<table><tr><td> </td><td><i>Primary Rd until progression (</i>n<i>=9)</i></td><td><i>Primary Rd stopped before progression (</i>n<i>=11)</i></td><td><i>Primary Rd stopped with progression and restarted (</i>n<i>=5)</i></td><td><i>Rd induction followed by SCT (</i>n<i>=8)</i></td></tr><tr><td>Age, years, median (range)</td><td>65 (36&#8211;70)</td><td>60 (40&#8211;78)</td><td>55 (32&#8211;75)</td><td>62 (36&#8211;73)</td></tr><tr><td>Prior plasma cell disorder, <i>N</i></td><td>6 (3 MGUS/SMM; 3 plasmacytoma)</td><td>3 (3 MGUS/SMM)</td><td>3 (2 MGUS/SMM; 1 plasmacytoma)</td><td>3 (1 MGUS/SMM; 2 plasmacytoma)</td></tr><tr><td>MDE at presentation</td><td>Bone, 8Anemia, 1</td><td>Bone, 10Anemia, 1</td><td>Bone, 3Anemia, 1Hypercalcemia, 1</td><td>Bone, 7Anemia, 1</td></tr><tr><td>Molecular classification, <i>N</i></td><td>Trisomies, 5t(11;14) 1t(11;14) plus trisomy, 1Isolated del 13, 1Normal/insufficient, 1</td><td>Trisomies, 6t(11;14), 1Not done, 4</td><td>Trisomies, 3Normal/insufficient, 1Not done, 1</td><td>Trisomies, 4Isolated del 13, 2Normal/insufficient, 2</td></tr><tr><td>Best response to therapy</td><td>CR, 7VGPR, 2</td><td>CR, 9VGPR, 1 PR, 1</td><td>CR, 2VGPR, 2 PR, 1</td><td>CR, 7PR, 1</td></tr></table>
<table><tr><td></td><td>Primary Rd until progression (n=9)</td><td>Primary Rd stopped before progression (n=11)</td><td>Primary Rd stopped with progression and restarted (n=5)</td><td>Rd induction followed by SCT (n=8)</td></tr></table>
<table><tr><td>Age, years, median (range)</td><td>65 (36–70)</td><td>60 (40–78)</td><td>55 (32–75)</td><td>62 (36–73)</td></tr><tr><td>Prior plasma cell disorder, N</td><td>6 (3 MGUS/SMM; 3 plasmacytoma)</td><td>3 (3 MGUS/SMM)</td><td>3 (2 MGUS/SMM; 1 plasmacytoma)</td><td>3 (1 MGUS/SMM; 2 plasmacytoma)</td></tr><tr><td>MDE at presentation</td><td>Bone, 8Anemia, 1</td><td>Bone, 10Anemia, 1</td><td>Bone, 3Anemia, 1Hypercalcemia, 1</td><td>Bone, 7Anemia, 1</td></tr><tr><td>Molecular classification, N</td><td>Trisomies, 5t(11;14) 1t(11;14) plus trisomy, 1Isolated del 13, 1Normal/insufficient, 1</td><td>Trisomies, 6t(11;14), 1Not done, 4</td><td>Trisomies, 3Normal/insufficient, 1Not done, 1</td><td>Trisomies, 4Isolated del 13, 2Normal/insufficient, 2</td></tr><tr><td>Best response to therapy</td><td>CR, 7VGPR, 2</td><td>CR, 9VGPR, 1 PR, 1</td><td>CR, 2VGPR, 2 PR, 1</td><td>CR, 7PR, 1</td></tr></table>
328bbed101b682a059de40ac5cc97baa2cf58280c8e4308eb764cca974fd666f.png
complex
<table><tr><td rowspan="2">Variable</td><td rowspan="2">Control M (SD)</td><td rowspan="2">MCI M (SD)</td><td rowspan="2">AD M (SD)</td><td rowspan="2">P<sup>1</sup></td><td>P*</td><td> </td><td>P*</td><td> </td><td>P*</td></tr><tr><td>Control &#215; MCI</td><td> </td><td>Control &#215; AD</td><td> </td><td>MCI &#215; AD</td></tr><tr><td> RAVLT &#8211; Immediate recall (A1 to A5)</td><td>46.55 (2.11)</td><td>38.35 (1.52)</td><td>25.45 (1.94)</td><td>&lt;0.001</td><td>0.006</td><td> </td><td>&lt;0.001</td><td> </td><td>&lt;0.001</td></tr><tr><td>Delayed Recall (A7)</td><td>9.53 (0.68)</td><td>6.79 (0.49)</td><td>2.69 (0.62)</td><td>&lt;0.001</td><td>0.004</td><td> </td><td>&lt;0.001</td><td> </td><td>&lt;0.001</td></tr><tr><td>REC</td><td>14.56 (0.54)</td><td>13.04 (0.39)</td><td>10.48 (0.52)</td><td>&lt;0.001</td><td>0.067</td><td> </td><td>&lt;0.001</td><td> </td><td>&lt;0.001</td></tr><tr><td>BNT</td><td>52.84 (1.54)</td><td>49.55 (1.1)</td><td>46.44 (1.41)</td><td>0.012</td><td>0.237</td><td> </td><td>0.009</td><td> </td><td>0.234</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td rowspan="2">Control M (SD)</td><td rowspan="2">MCI M (SD)</td><td rowspan="2">AD M (SD)</td><td rowspan="2">P1</td><td>P*</td><td></td><td>P*</td><td></td><td>P*</td></tr><tr><td>Control × MCI</td><td></td><td>Control × AD</td><td></td><td>MCI × AD</td></tr><tr><td>RAVLT – Immediate recall (A1 to A5)</td><td>46.55 (2.11)</td><td>38.35 (1.52)</td><td>25.45 (1.94)</td><td><0.001</td><td>0.006</td><td></td><td><0.001</td><td></td><td><0.001</td></tr><tr><td>Delayed Recall (A7)</td><td>9.53 (0.68)</td><td>6.79 (0.49)</td><td>2.69 (0.62)</td><td><0.001</td><td>0.004</td><td></td><td><0.001</td><td></td><td><0.001</td></tr></table>
<table><tr><td>REC</td><td>14.56 (0.54)</td><td>13.04 (0.39)</td><td>10.48 (0.52)</td><td><0.001</td><td>0.067</td><td><0.001</td><td><0.001</td></tr><tr><td>BNT</td><td>52.84 (1.54)</td><td>49.55 (1.1)</td><td>46.44 (1.41)</td><td>0.012</td><td>0.237</td><td>0.009</td><td>0.234</td></tr></table>
5741eaf6b90237ad17a282b5a48ffa9f80c407e55b04ea2b662ae49cc093314c.png
complex
<table><tr><td>Input</td><td colspan="3">Membership Function</td></tr><tr><td>RSSI Level</td><td>Weak</td><td>Medium</td><td>Strong</td></tr><tr><td>Number of Neighbours</td><td>Low</td><td>Medium</td><td>High</td></tr><tr><td>Distance to each neighbour</td><td>Near</td><td>Medium</td><td>Far</td></tr></table>
<table><tr><td>Input</td><td colspan="3">Membership Function</td></tr><tr><td>RSSI Level</td><td>Weak</td><td>Medium</td><td>Strong</td></tr></table>
<table><tr><td>Number of Neighbours</td><td>Low</td><td>Medium</td><td>High</td></tr><tr><td>Distance to each neighbour</td><td>Near</td><td>Medium</td><td>Far</td></tr></table>
46544ca7b0f480ccdeadfeeea0f127320e2ac6856f6fb9d7336c5425b79a04dc.png
complex
<table><tr><td>Characteristic (<i>N =</i> 148)</td><td>Number</td><td>Percent</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td> Female</td><td>126</td><td>85.1</td></tr><tr><td>Grade level</td><td></td><td></td></tr><tr><td> Freshman</td><td>36</td><td>24.3</td></tr><tr><td> Sophomore</td><td>38</td><td>25.7</td></tr><tr><td> Junior</td><td>39</td><td>26.4</td></tr><tr><td> Senior</td><td>35</td><td>23.6</td></tr><tr><td>Experience of dementia education</td><td></td><td></td></tr><tr><td> Yes</td><td>63</td><td>42.6</td></tr><tr><td colspan="3">Average time of Experienced education (<i>n =</i> 63)</td></tr><tr><td> Less than 2 h</td><td>35</td><td>55.6</td></tr><tr><td> More than 2 h</td><td>28</td><td>44.4</td></tr><tr><td>Family member with dementia</td><td></td><td></td></tr><tr><td> Yes</td><td>24</td><td>16.2</td></tr><tr><td colspan="3">Experience in caring for persons with dementia</td></tr><tr><td> Yes</td><td>63</td><td>42.6</td></tr><tr><td colspan="3">Cared for people with dementia during clinical placement</td></tr><tr><td> Yes</td><td>62</td><td>41.9</td></tr><tr><td>Exposure to information on dementia</td><td></td><td></td></tr><tr><td> Yes</td><td>111</td><td>75.0</td></tr><tr><td>Information sources<sup>a</sup> (<i>n =</i> 111)</td><td></td><td></td></tr><tr><td> Broadcasting</td><td>64</td><td>43.2</td></tr><tr><td>Educational resources</td><td>64</td><td>43.2</td></tr><tr><td> Internet</td><td>40</td><td>27.0</td></tr><tr><td> Family/relatives</td><td>24</td><td>16.2</td></tr><tr><td> Newspaper</td><td>21</td><td>14.2</td></tr><tr><td> Magazine</td><td>2</td><td>1.4</td></tr><tr><td> Others</td><td>10</td><td>6.8</td></tr></table>
<table><tr><td>Characteristic (N = 148)</td><td>Number</td><td>Percent</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Female</td><td>126</td><td>85.1</td></tr><tr><td>Grade level</td><td></td><td></td></tr><tr><td>Freshman</td><td>36</td><td>24.3</td></tr><tr><td>Sophomore</td><td>38</td><td>25.7</td></tr><tr><td>Junior</td><td>39</td><td>26.4</td></tr><tr><td>Senior</td><td>35</td><td>23.6</td></tr><tr><td>Experience of dementia education</td><td></td><td></td></tr><tr><td>Yes</td><td>63</td><td>42.6</td></tr><tr><td colspan="3">Average time of Experienced education (n = 63)</td></tr><tr><td>Less than 2 h</td><td>35</td><td>55.6</td></tr><tr><td>More than 2 h</td><td>28</td><td>44.4</td></tr><tr><td>Family member with dementia</td><td></td><td></td></tr><tr><td>Yes</td><td>24</td><td>16.2</td></tr><tr><td colspan="3">Experience in caring for persons with dementia</td></tr><tr><td>Yes</td><td>63</td><td>42.6</td></tr><tr><td colspan="3">Cared for people with dementia during clinical placement</td></tr><tr><td>Yes</td><td>62</td><td>41.9</td></tr><tr><td>Exposure to information on dementia</td><td></td><td></td></tr><tr><td>Yes</td><td>111</td><td>75.0</td></tr><tr><td>Information sourcesa (n = 111)</td><td></td><td></td></tr><tr><td>Broadcasting</td><td>64</td><td>43.2</td></tr><tr><td>Educational resources</td><td>64</td><td>43.2</td></tr><tr><td>Internet</td><td>40</td><td>27.0</td></tr><tr><td>Family/relatives</td><td>24</td><td>16.2</td></tr></table>
<table><tr><td>Characteristic (N = 148)</td><td>Number</td><td>Percent</td></tr><tr><td>Newspaper</td><td>21</td><td>14.2</td></tr><tr><td>Magazine</td><td>2</td><td>1.4</td></tr><tr><td>Others</td><td>10</td><td>6.8</td></tr></table>
1e7477e8a4e79c12d9ba99db7c4a72a9f9bed84e364e9313026dca88c304a622.png
simple
<table><tr><td>Degrees of freedom</td><td>90%</td><td>95%</td></tr><tr><td>1</td><td>2.71</td><td>3.84</td></tr><tr><td>2</td><td>4.61</td><td>5.99</td></tr><tr><td>3</td><td>6.25</td><td>7.81</td></tr><tr><td>4</td><td>7.78</td><td>9.49</td></tr></table>
<table><tr><td>Degrees of freedom</td><td>90%</td><td>95%</td></tr><tr><td>1</td><td>2.71</td><td>3.84</td></tr><tr><td>2</td><td>4.61</td><td>5.99</td></tr><tr><td>3</td><td>6.25</td><td>7.81</td></tr></table>
<table><tr><td>4</td><td>7.78</td><td>9.49</td></tr></table>
6b4d1cc752db497e4d985150024f5ad989fe8813f6e52ce0029d9dee5789efd1.png
simple
<table><tr><td>Scale</td><td>Factor</td><td>N</td><td>%</td></tr><tr><td>SCL-90-R</td><td>Without psychopathology &gt; 0.99</td><td>62</td><td>44.6</td></tr><tr><td></td><td>Somatization (SOM) &gt; 0.99</td><td>47</td><td>33.8</td></tr><tr><td></td><td>Obsessive-compulsive (OC) &gt; 0.99</td><td>43</td><td>30.9</td></tr><tr><td></td><td>Interpersonal sensitivity (IS) &gt; 0.99</td><td>19</td><td>13.7</td></tr><tr><td></td><td>Depression (DEP) &gt; 0.99</td><td>50</td><td>36.0</td></tr><tr><td></td><td>Anxiety (ANX) &gt; 0.99</td><td>33</td><td>23.7</td></tr><tr><td></td><td>Hostility (HOS) &gt; 0.99</td><td>28</td><td>20.1</td></tr><tr><td></td><td>Phobic anxiety (PHO) &gt; 0.99</td><td>18</td><td>12.9</td></tr><tr><td></td><td>Paranoid ideation (PAR) &gt; 0.99</td><td>23</td><td>16.5</td></tr><tr><td></td><td>Psychoticism (PSY) &gt; 0.99</td><td>7</td><td>5.0</td></tr><tr><td>MQ</td><td>Vital exhaustion &gt; 18</td><td>71</td><td>51.1</td></tr></table>
<table><tr><td>Scale</td><td>Factor</td><td>N</td><td>%</td></tr><tr><td>SCL-90-R</td><td>Without psychopathology > 0.99</td><td>62</td><td>44.6</td></tr></table>
<table><tr><td>Scale</td><td>Factor</td><td>N</td><td>%</td></tr><tr><td></td><td>Somatization (SOM) > 0.99</td><td>47</td><td>33.8</td></tr><tr><td></td><td>Obsessive-compulsive (OC) > 0.99</td><td>43</td><td>30.9</td></tr><tr><td></td><td>Interpersonal sensitivity (IS) > 0.99</td><td>19</td><td>13.7</td></tr><tr><td></td><td>Depression (DEP) > 0.99</td><td>50</td><td>36.0</td></tr><tr><td></td><td>Anxiety (ANX) > 0.99</td><td>33</td><td>23.7</td></tr><tr><td></td><td>Hostility (HOS) > 0.99</td><td>28</td><td>20.1</td></tr><tr><td></td><td>Phobic anxiety (PHO) > 0.99</td><td>18</td><td>12.9</td></tr><tr><td></td><td>Paranoid ideation (PAR) > 0.99</td><td>23</td><td>16.5</td></tr><tr><td></td><td>Psychoticism (PSY) > 0.99</td><td>7</td><td>5.0</td></tr><tr><td>MQ</td><td>Vital exhaustion > 18</td><td>71</td><td>51.1</td></tr></table>
3bccc8d9e82a743d16f3315e3d83c73139338e208bb11708765d524bbaa8fb05.png
simple
<table><tr><td>Clade</td><td>Combined-data and mtDNA</td><td>Combined-data and nucDNA</td><td>mtDNA and nucDNA</td></tr><tr><td>Balistid fish</td><td>16%</td><td>24%</td><td>11%</td></tr><tr><td>Scarine fish</td><td>83%</td><td>63%</td><td>50%</td></tr><tr><td>Hemiphractid frogs</td><td>64%</td><td>52%</td><td>30%</td></tr><tr><td>Hylid frogs</td><td>27%</td><td>44%</td><td>13%</td></tr><tr><td><i>Plethodon </i>salamanders</td><td>73%</td><td>27%</td><td>23%</td></tr><tr><td>Phrynosomatid lizards</td><td>37%</td><td>71%</td><td>26%</td></tr><tr><td>Alcid birds</td><td>91%</td><td>33%</td><td>23%</td></tr><tr><td>Caprimulgid birds</td><td>53%</td><td>82%</td><td>38%</td></tr><tr><td>Cotingid birds</td><td>53%</td><td>71%</td><td>35%</td></tr><tr><td>Dicaeid birds</td><td>80%</td><td>34%</td><td>24%</td></tr><tr><td>Emydid turtles</td><td>54%</td><td>60%</td><td>37%</td></tr><tr><td>Cervid mammals</td><td>99%</td><td>37%</td><td>27%</td></tr><tr><td>Murid rodents (Philippines)</td><td>30%</td><td>63%</td><td>23%</td></tr><tr><td>Murid rodents (Sahul)</td><td>55%</td><td>96%</td><td>53%</td></tr></table>
<table><tr><td>Clade</td><td>Combined-data and mtDNA</td><td>Combined-data and nucDNA</td><td>mtDNA and nucDNA</td></tr><tr><td>Balistid fish</td><td>16%</td><td>24%</td><td>11%</td></tr><tr><td>Scarine fish</td><td>83%</td><td>63%</td><td>50%</td></tr><tr><td>Hemiphractid frogs</td><td>64%</td><td>52%</td><td>30%</td></tr><tr><td>Hylid frogs</td><td>27%</td><td>44%</td><td>13%</td></tr><tr><td>Plethodon salamanders</td><td>73%</td><td>27%</td><td>23%</td></tr><tr><td>Phrynosomatid lizards</td><td>37%</td><td>71%</td><td>26%</td></tr><tr><td>Alcid birds</td><td>91%</td><td>33%</td><td>23%</td></tr><tr><td>Caprimulgid birds</td><td>53%</td><td>82%</td><td>38%</td></tr><tr><td>Cotingid birds</td><td>53%</td><td>71%</td><td>35%</td></tr><tr><td>Dicaeid birds</td><td>80%</td><td>34%</td><td>24%</td></tr><tr><td>Emydid turtles</td><td>54%</td><td>60%</td><td>37%</td></tr><tr><td>Cervid mammals</td><td>99%</td><td>37%</td><td>27%</td></tr><tr><td>Murid rodents (Philippines)</td><td>30%</td><td>63%</td><td>23%</td></tr><tr><td>Murid r</td><td></td><td></td><td>53%</td></tr></table>
<table><tr><td>Clade</td><td>Combined-data and mtDNA</td><td>Combined-data and nucDNA</td><td>mtDNA and nucDNA</td></tr><tr><td>odents (Sahul)</td><td>55%</td><td>96%</td><td></td></tr></table>
be7e1c255029bde7cda06ae6e238b0cdd8a1aac11f07e85df06184e09d0a0c13.png
complex
<table><tr><td></td><td>Mean</td><td>Sd</td><td>Median</td><td>Iqr</td><td><i>P</i>-value</td></tr><tr><td colspan="6">Sex</td></tr><tr><td> M</td><td>118.17</td><td>18.37</td><td>117.5</td><td>17</td><td>0.0326*</td></tr><tr><td> F</td><td>112.46</td><td>19.13</td><td>114</td><td>20</td><td></td></tr><tr><td colspan="6">University</td></tr><tr><td> Pavia</td><td>120</td><td>20.06</td><td>118</td><td>16</td><td>0.0001**</td></tr><tr><td> Rome Biomedico Campus</td><td>109.77</td><td>15.81</td><td>110.5</td><td>19</td><td></td></tr><tr><td> Rome Tor Vergata</td><td>111.70</td><td>20.81</td><td>116</td><td>14</td><td></td></tr><tr><td colspan="6">Education</td></tr><tr><td> Junior (I &#8211; II years)</td><td>112.46</td><td>14.31</td><td>114</td><td>17</td><td>0.0253*</td></tr><tr><td> Senior (III year)</td><td>116.18</td><td>26.59</td><td>118</td><td>24</td><td></td></tr></table>
<table><tr><td></td><td>Mean</td><td>Sd</td><td>Median</td><td>Iqr</td><td>P-value</td></tr><tr><td colspan="6">Sex</td></tr><tr><td>M</td><td>118.17</td><td>18.37</td><td>117.5</td><td>17</td><td>0.0326*</td></tr><tr><td>F</td><td>112.46</td><td>19.13</td><td>114</td><td>20</td><td></td></tr><tr><td colspan="6">University</td></tr><tr><td>Pavia</td><td>120</td><td>20.06</td><td>118</td><td>16</td><td>0.0001**</td></tr><tr><td>Rome Biomedico Campus</td><td>109.77</td><td>15.81</td><td>110.5</td><td>19</td><td></td></tr><tr><td>Rome Tor Vergata</td><td>111.70</td><td>20.81</td><td>116</td><td>14</td><td></td></tr></table>
<table><tr><td colspan="6">Education</td></tr><tr><td>Junior (I – II years)</td><td>112.46</td><td>14.31</td><td>114</td><td>17</td><td>0.0253*</td></tr><tr><td>Senior (III year)</td><td>116.18</td><td>26.59</td><td>118</td><td>24</td><td></td></tr></table>
4bab918b39dd5e367e5cecea23884918eaa587761664b88272ede27fb2d5a2ff.png
simple
<table><tr><td>Human region</td><td>Avian region</td><td>Reference</td></tr><tr><td>Nucleus accumbens (nAc)</td><td>Nucleus accumbens (nAc)</td><td>Balint and Csillag (2007), Husband and Shimizu (2011)</td></tr><tr><td>Ventral tegmental area (VTA)</td><td>Ventral tegmental area (VTA)</td><td>Bottjer (1993), Reiner et al. (1994)</td></tr><tr><td>Caudate nucleus</td><td>Lateral striatum (LSt)</td><td>Karten (1969), Reiner et al. (1998)</td></tr><tr><td>Hippocampus (Hp)</td><td>Hippocampus (Hp)</td><td>Erichsen et al. (1991)</td></tr><tr><td>Medial amygdala (MeA)</td><td>Nucleus taeniae of the amygdala (TnA)</td><td>Cheng et al. (1999), Reiner and Karten (1985)</td></tr><tr><td>Prefrontal cortex (PFC)</td><td>Caudolateral nidopallium (NCL)</td><td>Mogensen and Divac (1982), Waldmann and Gu&#776;ntu&#776;rku&#776;n (1993)</td></tr></table>
<table><tr><td>Human region</td><td>Avian region</td><td>Reference</td></tr><tr><td>Nucleus accumbens (nAc)</td><td>Nucleus accumbens (nAc)</td><td>Balint and Csillag (2007), Husband and Shimizu (2011)</td></tr><tr><td>Ventral tegmental area (VTA)</td><td>Ventral tegmental area (VTA)</td><td>Bottjer (1993), Reiner et al. (1994)</td></tr><tr><td>Caudate nucleu</td><td>La</td><td>K</td></tr></table>
<table><tr><td>Human region</td><td>Avian region</td><td>Reference</td></tr><tr><td>s</td><td>teral striatum (LSt)</td><td>arten (1969), Reiner et al. (1998)</td></tr><tr><td>Hippocampus (Hp)</td><td>Hippocampus (Hp)</td><td>Erichsen et al. (1991)</td></tr><tr><td>Medial amygdala (MeA)</td><td>Nucleus taeniae of the amygdala (TnA)</td><td>Cheng et al. (1999), Reiner and Karten (1985)</td></tr><tr><td>Prefrontal cortex (PFC)</td><td>Caudolateral nidopallium (NCL)</td><td>Mogensen and Divac (1982), Waldmann and Güntürkün (1993)</td></tr></table>
49359ce3f5daf4139004cef752c55d7ed8b66ff0372ce9ea67655efea17d0fae.png
complex
<table><tr><td></td><td>2007</td><td colspan="5">2012</td><td></td></tr><tr><td></td><td></td><td colspan="5">Exposed to the intervention</td><td></td></tr><tr><td rowspan="2"></td><td rowspan="2"></td><td>Never</td><td>Once</td><td>Twice or more</td><td rowspan="2">Total</td><td rowspan="2"><i>p*</i></td><td rowspan="2"><i>P**</i></td></tr><tr><td>(n = 210)</td><td>(n = 63)</td><td>(n = 180)</td></tr><tr><td>Knowledge of HIV prevention methods</td><td>38.8%</td><td>59.0%</td><td>71.4%</td><td>79.4%</td><td>68.6%</td><td><i>&lt;10</i><sup><i>&#8722;3</i></sup></td><td><i>&lt;10</i><sup><i>&#8722;3</i></sup></td></tr><tr><td>Condom use during the most recent sexual encounter with a sex worker</td><td>35.5%</td><td>40.5%</td><td>68.3%</td><td>78.5%</td><td>60.3%</td><td><i>&lt;10</i><sup><i>&#8722;3</i></sup></td><td><i>0.34</i></td></tr><tr><td>Systematic condom use with a sex worker in the previous 12 months</td><td>12.8%</td><td>10.5%</td><td>19.0</td><td>35.0</td><td>21.4%</td><td><i>&lt;10</i><sup><i>&#8722;3</i></sup></td><td><i>0.38</i></td></tr><tr><td>Voluntary HIV testing and counselling in the previous 12 months</td><td>4.3%</td><td>6.7%</td><td>27.0%</td><td>57.8%</td><td>29.6%</td><td><i>&lt;10</i><sup><i>&#8722;3</i></sup></td><td><i>0.20</i></td></tr><tr><td>Knowledge of non-AIDS STI symptoms (men)</td><td>24.6%</td><td>25.7%</td><td>31.7%</td><td>36.7%</td><td>30.7%</td><td><i>0.02</i></td><td><i>0.75</i></td></tr><tr><td>Knowledge of non-AIDS STI symptoms (women)</td><td>13.4%</td><td>9.5%</td><td>14.3%</td><td>20.0%</td><td>14.2%</td><td><i>0.03</i></td><td><i>0.15</i></td></tr><tr><td>Knowledge that the results of HIV test would remain confidential</td><td>23.3%</td><td>75.1%</td><td>83.9%</td><td>92.2%</td><td>83.2%</td><td><i>&lt;10</i><sup><i>&#8722;3</i></sup></td><td><i>&lt;10</i><sup><i>&#8722;3</i></sup></td></tr></table>
<table><tr><td></td><td>2007</td></tr><tr><td></td><td></td></tr><tr><td rowspan="2"></td><td rowspan="2"></td></tr><tr></tr><tr><td>Knowledge of HIV prevention methods</td><td>38.8%</td></tr><tr><td>Condom use during the most recent sexual encounter with a sex worker</td><td>35.5%</td></tr><tr><td>Systematic condom use with a sex worker in the previous 12 months</td><td>12.8%</td></tr><tr><td>Voluntary HIV testing and counselling in the previous 12 months</td><td>4.3%</td></tr><tr><td>Knowledge of non-AIDS STI symptoms (men)</td><td>24.6%</td></tr><tr><td>Knowledge of non-AIDS STI symptoms (women)</td><td>13.4%</td></tr><tr><td>Knowledge that the results of HIV test would remain confidential</td><td>23.3%</td></tr></table>
<table><tr><td colspan="5">2012</td><td></td></tr><tr><td colspan="5">Exposed to the intervention</td><td></td></tr><tr><td>Never</td><td>Once</td><td>Twice or more</td><td rowspan="2">Total</td><td rowspan="2">p*</td><td rowspan="2">P**</td></tr><tr><td>(n = 210)</td><td>(n = 63)</td><td>(n = 180)</td></tr><tr><td>59.0%</td><td>71.4%</td><td>79.4%</td><td>68.6%</td><td><10−3</td><td><10−3</td></tr><tr><td>40.5%</td><td>68.3%</td><td>78.5%</td><td>60.3%</td><td><10−3</td><td>0.34</td></tr><tr><td>10.5%</td><td>19.0</td><td>35.0</td><td>21.4%</td><td><10−3</td><td>0.38</td></tr><tr><td>6.7%</td><td>27.0%</td><td>57.8%</td><td>29.6%</td><td><10−3</td><td>0.20</td></tr><tr><td>25.7%</td><td>31.7%</td><td>36.7%</td><td>30.7%</td><td>0.02</td><td>0.75</td></tr><tr><td>9.5%</td><td>14.3%</td><td>20.0%</td><td>14.2%</td><td>0.03</td><td>0.15</td></tr><tr><td>75.1%</td><td>83.9%</td><td>92.2%</td><td>83.2%</td><td><10−3</td><td><10−3</td></tr></table>
27342fd9e5ce2f17e5f2853df36d74859aa5636e90f7a9fbf3238ece39dfc004.png
simple
<table><tr><td> </td><td>Mortality 2003</td><td>Mortality 2010</td><td>Unadjusted HR</td><td>Adjusted HR *</td><td>Adjusted HR &#8224;</td></tr><tr><td> </td><td>N/total (%)</td><td>N/total (%)</td><td>(95% CI)</td><td>(95% CI)</td><td>(95% CI)</td></tr><tr><td>Total</td><td>333/1624 (20.5)</td><td>488/3809 (12.8)</td><td>0.59 (0.51-0.67)</td><td>0.65 (0.56-0.75)</td><td>0.79 (0.65-0.96)</td></tr><tr><td>LVEF &#8804;40%</td><td>277/1379 (20.1)</td><td>408/3141 (13.0)</td><td>0.61 (0.52-0.71)</td><td>0.67 (0.57-0.78)</td><td>0.85 (0.69-1.05)</td></tr><tr><td>LVEF &gt;40%</td><td>56/245 (22.9)</td><td>79/668 (11.8)</td><td>0.47 (0.31-0.74)</td><td>0.58 (0.40-0.84)</td><td>0.51 (0.30-0.89)</td></tr></table>
<table><tr><td></td><td>Mortality 2003</td><td>Mortality 2010</td><td>Unadjusted HR</td><td>Adjusted HR *</td><td>Adjusted HR †</td></tr><tr><td></td><td>N/total (%)</td><td>N/total (%)</td><td>(95% CI)</td><td>(95% CI)</td><td>(95% CI)</td></tr></table>
<table><tr><td>Total</td><td>333/1624 (20.5)</td><td>488/3809 (12.8)</td><td>0.59 (0.51-0.67)</td><td>0.65 (0.56-0.75)</td><td>0.79 (0.65-0.96)</td></tr><tr><td>LVEF ≤40%</td><td>277/1379 (20.1)</td><td>408/3141 (13.0)</td><td>0.61 (0.52-0.71)</td><td>0.67 (0.57-0.78)</td><td>0.85 (0.69-1.05)</td></tr><tr><td>LVEF >40%</td><td>56/245 (22.9)</td><td>79/668 (11.8)</td><td>0.47 (0.31-0.74)</td><td>0.58 (0.40-0.84)</td><td>0.51 (0.30-0.89)</td></tr></table>
7922adb89048dcd95cc2b3449f075661df3cb51facc29134c46b3897f0a222fe.png
simple
<table><tr><td>Study</td><td>Type of study</td><td>No. of patients receiving short-term radiotherapy (%)</td><td>Experimental group^No of DR/No of patients(%)</td><td>Control groupNo of DR/No of patients (%)</td><td><i>P</i> value</td></tr><tr><td>Nowacki et al. (2004) [4]</td><td>Randomized</td><td>78 (40.4)</td><td>10/97(10.3)</td><td>27/96(28.1)</td><td>0.002</td></tr><tr><td>Collin et al. (2012) [19]</td><td>Randomized</td><td>54 (100.0)</td><td>9/26(34.6)</td><td>14/28(50.0)</td><td>0.467</td></tr><tr><td>Present study</td><td>Randomized</td><td>162 (100.0)</td><td>9/81(11.1)</td><td>21/81(25.9)</td><td>0.026</td></tr><tr><td>Total</td><td>&#8211;</td><td>294 (72.9)</td><td>28/204(13.7)</td><td>60/205(29.3)</td><td>&lt; 0.001</td></tr></table>
<table><tr><td>Study</td><td>Type of study</td><td>No. of patients receiving short-term radiotherapy (%)</td><td>Experimental group^No of DR/No of patients(%)</td><td>Control groupNo of DR/No of patients (%)</td><td>P value</td></tr><tr><td>Nowacki et al. (2004) [4]</td><td>Randomized</td><td>78 (40.4)</td><td>10/97(10.3)</td><td>27/96(28.1)</td><td>0.002</td></tr><tr><td>Collin et al. (2012) [19]</td><td>Randomized</td><td>54 (100.0)</td><td>9/26(34.6)</td><td>14/28(50.0)</td><td>0.467</td></tr><tr><td>Present study</td><td>Randomized</td><td>162 (100.0)</td><td>9/81(11.1)</td><td>21/81(25.9)</td><td>0.026</td></tr></table>
<table><tr><td>Study</td><td>Type of study</td><td>No. of patients receiving short-term radiotherapy (%)</td><td>Experimental group^No of DR/No of patients(%)</td><td>Control groupNo of DR/No of patients (%)</td><td>P value</td></tr><tr><td>Total</td><td>–</td><td>294 (72.9)</td><td>28/204(13.7)</td><td>60/205(29.3)</td><td>< 0.001</td></tr></table>
ebcc7b910d91f414f46b368af72afdc42c422ddb697601f2fba17506e8f94f0d.png
simple
<table><tr><td>Factor</td><td>Coefficient</td><td><i>Z</i></td><td><i>P</i></td></tr><tr><td>Range (native)</td><td>1.122</td><td>3.16</td><td>0.0016*</td></tr><tr><td>Fish (present)</td><td>0.106</td><td>0.25</td><td>0.8000</td></tr><tr><td>Food Quality (low)</td><td>1.128</td><td>3.18</td><td>0.0015*</td></tr><tr><td>Range*Fish</td><td>0.042</td><td>0.09</td><td>0.9300</td></tr><tr><td>Range*Food Quality</td><td>&#8722;1.178</td><td>&#8722;2.67</td><td>0.0075*</td></tr><tr><td>Fish*Food Quality</td><td>&#8722;0.988</td><td>&#8722;1.88</td><td>0.0600</td></tr><tr><td>Range*Fish*Food Quality</td><td>1.254</td><td>1.99</td><td>0.0470*</td></tr></table>
<table><tr><td>Factor</td><td>Coefficient</td></tr><tr><td>Range (native)</td><td>1.122</td></tr><tr><td>Fish (present)</td><td>0.106</td></tr><tr><td>Food Quality (low)</td><td>1.128</td></tr><tr><td>Range*Fish</td><td>0.042</td></tr><tr><td>Range*Food Quality</td><td>−1.178</td></tr><tr><td>Fish*Food Quality</td><td>−0.988</td></tr><tr><td>Range*Fish*Food Quality</td><td>1.254</td></tr></table>
<table><tr><td>Z</td><td>P</td></tr><tr><td>3.16</td><td>0.0016*</td></tr><tr><td>0.25</td><td>0.8000</td></tr><tr><td>3.18</td><td>0.0015*</td></tr><tr><td>0.09</td><td>0.9300</td></tr><tr><td>−2.67</td><td>0.0075*</td></tr><tr><td>−1.88</td><td>0.0600</td></tr><tr><td>1.99</td><td>0.0470*</td></tr></table>
a69638a84e030ba5621c0bff1ea17c475c167c4173ca9d2c847e634385125a2d.png
complex
<table><tr><td> </td><td colspan="4">Number of parathyroid glands in resected specimen</td><td colspan="2"><i>P</i>-value</td></tr><tr><td>Variable</td><td>0 (A) N = 364</td><td>1(B) N = 80</td><td>2 or more (C) N = 10</td><td>Total n = 454</td><td>A versus B</td><td>B versus C</td></tr><tr><td>CND</td><td> </td><td> </td><td> </td><td> </td><td>&lt;0.001</td><td>0.749</td></tr><tr><td>None</td><td>118 (32.4%)</td><td>4 (5.0%)</td><td>0</td><td>122 (26.9%)</td><td> </td><td> </td></tr><tr><td>Unilateral</td><td>91 (25.0%)</td><td>13 (16.3%)</td><td>2 (20.0%)</td><td>106 (23.3%)</td><td> </td><td> </td></tr><tr><td>Bilateral</td><td>155 (42.6%)</td><td>63 (78.8%)</td><td>8 (80.0%)</td><td>226 (49.8%)</td><td> </td><td> </td></tr><tr><td>Retrieved CLN (No)</td><td>5.0 &#177; 5.5</td><td>7.4 &#177; 5.2</td><td>7.7 &#177; 2.8</td><td>5.5 &#177; 5.5</td><td>&lt; 0.001</td><td>0.641</td></tr><tr><td>Metastatic CLN (No)</td><td>1.2 &#177; 2.6</td><td>2.1 &#177; 3.3</td><td>2.3 &#177; 2.8</td><td>1.4 &#177; 2.8</td><td>0.001</td><td>0.748</td></tr><tr><td>Lateral ND</td><td>51/364 (14.0%)</td><td>18/80 (22.5%)</td><td>2/10 (20%)</td><td>71/454 (15.6%)</td><td>0.062</td><td>0.610</td></tr><tr><td>Operation time (minutes)</td><td>162.2 &#177; 73.7</td><td>179.1 &#177; 93.6</td><td>198.0 &#177; 142.5</td><td>166.0 &#177; 79.6</td><td>0.218</td><td>0.651</td></tr><tr><td>PTH, preop</td><td>38.35 &#177; 15.06</td><td>39.13 &#177; 14.09</td><td>34.23 &#177; 12.37</td><td>38.38 &#177; 14.81</td><td>0.701</td><td>0.432</td></tr><tr><td>PTH, postop 1 day</td><td>14.77 &#177; 11.82</td><td>11.71 &#177; 8.90</td><td>11.95 &#177; 11.32</td><td>14.15 &#177; 11.32</td><td>0.062</td><td>0.716</td></tr><tr><td>PTH, postop 1 week</td><td>21.39 &#177; 13.46</td><td>18.89 &#177; 11.12</td><td>17.07 &#177; 9.13</td><td>20.86 &#177; 13.02</td><td>0.125</td><td>0.813</td></tr><tr><td>PTH, postop 6 months</td><td>32.54 &#177; 15.04</td><td>31.25 &#177; 15.33</td><td>26.22 &#177; 14.87</td><td>32.11 &#177; 15.10</td><td>0.378</td><td>0.346</td></tr><tr><td>Dec. ratio, postop 1 day</td><td>58.65 &#177; 33.43</td><td>63.54 &#177; 35.55</td><td>67.55 &#177; 15.98</td><td>59.74 &#177; 33.49</td><td>0177</td><td>0.722</td></tr><tr><td>Dec. ratio, postop 1 week</td><td>40.52 &#177; 38.23</td><td>49.45 &#177; 24.49</td><td>41.39 &#177; 38</td><td>41.39 &#177; 38.63</td><td>0.248</td><td>0.910</td></tr><tr><td>Dec. ratio, postop 6 months</td><td>7.09 &#177; 53.72</td><td>13.24 &#177; 50.51</td><td>21.49 &#177; 43.53</td><td>8.71 &#177; 52.80</td><td>0.124</td><td>0.813</td></tr><tr><td>Hypoparathyroidism</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Temporary</td><td>194/364 (53.3%)</td><td>53/80 (66.3%)</td><td>7/10 (70%)</td><td>254 (55.9%)</td><td>0.010</td><td>0.697</td></tr><tr><td>Permanent</td><td>13/364 (3.6%)</td><td>6/80 (7.5%)</td><td>1/10 (10%)</td><td>20 (4.4%)</td><td>0.128</td><td>0.575</td></tr><tr><td>IV calcium administration</td><td>27/364 (7.4%)</td><td>10/80 (12.5%)</td><td>3/10 (30%)</td><td>40/454 (8.8%)</td><td>0.177</td><td>0.155</td></tr><tr><td>Vocal cord paralysis</td><td> </td><td> </td><td> </td><td> </td><td>0.787</td><td>0.093</td></tr><tr><td>None</td><td>351 (96.2%)</td><td>77 (96.3%)</td><td>8 (80%)</td><td>436 (96.0%)</td><td> </td><td> </td></tr><tr><td>Temporary</td><td>12 (3.3%)</td><td>3 (3.8%)</td><td>2 (20%)</td><td>17 (3.7%)</td><td> </td><td> </td></tr><tr><td>Permanent</td><td>1 (0.3%)</td><td>0</td><td>0</td><td>1 (0.2%)</td><td> </td><td> </td></tr><tr><td>Hematoma</td><td>15/364 (4.1%)</td><td>4/80 (5%)</td><td>0</td><td>19/454 (4.2%)</td><td>0.760</td><td>0.619</td></tr></table>
<table><tr><td></td><td colspan="4">Number of parathyroid glands in resected specimen</td><td colspan="2">P-value</td></tr><tr><td>Variable</td><td>0 (A) N = 364</td><td>1(B) N = 80</td><td>2 or more (C) N = 10</td><td>Total n = 454</td><td>A versus B</td><td>B versus C</td></tr><tr><td>CND</td><td></td><td></td><td></td><td></td><td><0.001</td><td>0.749</td></tr><tr><td>None</td><td>118 (32.4%)</td><td>4 (5.0%)</td><td>0</td><td>122 (26.9%)</td><td></td><td></td></tr><tr><td>Unilateral</td><td>91 (25.0%)</td><td>13 (16.3%)</td><td>2 (20.0%)</td><td>106 (23.3%)</td><td></td><td></td></tr><tr><td>Bilateral</td><td>155 (42.6%)</td><td>63 (78.8%)</td><td>8 (80.0%)</td><td>226 (49.8%)</td><td></td><td></td></tr><tr><td>Retrieved CLN (No)</td><td>5.0 ± 5.5</td><td>7.4 ± 5.2</td><td>7.7 ± 2.8</td><td>5.5 ± 5.5</td><td>< 0.001</td><td>0.641</td></tr><tr><td>Metastatic CLN (No)</td><td>1.2 ± 2.6</td><td>2.1 ± 3.3</td><td>2.3 ± 2.8</td><td>1.4 ± 2.8</td><td>0.001</td><td>0.748</td></tr></table>
<table><tr><td>Lateral ND</td><td>51/364 (14.0%)</td><td>18/80 (22.5%)</td><td>2/10 (20%)</td><td>71/454 (15.6%)</td><td>0.062</td><td>0.610</td></tr><tr><td>Operation time (minutes)</td><td>162.2 ± 73.7</td><td>179.1 ± 93.6</td><td>198.0 ± 142.5</td><td>166.0 ± 79.6</td><td>0.218</td><td>0.651</td></tr><tr><td>PTH, preop</td><td>38.35 ± 15.06</td><td>39.13 ± 14.09</td><td>34.23 ± 12.37</td><td>38.38 ± 14.81</td><td>0.701</td><td>0.432</td></tr><tr><td>PTH, postop 1 day</td><td>14.77 ± 11.82</td><td>11.71 ± 8.90</td><td>11.95 ± 11.32</td><td>14.15 ± 11.32</td><td>0.062</td><td>0.716</td></tr><tr><td>PTH, postop 1 week</td><td>21.39 ± 13.46</td><td>18.89 ± 11.12</td><td>17.07 ± 9.13</td><td>20.86 ± 13.02</td><td>0.125</td><td>0.813</td></tr><tr><td>PTH, postop 6 months</td><td>32.54 ± 15.04</td><td>31.25 ± 15.33</td><td>26.22 ± 14.87</td><td>32.11 ± 15.10</td><td>0.378</td><td>0.346</td></tr><tr><td>Dec. ratio, postop 1 day</td><td>58.65 ± 33.43</td><td>63.54 ± 35.55</td><td>67.55 ± 15.98</td><td>59.74 ± 33.49</td><td>0177</td><td>0.722</td></tr><tr><td>Dec. ratio, postop 1 week</td><td>40.52 ± 38.23</td><td>49.45 ± 24.49</td><td>41.39 ± 38</td><td>41.39 ± 38.63</td><td>0.248</td><td>0.910</td></tr><tr><td>Dec. ratio, postop 6 months</td><td>7.09 ± 53.72</td><td>13.24 ± 50.51</td><td>21.49 ± 43.53</td><td>8.71 ± 52.80</td><td>0.124</td><td>0.813</td></tr><tr><td>Hypoparathyroidism</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Temporary</td><td>194/364 (53.3%)</td><td>53/80 (66.3%)</td><td>7/10 (70%)</td><td>254 (55.9%)</td><td>0.010</td><td>0.697</td></tr><tr><td>Permanent</td><td>13/364 (3.6%)</td><td>6/80 (7.5%)</td><td>1/10 (10%)</td><td>20 (4.4%)</td><td>0.128</td><td>0.575</td></tr><tr><td>IV calcium administration</td><td>27/364 (7.4%)</td><td>10/80 (12.5%)</td><td>3/10 (30%)</td><td>40/454 (8.8%)</td><td>0.177</td><td>0.155</td></tr><tr><td>Vocal cord paralysis</td><td></td><td></td><td></td><td></td><td>0.787</td><td>0.093</td></tr><tr><td>None</td><td>351 (96.2%)</td><td>77 (96.3%)</td><td>8 (80%)</td><td>436 (96.0%)</td><td></td><td></td></tr><tr><td>Temporary</td><td>12 (3.3%)</td><td>3 (3.8%)</td><td>2 (20%)</td><td>17 (3.7%)</td><td></td><td></td></tr><tr><td>Permanent</td><td>1 (0.3%)</td><td>0</td><td>0</td><td>1 (0.2%)</td><td></td><td></td></tr><tr><td>Hematoma</td><td>15/364 (4.1%)</td><td>4/80 (5%)</td><td>0</td><td>19/454 (4.2%)</td><td>0.760</td><td>0.619</td></tr></table>
95af753059c54a6745ead8b12ebca50699dc47f48ded7203dbda49cf4571ca5c.png
complex
<table><tr><td colspan="2">EGFR/ACTB (cutoff 0.05)</td><td colspan="5">EFEMP1/ACTB (cutoff 0.06)</td></tr><tr><td colspan="2">All gliomas<sup>a</sup></td><td colspan="2">All gliomas</td><td>GBM(95 pts, 88 died)</td><td>AA(36 pts, 23 died)</td><td>OT(35 pts, 18 died)</td></tr><tr><td>1.0 (0.7, 1.4)</td><td>P = 0.85</td><td>0.6 (0.4, 1.0)</td><td>P = 0.037</td><td>0.7 (0.4, 1.1)</td><td>1.0 (0.4, 2.3)</td><td>2.4 (0.5, 11)</td></tr></table>
<table><tr><td colspan="2">EGFR/ACTB (cutoff 0.05)</td><td colspan="5">EFEMP1/ACTB (cutoff 0.06)</td></tr><tr><td colspan="2">All gliomasa</td><td colspan="2">All gliomas</td><td>GBM(95 pts, 88 died)</td><td>AA(36 pts, 23 died)</td><td>OT(35 pts, 18 died)</td></tr></table>
<table><tr><td>1.0 (0.7, 1.4)</td><td>P = 0.85</td><td>0.6 (0.4, 1.0)</td><td>P = 0.037</td><td>0.7 (0.4, 1.1)</td><td>1.0 (0.4, 2.3)</td><td>2.4 (0.5, 11)</td></tr></table>
25d438393e0b59e8bd5f2c7f1692074c77595703bac48ecbaefb0794a65ae6fc.png
complex
<table><tr><td rowspan="2">Carbon source</td><td rowspan="2">Dry weight of mycelial mat (mg/flask)</td><td rowspan="2">Protein content (mg/ml)</td><td colspan="3">Cellulase</td></tr><tr><td><sup>a</sup>FPase (FPU/ml)</td><td><sup>b</sup>CMCase (U/ml)</td><td><sup>c</sup>&#914;-glucosidase (U/ml)</td></tr><tr><td>Sarbose</td><td>420</td><td>2.17</td><td>3.53</td><td>8.23</td><td>1.16</td></tr><tr><td>Maltose</td><td>369</td><td>2.37</td><td>8.24</td><td>10.35</td><td>1.67</td></tr><tr><td>Sucrose</td><td>275</td><td>2.05</td><td>5.40</td><td>13.18</td><td>1.87</td></tr><tr><td>Lactose</td><td>497</td><td>2.78</td><td>9.12</td><td>24.70</td><td>2.32</td></tr><tr><td>Dextrose</td><td>412</td><td>2.45</td><td>5.18</td><td>10.35</td><td>1.04</td></tr><tr><td>Galactose</td><td>445</td><td>2.12</td><td>6.82</td><td>14.35</td><td>2.01</td></tr><tr><td>Cellobiose</td><td>338</td><td>1.92</td><td>-nd-</td><td>14.12</td><td>1.46</td></tr><tr><td>CMC</td><td>529</td><td>1.97</td><td>4.71</td><td>18.82</td><td>1.95</td></tr><tr><td>Control</td><td>378</td><td>2.28</td><td>5.99</td><td>11.99</td><td>1.98</td></tr></table>
<table><tr><td rowspan="2">Carbon source</td><td rowspan="2">Dry weight of mycelial mat (mg/flask)</td><td rowspan="2">Protein content (mg/ml)</td><td colspan="3">Cellulase</td></tr><tr><td>aFPase (FPU/ml)</td><td>bCMCase (U/ml)</td><td>cΒ-glucosidase (U/ml)</td></tr></table>
<table><tr><td>Sarbose</td><td>420</td><td>2.17</td><td>3.53</td><td>8.23</td><td>1.16</td></tr><tr><td>Maltose</td><td>369</td><td>2.37</td><td>8.24</td><td>10.35</td><td>1.67</td></tr><tr><td>Sucrose</td><td>275</td><td>2.05</td><td>5.40</td><td>13.18</td><td>1.87</td></tr><tr><td>Lactose</td><td>497</td><td>2.78</td><td>9.12</td><td>24.70</td><td>2.32</td></tr><tr><td>Dextrose</td><td>412</td><td>2.45</td><td>5.18</td><td>10.35</td><td>1.04</td></tr><tr><td>Galactose</td><td>445</td><td>2.12</td><td>6.82</td><td>14.35</td><td>2.01</td></tr><tr><td>Cellobiose</td><td>338</td><td>1.92</td><td>-nd-</td><td>14.12</td><td>1.46</td></tr><tr><td>CMC</td><td>529</td><td>1.97</td><td>4.71</td><td>18.82</td><td>1.95</td></tr><tr><td>Control</td><td>378</td><td>2.28</td><td>5.99</td><td>11.99</td><td>1.98</td></tr></table>
c47fa62011d2415bfcb6e4d33673d2c1c201d1f99ab1f084328938a17e73cb69.png
complex
<table><tr><td rowspan="2">Source</td><td rowspan="2">WT categories</td><td rowspan="2">Sample size</td><td colspan="2">HR (95%CI)</td></tr><tr><td>OS</td><td>DFS/RFS/EFS</td></tr><tr><td rowspan="2">Pronzato <i>et al</i>. [13] 1989</td><td>&#8804;35 days</td><td>116</td><td>Reference</td><td>&#8722;</td></tr><tr><td>&gt;35 days</td><td>113</td><td>2.61 (1.26&#8722;5.39)</td><td></td></tr><tr><td rowspan="2">Colleoni <i>et al</i>. [30] 2000</td><td>&lt;21 days</td><td>599</td><td>&#8722;</td><td>0.88 (0.76&#8722;1.03)</td></tr><tr><td>&#8805;21 days</td><td>1,189</td><td></td><td>Reference</td></tr><tr><td rowspan="3">Kerbrat, <i>et al</i>. [31] 2005</td><td>&lt; 28 days</td><td>1,614</td><td>&#8722;</td><td>0.85 (0.65&#8722;1.05)</td></tr><tr><td>28&#8211;42 days</td><td>883</td><td></td><td>Reference</td></tr><tr><td>&gt;42 days</td><td>105</td><td></td><td></td></tr><tr><td rowspan="4">Cold <i>et al</i>. [8] 2005 (I)</td><td>1&#8211;3 wks</td><td>58</td><td>Reference</td><td>&#8722;</td></tr><tr><td>3&#8211;4 wks</td><td>92</td><td>0.929 (0.441&#8722;1.957)</td><td></td></tr><tr><td>4&#8211;5 wks</td><td>75</td><td>1.549 (0.761&#8722;3.149)</td><td></td></tr><tr><td>5&#8211;13 wks</td><td>127</td><td>1.588 (0.856&#8722;2.948)</td><td></td></tr><tr><td rowspan="4">Cold <i>et al</i>. [8] 2005 (II)</td><td>1&#8211;3 wks</td><td>1,509</td><td>Reference</td><td>&#8722;</td></tr><tr><td>3&#8211;4 wks</td><td>1,581</td><td>1.021 (0.903&#8722;1.155)</td><td></td></tr><tr><td>4&#8211;5 wks</td><td>1,423</td><td>0.890 (0.782&#8722;1.012)</td><td></td></tr><tr><td>5&#8211;13 wks</td><td>1,552</td><td>1.002 (0.884&#8722;1.136)</td><td></td></tr><tr><td rowspan="4">Cold <i>et al</i>. [8] 2005 (III)</td><td>1&#8211;3 wks</td><td>188</td><td>Reference</td><td>&#8722;</td></tr><tr><td>3&#8211;4 wks</td><td>305</td><td>1.218 (0.800&#8722;1.854)</td><td></td></tr><tr><td>4&#8211;5 wks</td><td>263</td><td>1.045 (0.716&#8722;1.525)</td><td></td></tr><tr><td>5&#8211;13 wks</td><td>328</td><td>1.238 (0.861&#8722;1.782)</td><td></td></tr><tr><td rowspan="4">Hershman <i>et al</i>. [18] 2006</td><td>&lt;1 month</td><td>2,361</td><td>Reference</td><td>&#8722;</td></tr><tr><td>1&#8211;2 months</td><td>1,846</td><td>1.00 (0.88&#8722;1.14)</td><td></td></tr><tr><td>2&#8211;3 months</td><td>323</td><td>1.08 (0.85&#8722;1.36)</td><td></td></tr><tr><td>&gt;3 months</td><td>477</td><td>1.46 (1.21&#8722;1.75)</td><td></td></tr><tr><td rowspan="4">Lohrisch <i>et al</i>. [16] 2006</td><td>&#8804;4 wks</td><td>993</td><td>Reference</td><td>&#8722;</td></tr><tr><td>4&#8211;8 wks</td><td>1,272</td><td></td><td></td></tr><tr><td>8&#8211;12 wks</td><td>217</td><td></td><td></td></tr><tr><td>12&#8211;24 wks</td><td>112</td><td>1.6 (1.2&#8722;2.3)</td><td></td></tr><tr><td rowspan="2">Nurgalieva <i>et al</i>. [19] 2013</td><td>&#8804;3 months</td><td>12,748</td><td>Reference</td><td>&#8722;</td></tr><tr><td>&gt;3 months</td><td>1,632</td><td>1.53 (1.32&#8211; 1.80)</td><td></td></tr><tr><td rowspan="4">Downing <i>et al</i>. [15] 2014 (I)</td><td>&#8804;3 wks</td><td>557</td><td>Reference</td><td>&#8722;</td></tr><tr><td>3&#8211;6wks</td><td>3,253</td><td>0.90 (0.73&#8722;1.12)</td><td></td></tr><tr><td>6&#8211;10wks</td><td>1,897</td><td>0.88 (0.70&#8722;1.10)</td><td></td></tr><tr><td>&gt;10wks</td><td>393</td><td>1.49 (1.13&#8722;1.95)</td><td></td></tr><tr><td rowspan="4">Downing <i>et al</i>. [15] 2014 (II)</td><td>&#8804;3 wks</td><td>1,186</td><td>Reference</td><td>&#8722;</td></tr><tr><td>3&#8211;6wks</td><td>2,279</td><td>1.00 (0.85&#8722;1.18)</td><td></td></tr><tr><td>6&#8211;10wks</td><td>652</td><td>1.10 (0.88&#8722;1.37)</td><td></td></tr><tr><td>&gt;10wks</td><td>149</td><td>1.16 (0.80&#8722;1.67)</td><td></td></tr><tr><td rowspan="3">Gagliato <i>et al</i>. [14] 2014</td><td>&#8804;30 days</td><td>2,716</td><td>Reference</td><td>Reference</td></tr><tr><td>31&#8211;60 days</td><td>2,994</td><td>1.05 (0.94&#8211; 1.18)</td><td>1.04 (0.94&#8722;1.14)</td></tr><tr><td>&#8805;61 days</td><td>1,117</td><td>1.19 (1.02&#8211; 1.38)</td><td>1.10 (0.97&#8722;1.25)</td></tr><tr><td rowspan="2">Farolfi <i>et al</i>. [12] 2015</td><td>&#8804;7 wks</td><td>818</td><td>Reference</td><td>Reference</td></tr><tr><td>&gt;7 wks</td><td>103</td><td>1.14 (0.96&#8211;1.34)</td><td>1.15 (1.02&#8211;1.30)</td></tr><tr><td rowspan="4">chavez <i>et al</i>. [17] 2015</td><td>&#8804;30 days</td><td>5,224</td><td>Reference</td><td>&#8722;</td></tr><tr><td>31&#8211;60 days</td><td>12,432</td><td>0.98 (0.87&#8211;1.09)</td><td></td></tr><tr><td>61&#8211;90 days</td><td>4,765</td><td>1.01 (0.88&#8211;1.16)</td><td></td></tr><tr><td>&#8805;91 days</td><td>2,422</td><td>1.34 (1.15&#8211;1.57)</td><td></td></tr><tr><td rowspan="3">Ke-Da <i>et al</i>. [11] 2016</td><td>0&#8211;4 wks</td><td>871</td><td>Reference</td><td>Reference</td></tr><tr><td>4&#8211;8 wks</td><td>446</td><td>1.43 (0.94&#8722;2.19 )</td><td>1.14 (0.83&#8211;1.56)</td></tr><tr><td>&gt;8 wks</td><td>91</td><td>2.02 (1.10&#8211; 3.71)</td><td>1.86 (1.19&#8211;2.90)</td></tr></table>
<table><tr><td rowspan="2">Source</td><td rowspan="2">WT categories</td><td rowspan="2">Sample size</td><td colspan="2">HR (95%CI)</td></tr><tr><td>OS</td><td>DFS/RFS/EFS</td></tr><tr><td>Pronzato et al. [13] 1989</td><td>≤35 days</td><td>116</td><td>Reference</td><td>−</td></tr></table>
<table><tr><td rowspan="2">Source</td><td rowspan="2">WT categories</td><td rowspan="2">Sample size</td><td colspan="2">HR (95%CI)</td></tr><tr><td>OS</td><td>DFS/RFS/EFS</td></tr><tr><td>Pronzato et al. [13] 1989</td><td>>35 days</td><td>113</td><td>2.61 (1.26−5.39)</td><td></td></tr><tr><td rowspan="2">Colleoni et al. [30] 2000</td><td><21 days</td><td>599</td><td>−</td><td>0.88 (0.76−1.03)</td></tr><tr><td>≥21 days</td><td>1,189</td><td></td><td>Reference</td></tr><tr><td rowspan="3">Kerbrat, et al. [31] 2005</td><td>< 28 days</td><td>1,614</td><td>−</td><td>0.85 (0.65−1.05)</td></tr><tr><td>28–42 days</td><td>883</td><td></td><td>Reference</td></tr><tr><td>>42 days</td><td>105</td><td></td><td></td></tr><tr><td rowspan="4">Cold et al. [8] 2005 (I)</td><td>1–3 wks</td><td>58</td><td>Reference</td><td>−</td></tr><tr><td>3–4 wks</td><td>92</td><td>0.929 (0.441−1.957)</td><td></td></tr><tr><td>4–5 wks</td><td>75</td><td>1.549 (0.761−3.149)</td><td></td></tr><tr><td>5–13 wks</td><td>127</td><td>1.588 (0.856−2.948)</td><td></td></tr><tr><td rowspan="4">Cold et al. [8] 2005 (II)</td><td>1–3 wks</td><td>1,509</td><td>Reference</td><td>−</td></tr><tr><td>3–4 wks</td><td>1,581</td><td>1.021 (0.903−1.155)</td><td></td></tr><tr><td>4–5 wks</td><td>1,423</td><td>0.890 (0.782−1.012)</td><td></td></tr><tr><td>5–13 wks</td><td>1,552</td><td>1.002 (0.884−1.136)</td><td></td></tr><tr><td rowspan="4">Cold et al. [8] 2005 (III)</td><td>1–3 wks</td><td>188</td><td>Reference</td><td>−</td></tr><tr><td>3–4 wks</td><td>305</td><td>1.218 (0.800−1.854)</td><td></td></tr><tr><td>4–5 wks</td><td>263</td><td>1.045 (0.716−1.525)</td><td></td></tr><tr><td>5–13 wks</td><td>328</td><td>1.238 (0.861−1.782)</td><td></td></tr><tr><td rowspan="4">Hershman et al. [18] 2006</td><td><1 month</td><td>2,361</td><td>Reference</td><td>−</td></tr><tr><td>1–2 months</td><td>1,846</td><td>1.00 (0.88−1.14)</td><td></td></tr><tr><td>2–3 months</td><td>323</td><td>1.08 (0.85−1.36)</td><td></td></tr><tr><td>>3 months</td><td>477</td><td>1.46 (1.21−1.75)</td><td></td></tr><tr><td rowspan="4">Lohrisch et al. [16] 2006</td><td>≤4 wks</td><td>993</td><td>Reference</td><td>−</td></tr><tr><td>4–8 wks</td><td>1,272</td><td></td><td></td></tr><tr><td>8–12 wks</td><td>217</td><td></td><td></td></tr><tr><td>12–24 wks</td><td>112</td><td>1.6 (1.2−2.3)</td><td></td></tr><tr><td rowspan="2">Nurgalieva et al. [19] 2013</td><td>≤3 months</td><td>12,748</td><td>Reference</td><td>−</td></tr><tr><td>>3 months</td><td>1,632</td><td>1.53 (1.32– 1.80)</td><td></td></tr><tr><td rowspan="4">Downing et al. [15] 2014 (I)</td><td>≤3 wks</td><td>557</td><td>Reference</td><td>−</td></tr><tr><td>3–6wks</td><td>3,253</td><td>0.90 (0.73−1.12)</td><td></td></tr><tr><td>6–10wks</td><td>1,897</td><td>0.88 (0.70−1.10)</td><td></td></tr><tr><td>>10wks</td><td>393</td><td>1.49 (1.13−1.95)</td><td></td></tr><tr><td rowspan="4">Downing et al. [15] 2014 (II)</td><td>≤3 wks</td><td>1,186</td><td>Reference</td><td>−</td></tr><tr><td>3–6wks</td><td>2,279</td><td>1.00 (0.85−1.18)</td><td></td></tr><tr><td>6–10wks</td><td>652</td><td>1.10 (0.88−1.37)</td><td></td></tr><tr><td>>10wks</td><td>149</td><td>1.16 (0.80−1.67)</td><td></td></tr><tr><td rowspan="3">Gagliato et al. [14] 2014</td><td>≤30 days</td><td>2,716</td><td>Reference</td><td>Reference</td></tr><tr><td>31–60 days</td><td>2,994</td><td>1.05 (0.94– 1.18)</td><td>1.04 (0.94−1.14)</td></tr><tr><td>≥61 days</td><td>1,117</td><td>1.19 (1.02– 1.38)</td><td>1.10 (0.97−1.25)</td></tr><tr><td rowspan="2">Farolfi et al. [12] 2015</td><td>≤7 wks</td><td>818</td><td>Reference</td><td>Reference</td></tr><tr><td>>7 wks</td><td>103</td><td>1.14 (0.96–1.34)</td><td>1.15 (1.02–1.30)</td></tr><tr><td rowspan="4">chavez et al. [17] 2015</td><td>≤30 days</td><td>5,224</td><td>Reference</td><td>−</td></tr><tr><td>31–60 days</td><td>12,432</td><td>0.98 (0.87–1.09)</td><td></td></tr><tr><td>61–90 days</td><td>4,765</td><td>1.01 (0.88–1.16)</td><td></td></tr><tr><td>≥91 days</td><td>2,422</td><td>1.34 (1.15–1.57)</td><td></td></tr><tr><td rowspan="3">Ke-Da et al. [11] 2016</td><td>0–4 wks</td><td>871</td><td>Reference</td><td>Reference</td></tr><tr><td>4–8 wks</td><td>446</td><td>1.43 (0.94−2.19 )</td><td>1.14 (0.83–1.56)</td></tr><tr><td>>8 wks</td><td>91</td><td>2.02 (1.10– 3.71)</td><td>1.86 (1.19–2.90)</td></tr></table>
5bdddfacefc37a5806c147b5d29f408960630240fdde630f069d5b3f47aea7ea.png
complex
<table><tr><td></td><td>Difficulty</td><td>SE</td><td colspan="4">Classified groups for DIF</td><td colspan="2">MNSQ</td></tr><tr><td></td><td>Logits</td><td>Logits</td><td><i>Gender</i></td><td><i>Education</i></td><td><i>Age</i></td><td><i>Disease</i></td><td><i>Outfit</i></td><td><i>Infit</i></td></tr><tr><td colspan="9">Interpersonal skills</td></tr><tr><td>2</td><td>0.27</td><td>0.10</td><td>0.05</td><td>0.08</td><td>0.36</td><td>0.63*</td><td>1.05</td><td>1.05</td></tr><tr><td>4</td><td>0.17</td><td>0.11</td><td>0.00</td><td>0.04</td><td>0.50</td><td>0.35</td><td>0.82</td><td>0.80</td></tr><tr><td>3</td><td>-0.01</td><td>0.10</td><td>0.06</td><td>0.01</td><td>1.46*</td><td>0.38</td><td>1.11</td><td>1.09</td></tr><tr><td>1</td><td>-0.11</td><td>0.10</td><td>0.06</td><td>0.08</td><td>0.95*</td><td>0.34</td><td>0.98</td><td>1.01</td></tr><tr><td>5</td><td>-0.52</td><td>0.10</td><td>0.04</td><td>0.08</td><td>0.70*</td><td>0.34</td><td>0.85</td><td>0.85</td></tr><tr><td colspan="9">Communication of information</td></tr><tr><td>9</td><td>0.51</td><td>0.10</td><td>0.10</td><td>0.08</td><td>0.73*</td><td>0.14</td><td>0.81</td><td>0.84</td></tr><tr><td>8</td><td>0.22</td><td>0.10</td><td>0.08</td><td>0.13</td><td>1.09*</td><td>0.44</td><td>0.90</td><td>0.86</td></tr><tr><td>6</td><td>0.01</td><td>0.10</td><td>0.13</td><td>0.05</td><td>0.60*</td><td>0.15</td><td>0.95</td><td>0.90</td></tr><tr><td>7</td><td>0.00</td><td>0.10</td><td>0.08</td><td>0.06</td><td>0.33</td><td>0.36</td><td>0.88</td><td>0.84</td></tr><tr><td colspan="9">Patient engagement and enablement</td></tr><tr><td>9</td><td>0.52</td><td>0.10</td><td>0.06</td><td>0.03</td><td>0.76*</td><td>0.50</td><td>1.24</td><td>1.24</td></tr><tr><td>6</td><td>0.3</td><td>0.10</td><td>0.06</td><td>0.09</td><td>0.74*</td><td>0.75*</td><td>0.83</td><td>0.80</td></tr><tr><td>7</td><td>0.1</td><td>0.10</td><td>0.04</td><td>0.04</td><td>0.57*</td><td>0.34</td><td>1.05</td><td>1.10</td></tr><tr><td>15</td><td>0.03</td><td>0.10</td><td>0.04</td><td>0.17</td><td>1.25*</td><td>0.65*</td><td>1.18</td><td>1.11</td></tr><tr><td>16</td><td>-0.13</td><td>0.10</td><td>0.24</td><td>0.09</td><td>0.54*</td><td>0.31</td><td>0.76</td><td>0.69</td></tr><tr><td>14</td><td>-0.21</td><td>0.10</td><td>0.23</td><td>0.19</td><td>1.07*</td><td>0.77*</td><td>1.30</td><td>1.22</td></tr><tr><td>8</td><td>-0.3</td><td>0.10</td><td>0.00</td><td>0.12</td><td>0.36</td><td>0.19</td><td>1.00</td><td>0.89</td></tr><tr><td colspan="9">Overall satisfaction</td></tr><tr><td>19</td><td>-0.06</td><td>0.10</td><td>0.11</td><td>0.10</td><td>0.47</td><td>0.24</td><td>1.22</td><td>1.10</td></tr><tr><td>17</td><td>-0.26</td><td>0.10</td><td>0.14</td><td>0.02</td><td>0.80*</td><td>0.33</td><td>1.04</td><td>1.10</td></tr><tr><td>18</td><td>-0.69</td><td>0.11</td><td>0.09</td><td>0.05</td><td>0.37</td><td>0.59*</td><td>0.83</td><td>0.76</td></tr><tr><td colspan="9">Technical competence</td></tr><tr><td>21</td><td>0.27</td><td>0.10</td><td>0.08</td><td>0.08</td><td>0.84*</td><td>0.59*</td><td>1.14</td><td>1.12</td></tr><tr><td>20</td><td>-0.13</td><td>0.10</td><td>0.03</td><td>0.05</td><td>0.21</td><td>0.85*</td><td>1.02</td><td>0.95</td></tr><tr><td>MEAN</td><td>0.00</td><td>0.10</td><td>0.08</td><td>0.08</td><td>0.70</td><td>0.44</td><td>1.00</td><td>0.97</td></tr><tr><td>S.D.</td><td>0.30</td><td>0.00</td><td>0.06</td><td>0.05</td><td>0.33</td><td>0.21</td><td>0.16</td><td>0.15</td></tr></table>
<table><tr><td></td><td>Difficulty</td><td>SE</td><td colspan="4">Classified groups for DIF</td><td colspan="2">MNSQ</td></tr><tr><td></td><td>Logits</td><td>Logits</td><td>Gender</td><td>Education</td><td>Age</td><td>Disease</td><td>Outfit</td><td>Infit</td></tr><tr><td colspan="9">Interpersonal skills</td></tr><tr><td>2</td><td>0.27</td><td>0.10</td><td>0.05</td><td>0.08</td><td>0.36</td><td>0.63*</td><td>1.05</td><td>1.05</td></tr><tr><td>4</td><td>0.17</td><td>0.11</td><td>0.00</td><td>0.04</td><td>0.50</td><td>0.35</td><td>0.82</td><td>0.80</td></tr><tr><td>3</td><td>-0.01</td><td>0.10</td><td>0.06</td><td>0.01</td><td>1.46*</td><td>0.38</td><td>1.11</td><td>1.09</td></tr><tr><td>1</td><td>-0.11</td><td>0.10</td><td>0.06</td><td>0.08</td><td>0.95*</td><td>0.34</td><td>0.98</td><td>1.01</td></tr><tr><td>5</td><td>-0.52</td><td>0.10</td><td>0.04</td><td>0.08</td><td>0.70*</td><td>0.34</td><td>0.85</td><td>0.85</td></tr><tr><td colspan="9">Communication of information</td></tr><tr><td>9</td><td>0.51</td><td>0.10</td><td>0.10</td><td>0.08</td><td>0.73*</td><td>0.14</td><td>0.81</td><td>0.84</td></tr><tr><td>8</td><td>0.22</td><td>0.10</td><td>0.08</td><td>0.13</td><td>1.09*</td><td>0.44</td><td>0.90</td><td>0.86</td></tr><tr><td>6</td><td>0.01</td><td>0.10</td><td>0.13</td><td>0.05</td><td>0.60*</td><td>0.15</td><td>0.95</td><td>0.90</td></tr><tr><td>7</td><td>0.00</td><td>0.10</td><td>0.08</td><td>0.06</td><td>0.33</td><td>0.36</td><td>0.88</td><td>0.84</td></tr><tr><td colspan="9">Patient engagement and enablement</td></tr><tr><td>9</td><td>0.52</td><td>0.10</td><td>0.06</td><td>0.03</td><td>0.76*</td><td>0.50</td><td>1.24</td><td>1.24</td></tr></table>
<table><tr><td>6</td><td>0.3</td><td>0.10</td><td>0.06</td><td>0.09</td><td>0.74*</td><td>0.75*</td><td>0.83</td><td>0.80</td></tr><tr><td>7</td><td>0.1</td><td>0.10</td><td>0.04</td><td>0.04</td><td>0.57*</td><td>0.34</td><td>1.05</td><td>1.10</td></tr><tr><td>15</td><td>0.03</td><td>0.10</td><td>0.04</td><td>0.17</td><td>1.25*</td><td>0.65*</td><td>1.18</td><td>1.11</td></tr><tr><td>16</td><td>-0.13</td><td>0.10</td><td>0.24</td><td>0.09</td><td>0.54*</td><td>0.31</td><td>0.76</td><td>0.69</td></tr><tr><td>14</td><td>-0.21</td><td>0.10</td><td>0.23</td><td>0.19</td><td>1.07*</td><td>0.77*</td><td>1.30</td><td>1.22</td></tr><tr><td>8</td><td>-0.3</td><td>0.10</td><td>0.00</td><td>0.12</td><td>0.36</td><td>0.19</td><td>1.00</td><td>0.89</td></tr><tr><td colspan="9">Overall satisfaction</td></tr><tr><td>19</td><td>-0.06</td><td>0.10</td><td>0.11</td><td>0.10</td><td>0.47</td><td>0.24</td><td>1.22</td><td>1.10</td></tr><tr><td>17</td><td>-0.26</td><td>0.10</td><td>0.14</td><td>0.02</td><td>0.80*</td><td>0.33</td><td>1.04</td><td>1.10</td></tr><tr><td>18</td><td>-0.69</td><td>0.11</td><td>0.09</td><td>0.05</td><td>0.37</td><td>0.59*</td><td>0.83</td><td>0.76</td></tr><tr><td colspan="9">Technical competence</td></tr><tr><td>21</td><td>0.27</td><td>0.10</td><td>0.08</td><td>0.08</td><td>0.84*</td><td>0.59*</td><td>1.14</td><td>1.12</td></tr><tr><td>20</td><td>-0.13</td><td>0.10</td><td>0.03</td><td>0.05</td><td>0.21</td><td>0.85*</td><td>1.02</td><td>0.95</td></tr><tr><td>MEAN</td><td>0.00</td><td>0.10</td><td>0.08</td><td>0.08</td><td>0.70</td><td>0.44</td><td>1.00</td><td>0.97</td></tr><tr><td>S.D.</td><td>0.30</td><td>0.00</td><td>0.06</td><td>0.05</td><td>0.33</td><td>0.21</td><td>0.16</td><td>0.15</td></tr></table>
e5142b67824a78e6313e3ca17dbfc1f7ba9f76428ef49c2802a8021bef4bb3c3.png
complex
<table><tr><td rowspan="2">Study groups</td><td colspan="3">No. tested/no. (%) seropositive</td></tr><tr><td>Females</td><td>Males</td><td>Total</td></tr><tr><td>KNP employees with outdoor activity</td><td>5/2 (40)</td><td>23/12 (52.2)</td><td>28/14 (50.0)</td></tr><tr><td>KNP employees with indoor activity</td><td>18/0 (0.0)</td><td>14/7 (50.0)</td><td>32/7 (21.9)</td></tr><tr><td>Subtotal</td><td>23/2 (8.7)</td><td>37/19 (51.4)</td><td>60/21 (35.0)</td></tr><tr><td>Recreational group</td><td>9/2 (22.2)</td><td>5/0 (0.0)</td><td>14/2 (14.3)</td></tr><tr><td>Total</td><td>32/4 (12.5)</td><td>42/19 (45.2)</td><td>74/23 (31.1)</td></tr><tr><td>Control group<sup>a</sup></td><td>8/1 (12.0)</td><td>22/3 (13.6)</td><td>30/4 (13.3)</td></tr></table>
<table><tr><td>Study groups</td><td colspan="3">No. tested/no. (%) seropositive</td></tr></table>
<table><tr><td>Study groups</td><td>Females</td><td>Males</td><td>Total</td></tr><tr><td>KNP employees with outdoor activity</td><td>5/2 (40)</td><td>23/12 (52.2)</td><td>28/14 (50.0)</td></tr><tr><td>KNP employees with indoor activity</td><td>18/0 (0.0)</td><td>14/7 (50.0)</td><td>32/7 (21.9)</td></tr><tr><td>Subtotal</td><td>23/2 (8.7)</td><td>37/19 (51.4)</td><td>60/21 (35.0)</td></tr><tr><td>Recreational group</td><td>9/2 (22.2)</td><td>5/0 (0.0)</td><td>14/2 (14.3)</td></tr><tr><td>Total</td><td>32/4 (12.5)</td><td>42/19 (45.2)</td><td>74/23 (31.1)</td></tr><tr><td>Control groupa</td><td>8/1 (12.0)</td><td>22/3 (13.6)</td><td>30/4 (13.3)</td></tr></table>
a578072286f2bfe36de24b657a6b64798886151e8fc016d5d7575c172fb656a5.png
simple
<table><tr><td>Thyroid lesions simulating a squamoid pattern</td><td>Differential features</td></tr><tr><td>Pure squamous cells carcinoma</td><td>(i) Entirely composed of squamous cells; (ii) no evidence of another type of thyroid carcinoma in close proximity.</td></tr><tr><td>Primary head and neck squamous cell carcinoma</td><td>(i) Presence of in situ component in head and neck structures;(ii) features of &#8220;ab extrinseco&#8221; involvement of thyroid parenchyma; (iii) PAX8 is consistently negative.</td></tr><tr><td>Metastatic squamous cell carcinoma of the lung</td><td>(i) Presence of a lung nodule clinically detected;(ii) PAX8 is consistently negative.</td></tr><tr><td>Diffuse sclerosing variant of papillary thyroid carcinoma</td><td>(i) Abundant psammoma bodies;(ii) neoplastic cells retain nuclear features of PTC;(iii) immunoreactivity for thyroglobulin.</td></tr><tr><td>Mucoepidermoid carcinoma</td><td>(i) Combination of squamoid and mucinous components; (ii) thought to represent papillary carcinoma with extreme degree of squamous and mucinous metaplasia; (iii) low grade thyroid neoplasm.</td></tr><tr><td>Sclerosing mucoepidermoid carcinoma with eosinophilia</td><td>(i) Fibrohyaline stroma;(ii) striking infiltration of eosinophils; (iii) mucin secretion is often present; (iv) typically arising in Hashimoto thyroiditis (thought to derive from metaplastic squamous nests associated with inflammatory infiltrate).</td></tr><tr><td>CASTLE(carcinoma with thymus-like elements)</td><td>(i) Lymphoepithelioma-like carcinoma with foci of squamous differentiation; (ii) pushing margins; (iii) immunoreactivity for CD5, bcl-2, high molecular weight keratin, mcl-1 (thought to be ectopic thymic carcinoma arising from remnants of the branchial pouch); (iv) usually indolent behavior with tendency to late recurrences.</td></tr></table>
<table><tr><td>Thyroid lesions simulating a squamoid pattern</td><td>Differential features</td></tr><tr><td>Pure squamous cells carcinoma</td><td>(i) Entirely composed of squamous cells; (ii) no evidence of another type of thyroid carcinoma in close proximity.</td></tr><tr><td>Primary head and neck squamous cell carcinoma</td><td>(i) Presence of in situ component in head and neck structures;(ii) features of “ab extrinseco” involvement of thyroid parenchyma; (iii) PAX8 is consistently negative.</td></tr><tr><td>Metastatic squamous cell carcinoma of the lung</td><td>(i) Presence of a lung nodule clinically detected;(ii) PAX8 is consistently negative.</td></tr><tr><td>Diffuse sclerosing variant of papillary thyroid carcinoma</td><td>(i) Abundant psammoma bodies;(ii) neoplastic cells retain nuclear features of PTC;(iii) immunoreactivity for thyroglobulin.</td></tr><tr><td>Mucoepidermoid carcinoma</td><td>(i) Combination of squamoid and mucinous components; (ii) thought to represent papillary carcinoma with extreme degree of squamous and mucinous metaplasia; (iii) low grade thyroid neoplasm.</td></tr></table>
<table><tr><td>Thyroid lesions simulating a squamoid pattern</td><td>Differential features</td></tr><tr><td>Sclerosing mucoepidermoid carcinoma with eosinophilia</td><td>(i) Fibrohyaline stroma;(ii) striking infiltration of eosinophils; (iii) mucin secretion is often present; (iv) typically arising in Hashimoto thyroiditis (thought to derive from metaplastic squamous nests associated with inflammatory infiltrate).</td></tr><tr><td>CASTLE(carcinoma with thymus-like elements)</td><td>(i) Lymphoepithelioma-like carcinoma with foci of squamous differentiation; (ii) pushing margins; (iii) immunoreactivity for CD5, bcl-2, high molecular weight keratin, mcl-1 (thought to be ectopic thymic carcinoma arising from remnants of the branchial pouch); (iv) usually indolent behavior with tendency to late recurrences.</td></tr></table>
724d6cde3059b1e5f72a3c02db0e1311133686ceb4069cf3dc849e186d1a0cc8.png
complex
<table><tr><td rowspan="3"><i>Terms of Delivery</i></td><td colspan="4"><i>Trichomonas vaginalis infection</i></td><td rowspan="3"><i>P-value</i></td></tr><tr><td colspan="2">Study group (positive cases)</td><td colspan="2">Control group (negative cases)</td></tr><tr><td>No.</td><td>(%)</td><td>No.</td><td>(%)</td></tr><tr><td>Preterm birth</td><td>19</td><td>(54.28)</td><td>36</td><td>(13.58)</td><td>0.001</td></tr><tr><td>Full term birth</td><td>14</td><td>(40)</td><td>216</td><td>(81.5)</td><td>0.001</td></tr><tr><td>Post term birth</td><td>2</td><td>(5.7)</td><td>13</td><td>(4.9)</td><td>0.83</td></tr><tr><td>Total</td><td>35</td><td>(100)</td><td>265</td><td>(100)</td><td></td></tr></table>
<table><tr><td rowspan="3">Terms of Delivery</td><td colspan="4">Trichomonas vaginalis infection</td><td rowspan="3">P-value</td></tr><tr><td colspan="2">Study group (positive cases)</td><td colspan="2">Control group (negative cases)</td></tr><tr><td>No.</td><td>(%)</td><td>No.</td><td>(%)</td></tr><tr><td>Preterm bi</td><td></td><td></td><td>3</td><td>(13.58)</td><td>0.00</td></tr></table>
<table><tr><td>rth</td><td>19</td><td>(54.28)</td><td>6</td><td></td><td>1</td></tr><tr><td>Full term birth</td><td>14</td><td>(40)</td><td>216</td><td>(81.5)</td><td>0.001</td></tr><tr><td>Post term birth</td><td>2</td><td>(5.7)</td><td>13</td><td>(4.9)</td><td>0.83</td></tr><tr><td>Total</td><td>35</td><td>(100)</td><td>265</td><td>(100)</td><td></td></tr></table>
6cbba4646d94def7de14c3bce2974585960be875ffa59e61efcd82127fd8ee16.png
complex
<table><tr><td rowspan="2">Assumptions</td><td colspan="4">Projected reduction in diabetes prevalence compared to no intervention</td></tr><tr><td>Moderate-risk [millions]</td><td>High-risk [millions]</td><td>Population [millions]</td><td>Combined [millions]</td></tr><tr><td colspan="5">Base case assumptions:</td></tr><tr><td>Flat background diabetes incidence rate*</td><td rowspan="3">1.2 [3.1]</td><td rowspan="3">0.5 [1.2]</td><td rowspan="3">0.3 [0.7]</td><td rowspan="3">1.4 [3.6]</td></tr><tr><td>Lifestyle intervention will reduce yearly diabetes incidence rate by 12.5% in target population</td></tr><tr><td>Population-wide intervention will reduce the yearly diabetes incidence rate by 2% among all US adults</td></tr><tr><td colspan="5">Adjustments to base case assumptions</td></tr><tr><td>Increasing background incidence rate*</td><td>1.4 [3.7]</td><td>0.5 [1.4]</td><td>0.3 [0.8]</td><td>1.6 [4.2]</td></tr><tr><td>Lifestyle intervention will reduce yearly diabetes incidence rate by 25% in target population</td><td>2.5 [6.4]</td><td>1.0 [2.6]</td><td>0.3 [0.7]</td><td>2.7 [6.9]</td></tr><tr><td>Lifestyle intervention will reduce yearly diabetes incidence rate by 6.25% in target population</td><td>0.6 [1.5]</td><td>0.3 [0.6]</td><td>0.3 [0.7]</td><td>0.8 [2.0]</td></tr><tr><td>Population-wide intervention will reduce yearly diabetes incidence rate by 1% among all US adults</td><td>1.2 [3.1]</td><td>0.5 [1.2]</td><td>0.2 [0.3]</td><td>1.1 [2.8]</td></tr><tr><td>Population-wide intervention will reduce yearly diabetes incidence rate by 4% among all US adults</td><td>1.2 [3.1]</td><td>0.5 [1.2]</td><td>0.6 [1.4]</td><td>1.6 [4.0]</td></tr></table>
<table><tr><td rowspan="2">Assumptions</td><td colspan="2">Projected reduction in diabetes prevalence compared to no intervention</td></tr><tr><td>Moderate-risk [millions]</td><td>High-risk [millions]</td></tr><tr><td colspan="3">Base case assumptions:</td></tr><tr><td>Flat background diabetes incidence rate*</td><td rowspan="3">1.2 [3.1]</td><td rowspan="3">0.5 [1.2]</td></tr><tr><td>Lifestyle intervention will reduce yearly diabetes incidence rate by 12.5% in target population</td></tr><tr><td>Population-wide intervention will reduce the yearly diabetes incidence rate by 2% among all US adults</td></tr><tr><td colspan="3">Adjustments to base case assumptions</td></tr><tr><td>Increasing background incidence rate*</td><td>1.4 [3.7]</td><td>0.5 [1.4]</td></tr><tr><td>Lifestyle intervention will reduce yearly diabetes incidence rate by 25% in target population</td><td>2.5 [6.4]</td><td>1.0 [2.6]</td></tr><tr><td>Lifestyle intervention will reduce yearly diabetes incidence rate by 6.25% in target population</td><td>0.6 [1.5]</td><td>0.3 [0.6]</td></tr><tr><td>Population-wide intervention will reduce yearly diabetes incidence rate by 1% among all US adults</td><td>1.2 [3.1]</td><td>0.5 [1.2]</td></tr><tr><td>Population-wide intervention will reduce yearly diabetes incidence rate by 4% among all US adults</td><td>1.2 [3.1]</td><td>0.5 [1.2]</td></tr></table>
<table><tr><td colspan="2">Projected reduction in diabetes prevalence compared to no intervention</td></tr><tr><td>Population [millions]</td><td>Combined [millions]</td></tr><tr><td colspan="2">Base case assumptions:</td></tr><tr><td rowspan="3">0.3 [0.7]</td><td rowspan="3">1.4 [3.6]</td></tr><tr></tr><tr></tr><tr><td colspan="2">Adjustments to base case assumptions</td></tr><tr><td>0.3 [0.8]</td><td>1.6 [4.2]</td></tr><tr><td>0.3 [0.7]</td><td>2.7 [6.9]</td></tr><tr><td>0.3 [0.7]</td><td>0.8 [2.0]</td></tr><tr><td>0.2 [0.3]</td><td>1.1 [2.8]</td></tr><tr><td>0.6 [1.4]</td><td>1.6 [4.0]</td></tr></table>
4c07617c1a54ed4d77de2bb45457c8beabe00dcf20c959b29d932ff7387db154.png
complex
<table><tr><td> </td><td> </td><td>Coefficient (95%CI of coefficient)</td><td>P-value</td></tr><tr><td rowspan="5">Axial length (mm)</td><td>Age (years)</td><td>&#8722;0.007 (&#8722;0.012 to &#8722;0.003)</td><td>&lt;0.001</td></tr><tr><td>Sex (male/female)</td><td>0.111 (0.035 to 0.186)</td><td>0.004</td></tr><tr><td>Education (Each year in school)</td><td>0.011 (0.005 to 0.016)</td><td>&lt;0.001</td></tr><tr><td>Height (cm)</td><td>0.025 (0.021 to 0.029)</td><td>&lt;0.001</td></tr><tr><td>Weight (Kg)</td><td>0.005 (0.003 to 0.007)</td><td>&lt;0.001</td></tr><tr><td rowspan="5">Anterior Chamber depth (mm)</td><td>Age (years)</td><td>&#8722;0.013 (&#8722;0.014 to &#8722;0.012)</td><td>&lt;0.001</td></tr><tr><td>Sex (male/female)</td><td>0.038 (0.012 to 0.064)</td><td>0.004</td></tr><tr><td>Education (Each year in school)</td><td>0.004 (0.002 to 0.005)</td><td>&lt;0.001</td></tr><tr><td>Height (cm)</td><td>0.003 (0.002 to 0.004)</td><td>&lt;0.001</td></tr><tr><td>Weight (Kg)</td><td>0.002 (0.002 to 0.003)</td><td>&lt;0.001</td></tr><tr><td rowspan="5">Lens thickness (mm)</td><td>Age (years)</td><td>0.018 (0.017 to 0.019)</td><td>&lt;0.001</td></tr><tr><td>Sex (male/female)</td><td>0.026 (0.01 to 0.043)</td><td>&lt;0.001</td></tr><tr><td>Education (Each year in school)</td><td>&#8722;0.002 (&#8722;0.004 to &#8722;0.001)</td><td>0.005</td></tr><tr><td>Height (cm)</td><td> </td><td>NS</td></tr><tr><td>Weight (Kg)</td><td>&#8722;0.001 (&#8722;0.002 to &#8722;0.001)</td><td>&lt;0.001</td></tr><tr><td rowspan="5">Vitreous chamber depth (mm)</td><td>Age (years)</td><td>&#8722;0.011 (&#8722;0.015 to &#8722;0.007)</td><td>&lt;0.001</td></tr><tr><td>Sex (male/female)</td><td> </td><td>NS</td></tr><tr><td>Education (Each year in school)</td><td>0.009 (0.004 to &#8722;0.014)</td><td>&lt;0.001</td></tr><tr><td>Height (cm)</td><td>0.023 (0.021 to &#8722;0.026)</td><td>&lt;0.001</td></tr><tr><td>Weight (Kg)</td><td>0.004 (0.001 to &#8722;0.006)</td><td>&lt;0.001</td></tr></table>
<table><tr><td></td><td></td><td>Coefficient (95%CI of coefficient)</td><td>P-value</td></tr><tr><td rowspan="5">Axial length (mm)</td><td>Age (years)</td><td>−0.007 (−0.012 to −0.003)</td><td><0.001</td></tr><tr><td>Sex (male/female)</td><td>0.111 (0.035 to 0.186)</td><td>0.004</td></tr><tr><td>Education (Each year in school)</td><td>0.011 (0.005 to 0.016)</td><td><0.001</td></tr><tr><td>Height (cm)</td><td>0.025 (0.021 to 0.029)</td><td><0.001</td></tr><tr><td>Weight (Kg)</td><td>0.005 (0.003 to 0.007)</td><td><0.001</td></tr></table>
<table><tr><td></td><td></td><td>Coefficient (95%CI of coefficient)</td><td>P-value</td></tr><tr><td rowspan="5">Anterior Chamber depth (mm)</td><td>Age (years)</td><td>−0.013 (−0.014 to −0.012)</td><td><0.001</td></tr><tr><td>Sex (male/female)</td><td>0.038 (0.012 to 0.064)</td><td>0.004</td></tr><tr><td>Education (Each year in school)</td><td>0.004 (0.002 to 0.005)</td><td><0.001</td></tr><tr><td>Height (cm)</td><td>0.003 (0.002 to 0.004)</td><td><0.001</td></tr><tr><td>Weight (Kg)</td><td>0.002 (0.002 to 0.003)</td><td><0.001</td></tr><tr><td rowspan="5">Lens thickness (mm)</td><td>Age (years)</td><td>0.018 (0.017 to 0.019)</td><td><0.001</td></tr><tr><td>Sex (male/female)</td><td>0.026 (0.01 to 0.043)</td><td><0.001</td></tr><tr><td>Education (Each year in school)</td><td>−0.002 (−0.004 to −0.001)</td><td>0.005</td></tr><tr><td>Height (cm)</td><td></td><td>NS</td></tr><tr><td>Weight (Kg)</td><td>−0.001 (−0.002 to −0.001)</td><td><0.001</td></tr><tr><td rowspan="5">Vitreous chamber depth (mm)</td><td>Age (years)</td><td>−0.011 (−0.015 to −0.007)</td><td><0.001</td></tr><tr><td>Sex (male/female)</td><td></td><td>NS</td></tr><tr><td>Education (Each year in school)</td><td>0.009 (0.004 to −0.014)</td><td><0.001</td></tr><tr><td>Height (cm)</td><td>0.023 (0.021 to −0.026)</td><td><0.001</td></tr><tr><td>Weight (Kg)</td><td>0.004 (0.001 to −0.006)</td><td><0.001</td></tr></table>
bf800c00b2ac368a62a6678739240414350244d1f5038148d4e01eddcf770740.png
complex
<table><tr><td></td><td colspan="7">Target head angle (degrees)</td></tr><tr><td></td><td>&#8722;80</td><td>&#8722;60</td><td>&#8722;40</td><td>&#8722;20</td><td>0</td><td>20</td><td>40</td></tr><tr><td colspan="8">Pitch experiment</td></tr><tr><td>Qualitative descriptions</td><td>11</td><td>12</td><td>12</td><td>11</td><td>12</td><td>11</td><td>12</td></tr><tr><td>Switch&#8208;press measures</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>DI, MV, PV, D</td><td>8</td><td>8</td><td>12</td><td>10</td><td>12</td><td>11</td><td>11</td></tr><tr><td>OF, in&#8208;phase</td><td>7</td><td>3</td><td>10</td><td>9</td><td>10</td><td>2</td><td>4</td></tr><tr><td>OF, out&#8208;phase</td><td>5</td><td>3</td><td>7</td><td>7</td><td>8</td><td>3</td><td>2</td></tr><tr><td colspan="8">Roll experiment</td></tr><tr><td>Qualitative descriptions</td><td>N/A</td><td>N/A</td><td>10</td><td>11</td><td>11</td><td>11</td><td>10</td></tr><tr><td>Switch&#8208;press measures</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>DI, MV, PV, D</td><td>N/A</td><td>N/A</td><td>10</td><td>11</td><td>11</td><td>11</td><td>10</td></tr><tr><td>OF, in&#8208;phase</td><td>N/A</td><td>N/A</td><td>8</td><td>8</td><td>10</td><td>8</td><td>4</td></tr><tr><td>OF, out&#8208;phase</td><td>N/A</td><td>N/A</td><td>5</td><td>7</td><td>8</td><td>8</td><td>6</td></tr></table>
<table><tr><td></td><td colspan="7">Target head angle (degrees)</td></tr><tr><td></td><td>−80</td><td>−60</td><td>−40</td><td>−20</td><td>0</td><td>20</td><td>40</td></tr><tr><td colspan="8">Pitch experiment</td></tr><tr><td>Qualitative descriptions</td><td>11</td><td>12</td><td>12</td><td>11</td><td>12</td><td>11</td><td>12</td></tr><tr><td>Switch‐press measures</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>DI, MV, PV, D</td><td>8</td><td>8</td><td>12</td><td>10</td><td>12</td><td>11</td><td>11</td></tr><tr><td>OF, in‐phase</td><td>7</td><td>3</td><td>10</td><td>9</td><td>10</td><td>2</td><td>4</td></tr><tr><td>OF, out‐phase</td><td>5</td><td>3</td><td>7</td><td>7</td><td>8</td><td>3</td><td>2</td></tr><tr><td colspan="8">Roll experiment</td></tr><tr><td>Qualitative descriptions</td><td>N/A</td><td>N/A</td><td>10</td><td>11</td><td>11</td><td>11</td><td>10</td></tr><tr><td>Switch‐press measures</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>DI, MV, PV, D</td><td>N/A</td><td>N/A</td><td>10</td><td>11</td><td>11</td><td>11</td><td>10</td></tr><tr><td>OF, in</td><td>N</td><td></td><td>8</td><td>8</td><td></td><td></td><td></td></tr></table>
<table><tr><td></td><td colspan="7">Target head angle (degrees)</td></tr><tr><td></td><td>−80</td><td>−60</td><td>−40</td><td>−20</td><td>0</td><td>20</td><td>40</td></tr><tr><td>‐phase</td><td>/A</td><td>N/A</td><td></td><td></td><td>10</td><td>8</td><td>4</td></tr><tr><td>OF, out‐phase</td><td>N/A</td><td>N/A</td><td>5</td><td>7</td><td>8</td><td>8</td><td>6</td></tr></table>
bf37ad9e9e4039e88668875f19c55b4835ea361c8a145d0b62905c1e2b8f8c41.png
complex
<table><tr><td></td><td>Ofloxacin</td><td colspan="2">Injectable drugs</td><td>TotalResistance to either Fluoroquinolone or injectable drugsN (%)</td></tr><tr><td></td><td>OfloxacinR, n (%)</td><td>KanamycinR, n (%)</td><td>CapreomycinR, n (%)</td><td></td></tr><tr><td>New MDR patients (<i>n</i> = 5)</td><td>0 (0)</td><td>0 (0)</td><td>0</td><td>0 (0)</td></tr><tr><td>Previously treated MDR patients (<i>n</i> = 33)</td><td>1 (3)</td><td>1 (3)</td><td>5 (15.2)</td><td>7 (21.2)</td></tr><tr><td>Total</td><td>1</td><td>1</td><td>5</td><td>7 (18.4)</td></tr></table>
<table><tr><td></td><td>Ofloxacin</td><td colspan="2">Injectable drugs</td><td>TotalResistance to either Fluoroquinolone or injectable drugsN (%)</td></tr><tr><td></td><td>OfloxacinR, n (%)</td><td>KanamycinR, n (%)</td><td>CapreomycinR, n (%)</td><td></td></tr><tr><td>New MDR patients (n = 5</td><td>0</td><td>0 (</td><td>0</td><td>0 (0)</td></tr></table>
<table><tr><td></td><td>Ofloxacin</td><td colspan="2">Injectable drugs</td><td>TotalResistance to either Fluoroquinolone or injectable drugsN (%)</td></tr><tr><td></td><td>OfloxacinR, n (%)</td><td>KanamycinR, n (%)</td><td>CapreomycinR, n (%)</td><td></td></tr><tr><td>)</td><td> (0)</td><td>0)</td><td></td><td></td></tr><tr><td>Previously treated MDR patients (n = 33)</td><td>1 (3)</td><td>1 (3)</td><td>5 (15.2)</td><td>7 (21.2)</td></tr><tr><td>Total</td><td>1</td><td>1</td><td>5</td><td>7 (18.4)</td></tr></table>
7445c6d458607ed471eee32dc6a2b7c3909b01e5ae51af2ee66864c764908539.png
simple
<table><tr><td>Ectoparasite</td><td> Postlactating females</td><td> Nonreproductive females</td></tr><tr><td></td><td>(<i>n</i> = 17)</td><td>(<i>n</i> = 97)</td></tr><tr><td><i>Spinturnix americanus</i></td><td>41.2%, 0.5 (0.7, 0&#8211;2)</td><td>38%, 0.7 (1.2, 0&#8211;5)</td></tr><tr><td><i>Myodopsylla insignis</i></td><td>47.1%, 1.1 (1.6, 0&#8211;5)</td><td>32%, 0.7 (1.3, 0&#8211;7)</td></tr><tr><td><i>Macronyssus crosbyi</i></td><td>0</td><td>7.2%, 0.1 (0.3, 0&#8211;2)</td></tr><tr><td><i>Cimex adjunctus</i></td><td>0</td><td>0</td></tr><tr><td><i>Androlaeps casalis</i></td><td>0</td><td>1%, 0.02 (0.2, 0&#8211;2)</td></tr><tr><td><i>Acanthophthirius spp.</i></td><td>0</td><td>1%, 0.02 (0.2, 0&#8211;2) </td></tr><tr><td><i>Any ectoparasite</i></td><td>76.5%, 1.6 (1.4, 0&#8211;5)</td><td>66%, 1.5 (1.7, 0&#8211;5)</td></tr></table>
<table><tr><td>Ectoparasite</td><td>Postlactating females</td></tr><tr><td></td><td>(n = 17)</td></tr><tr><td>Spinturnix americanus</td><td>41.2%, 0.5 (0.7, 0–2)</td></tr><tr><td>Myodopsylla insignis</td><td>47.1%, 1.1 (1.6, 0–5)</td></tr><tr><td>Macronyssus crosbyi</td><td>0</td></tr><tr><td>Cimex adjunctus</td><td>0</td></tr><tr><td>Androlaeps casalis</td><td>0</td></tr><tr><td>Acanthophthirius spp.</td><td>0</td></tr><tr><td>Any ectoparasite</td><td>76.5%, 1.6 (1.4, 0–5)</td></tr></table>
<table><tr><td>Nonreproductive females</td></tr><tr><td>(n = 97)</td></tr><tr><td>38%, 0.7 (1.2, 0–5)</td></tr><tr><td>32%, 0.7 (1.3, 0–7)</td></tr><tr><td>7.2%, 0.1 (0.3, 0–2)</td></tr><tr><td>0</td></tr><tr><td>1%, 0.02 (0.2, 0–2)</td></tr><tr><td>1%, 0.02 (0.2, 0–2)</td></tr><tr><td>66%, 1.5 (1.7, 0–5)</td></tr></table>
f23c799c1365bc27ce9d836632777589d275cc3664f9220d18148008638b19ad.png
complex
<table><tr><td>Finding</td><td>Illustrating data</td></tr><tr><td>Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily</td><td><i>Case D</i>: &#8216;The long term viability is very, very strong, it's viewed as an essential service, the patients need to be seen by a [clinical specialist in the mainstream clinical area] and they need to be seen by a geneticist, so they either come to our clinic or they get pushed back into the existing clinics. [...] I think we're probably pretty cost neutral for the trust, the activity we're doing is probably no different to what would be happening in the clinic and we're probably a little bit more economically efficient I would guess&#8217;. (Mainstream consultant clinical specialist)</td></tr><tr><td rowspan="2">Where impact on wider clinical systems and resource-allocation decisions is present, embedding the organizational innovation into the wider clinical system may secure its sustainability</td><td><i>Case C</i>: &#8216;We've got an established service that everyone knows about, and the route for all these patients is through [Case C service], so there isn't any gynaecologist messing around&#8212;in my view, that's what I would have called it, they'd be messing around with patients who had been referred by their GP. Now these patients are all passed through [the service] before they come to gynaecology. So they may still come [to me], but they come with expert information upfront about the risk and the options that they've got available&#8217;. (Gynaecological oncologist in referring department)</td></tr><tr><td>&#8216;In the end [our case to the commissioners] was more, &#8216;If you don't fund this there's going to be a great black hole that no-one can pick up&#8217;. I think that's how it was funded in the end&#8217;. (Lead nurse)</td></tr><tr><td>Services that are not embedded into the wider system may be seen as supplementary rather than as a core part of provision, and are more vulnerable to decommissioning</td><td><i>Case B</i>: &#8216;The money wasn't there, there wasn't identified any money, but I think there's also that it wasn't priority for the Primary Care Trust, nobody had any targets to reach for genetics, there was no &#8216;must dos&#8217; about genetics and so it was easy for it to slip down the radar. [...] The priorities were the national priorities to do with waiting times, with, cancer, for heart disease, for prevention, so there were quite a large number of priorities for any Primary Care Trust, we didn't have unusual priorities other than the national priorities in health. And there were so many, there still are, but there were so many it's quite hard to do anything other than to meet the priorities&#8217;. (PCT former senior clinical manager)</td></tr></table>
<table><tr><td>Finding</td></tr><tr><td>Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily</td></tr><tr><td rowspan="2">Where impact on wider clinical systems and resource-allocation decisions is present, embedding the organizational innovation into the wider clinical system may secure its sustainability</td></tr><tr></tr><tr><td>Services that are not embedded into the wider system may be seen as supplementary rather than as a core part of provision, and are more vulnerable to decommissioning</td></tr></table>
<table><tr><td>Illustrating data</td></tr><tr><td>Case D: ‘The long term viability is very, very strong, it's viewed as an essential service, the patients need to be seen by a [clinical specialist in the mainstream clinical area] and they need to be seen by a geneticist, so they either come to our clinic or they get pushed back into the existing clinics. [...] I think we're probably pretty cost neutral for the trust, the activity we're doing is probably no different to what would be happening in the clinic and we're probably a little bit more economically efficient I would guess’. (Mainstream consultant clinical specialist)</td></tr><tr><td>Case C: ‘We've got an established service that everyone knows about, and the route for all these patients is through [Case C service], so there isn't any gynaecologist messing around—in my view, that's what I would have called it, they'd be messing around with patients who had been referred by their GP. Now these patients are all passed through [the service] before they come to gynaecology. So they may still come [to me], but they come with expert information upfront about the risk and the options that they've got available’. (Gynaecological oncologist in referring department)</td></tr><tr><td>‘In the end [our case to the commissioners] was more, ‘If you don't fund this there's going to be a great black hole that no-one can pick up’. I think that's how it was funded in the end’. (Lead nurse)</td></tr><tr><td>Case B: ‘The money wasn't there, there wasn't identified any money, but I think there's also that it wasn't priority for the Primary Care Trust, nobody had any targets to reach for genetics, there was no ‘must dos’ about genetics and so it was easy for it to slip down the radar. [...] The priorities were the national priorities to do with waiting times, with, cancer, for heart disease, for prevention, so there were quite a large number of priorities for any Primary Care Trust, we didn't have unusual priorities other than the national priorities in health. And there were so many, there still are, but there were so many it's quite hard to do anything other than to meet the priorities’. (PCT former senior clinical manager)</td></tr></table>
7d4a134bcacd225568c66932266fcabfe2ead6f8e98f1017f546a1dc94d55489.png
simple
<table><tr><td><i>No.</i></td><td><i>Themes</i></td><td><i>OSPE</i></td><td><i>OSCE</i></td><td><i>Frequency</i></td><td><i>Total</i></td></tr><tr><td>1.</td><td><i>Curriculum</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> Syllabus</td><td>+</td><td>++</td><td>3</td><td>7</td></tr><tr><td> </td><td> Repetition</td><td>+++</td><td>+</td><td>4</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>2.</td><td><i>Skills assessment</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> Practical/clinical skills</td><td>++</td><td>+++</td><td>5</td><td>12</td></tr><tr><td> </td><td> Concepts</td><td>+++</td><td>+</td><td>4</td><td> </td></tr><tr><td> </td><td> Competence</td><td>++</td><td>+</td><td>3</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>3.</td><td><i>Confidence</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> Confidence</td><td>++</td><td>+</td><td>3</td><td>6</td></tr><tr><td> </td><td> Comfort</td><td>++</td><td>+</td><td>3</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>4.</td><td><i>Fairness of exam</i></td><td>++</td><td>++</td><td>4</td><td>4</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>5.</td><td><i>Impact on learning</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> Improved learning</td><td>+</td><td>+</td><td>2</td><td>5</td></tr><tr><td> </td><td> Future learning</td><td>+</td><td>++</td><td>3</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>6.</td><td><i>Stress</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> Stress</td><td>++++</td><td>++++</td><td>8</td><td>17</td></tr><tr><td> </td><td> Time</td><td>++++++</td><td>+++</td><td>9</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>7.</td><td>Organisation of exam</td><td>++</td><td>++</td><td>4</td><td>4</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>8.</td><td>Examiners&#8217; calibration</td><td>+++</td><td>++++++++</td><td>8</td><td>11</td></tr></table>
<table><tr><td>No.</td><td>Themes</td><td>OSPE</td><td>OSCE</td><td>Frequency</td></tr><tr><td>1.</td><td>Curriculum</td><td></td><td></td><td></td></tr><tr><td></td><td>Syllabus</td><td>+</td><td>++</td><td>3</td></tr><tr><td></td><td>Repetition</td><td>+++</td><td>+</td><td>4</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2.</td><td>Skills assessment</td><td></td><td></td><td></td></tr><tr><td></td><td>Practical/clinical skills</td><td>++</td><td>+++</td><td>5</td></tr><tr><td></td><td>Concepts</td><td>+++</td><td>+</td><td>4</td></tr><tr><td></td><td>Competence</td><td>++</td><td>+</td><td>3</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3.</td><td>Confidence</td><td></td><td></td><td></td></tr><tr><td></td><td>Confidence</td><td>++</td><td>+</td><td>3</td></tr><tr><td></td><td>Comfort</td><td>++</td><td>+</td><td>3</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4.</td><td>Fairness of exam</td><td>++</td><td>++</td><td>4</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>5.</td><td>Impact on learning</td><td></td><td></td><td></td></tr><tr><td></td><td>Improved learning</td><td>+</td><td>+</td><td>2</td></tr><tr><td></td><td>Future learning</td><td>+</td><td>++</td><td>3</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>6.</td><td>Stress</td><td></td><td></td><td></td></tr><tr><td></td><td>Stress</td><td>++++</td><td>++++</td><td>8</td></tr><tr><td></td><td>Time</td><td>++++++</td><td>+++</td><td>9</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>7.</td><td>Organisation of exam</td><td>++</td><td>++</td><td>4</td></tr><tr><td></td><td></td><td></td><td></td><td></td></tr><tr><td>8.</td><td>Examiners’ calibration</td><td>+++</td><td>++++++++</td><td>8</td></tr></table>
<table><tr><td>Total</td></tr><tr><td></td></tr><tr><td>7</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>12</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>6</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>4</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>5</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>17</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>4</td></tr><tr><td></td></tr><tr><td>11</td></tr></table>
17029d86268870618e765d54bc7a1f76d35470882b42caa5076bbf5e9da712a2.png
complex
<table><tr><td></td><td colspan="3">Intention to treat</td><td colspan="3">Modified intention to treat</td></tr><tr><td></td><td>Antibiotic treatmentn = 22</td><td>No antibiotic treatmentn = 36</td><td><i>P </i>value</td><td>Antibiotic treatmentn = 18</td><td>No antibiotic treatmentn = 26</td><td><i>P </i>value</td></tr><tr><td>Tracheostomy</td><td>5 (22)</td><td>5 (13)</td><td>&gt;0.999</td><td>5 (27)</td><td>5 (19)</td><td>0.716</td></tr><tr><td>Corticosteroid use</td><td>8 (36)</td><td>19 (52)</td><td>0.283</td><td>6 (33)</td><td>13 (50)</td><td>0.359</td></tr><tr><td>Septic shock</td><td>1 (4)</td><td>7 (19)</td><td>0.134</td><td>1 (5)</td><td>5 (19)</td><td>0.375</td></tr><tr><td>ICU-acquired infections other than VAT and VAP<sup>a</sup></td><td>7 (31)</td><td>18 (50)</td><td>0.274</td><td>6 (33)</td><td>13 (50)</td><td>0.359</td></tr><tr><td> Bacteremia</td><td>6 (27)</td><td>13 (36)</td><td>0.572</td><td>5 (27)</td><td>8 (30)</td><td>&gt;0.999</td></tr><tr><td> Urinary tract infection</td><td>2 (9)</td><td>5 (13)</td><td>0.698</td><td>2 (11)</td><td>5 (19)</td><td>0.682</td></tr><tr><td> Others</td><td>2 (9)</td><td>2 (5)</td><td>&gt;0.999</td><td>2 (11)</td><td>2 (7)</td><td>&gt;0.999</td></tr><tr><td>Total duration of antibiotic treatment, days</td><td>25 &#177; 14</td><td>19 &#177; 15</td><td>0.149</td><td>24 &#177; 15</td><td>17 &#177; 15</td><td>0.104</td></tr><tr><td>Antibiotic treatment before VAT</td><td>18 (81)</td><td>29 (80)</td><td>&gt;0.999</td><td>15 (83)</td><td>23 (88)</td><td>0.676</td></tr><tr><td>Antibiotic treatment during the 8 days following random assignment</td><td>22 (100)</td><td>21 (58)</td><td>&lt;0.001</td><td>18 (100)</td><td>10 (38)</td><td>&lt;0.001</td></tr><tr><td>Reasons for antibiotic treatment during the 8 days following random assignment</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> VAT</td><td>22 (100)</td><td>0 (0)</td><td>&lt;0.001</td><td>18 (100)</td><td>0 (0)</td><td>&lt;0.001</td></tr><tr><td> VAP</td><td>0 (0)</td><td>15 (41)</td><td>&lt;0.001</td><td>0 (0)</td><td>10 (38)</td><td>0.003</td></tr><tr><td> Other infections</td><td>0 (0)</td><td>6 (16)</td><td>0.073</td><td>0 (0)</td><td>0 (0)</td><td>NA</td></tr><tr><td>Antibiotic treatment after day 8 post-random assignment</td><td>6 (27)</td><td>8 (22)</td><td>0.756</td><td>3 (16)</td><td>5 (19)</td><td>&gt;0.999</td></tr></table>
<table><tr><td></td><td colspan="3">Intention to treat</td><td colspan="3">Modified intention to treat</td></tr><tr><td></td><td>Antibiotic treatmentn = 22</td><td>No antibiotic treatmentn = 36</td><td>P value</td><td>Antibiotic treatmentn = 18</td><td>No antibiotic treatmentn = 26</td><td>P value</td></tr><tr><td>Tracheostomy</td><td>5 (22)</td><td>5 (13)</td><td>>0.999</td><td>5 (27)</td><td>5 (19)</td><td>0.716</td></tr><tr><td>Corticosteroid use</td><td>8 (36)</td><td>19 (52)</td><td>0.283</td><td>6 (33)</td><td>13 (50)</td><td>0.359</td></tr><tr><td>Septic shock</td><td>1 (4)</td><td>7 (19)</td><td>0.134</td><td>1 (5)</td><td>5 (19)</td><td>0.375</td></tr><tr><td>ICU-acquired infections other than VAT and VAPa</td><td>7 (31)</td><td>18 (50)</td><td>0.274</td><td>6 (33)</td><td>13 (50)</td><td>0.359</td></tr><tr><td>Bacteremia</td><td>6 (27)</td><td>13 (36)</td><td>0.572</td><td>5 (27)</td><td>8 (30)</td><td>>0.999</td></tr><tr><td>Urinary tract infection</td><td>2 (9)</td><td>5 (13)</td><td>0.698</td><td>2 (11)</td><td>5 (19)</td><td>0.682</td></tr><tr><td>Others</td><td>2 (9)</td><td>2 (5)</td><td>>0.999</td><td>2 (11)</td><td>2 (7)</td><td>>0.999</td></tr><tr><td>Total duration of antibiotic treatment, days</td><td>25 ± 14</td><td>19 ± 15</td><td>0.149</td><td>24 ± 15</td><td>17 ± 15</td><td>0.104</td></tr><tr><td>Antibiotic treatment before VAT</td><td>18 (81)</td><td>29 (80)</td><td>>0.999</td><td>15 (83)</td><td>23 (88)</td><td>0.676</td></tr><tr><td>Antibiotic treatment during the 8 days following random assignment</td><td>22 (100)</td><td>21 (58)</td><td><0.001</td><td>18 (100)</td><td>10 (38)</td><td><0.001</td></tr><tr><td>Reasons for antibiotic treatment during the 8 days following random assignment</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>VAT</td><td>22 (100)</td><td>0 (0)</td><td><0.001</td><td>18 (100)</td><td>0 (0)</td><td><0.001</td></tr><tr><td>VAP</td><td>0 (0)</td><td>15 (41)</td><td><0.001</td><td>0 (0)</td><td>10 (38)</td><td>0.003</td></tr></table>
<table><tr><td>Other infections</td><td>0 (0)</td><td>6 (16)</td><td>0.073</td><td>0 (0)</td><td>0 (0)</td><td>NA</td></tr><tr><td>Antibiotic treatment after day 8 post-random assignment</td><td>6 (27)</td><td>8 (22)</td><td>0.756</td><td>3 (16)</td><td>5 (19)</td><td>>0.999</td></tr></table>
1419b03df6458ee6e5d54931cd53374526853019363efc48b43f7227b0f583df.png
simple
<table><tr><td>Site</td><td>Ever smoked cigarettes, even one or two puffs</td><td>Ever smokers who initiated smoking before age 10</td><td>Never smokers susceptible to initiate smoking in the next year</td></tr><tr><td>Huancayo, 2000</td><td>47.1 (40.9&#8211;53.5) (n = 963)</td><td>18.1 (13.6&#8211;23.6) (n = 429)</td><td>29.7 (24.8&#8211;35.1) (n = 495)</td></tr><tr><td>Lima, 2000</td><td>54.6 (49.5&#8211;59.6) (n = 1,189)</td><td>13.5 (11.1&#8211;16.4) (n = 605)</td><td>25.4 (20.6&#8211;31.0) (n = 545)</td></tr><tr><td>Tarapoto, 2000</td><td>42.5 (35.6&#8211;49.8) (n = 750)</td><td>10.9 (7.6&#8211;15.3) (n = 305)</td><td>19.2 (15.5&#8211;23.6) (n = 416)</td></tr><tr><td>Trujillo, 2000</td><td>46.5 (38.7&#8211;54.5) (n = 1,005)</td><td>12.3 (9.1&#8211;16.4) (n = 429)</td><td>25.5 (19.7&#8211;32.2) (n = 553)</td></tr><tr><td>Huancayo, 2003</td><td>58.6 (52.9&#8211;64.1) (n = 966)</td><td>11.6 (8.4&#8211;15.7) (n = 550)</td><td>25.8 (22.0&#8211;29.9) (n = 384)</td></tr><tr><td>Lima, 2003</td><td>59.6 (52.9&#8211;66.0) (n = 998)</td><td>13.6 (10.2&#8211;17.8) (n = 587)</td><td>30.5 (24.2&#8211;37.8) (n = 388)</td></tr><tr><td>Tarapoto, 2003</td><td>48.7 (43.5&#8211;54.0) (n = 1,082)</td><td>8.3 (5.9&#8211;11.6) (n = 505)</td><td>19.6 (15.6&#8211;24.4) (n = 554)</td></tr><tr><td>Trujillo, 2003</td><td>44.5 (39.0&#8211;50.2) (n = 1,305)</td><td>13.1 (9.6&#8211;17.7) (n = 585)</td><td>22.7 (20.8&#8211;24.7) (n = 697)</td></tr></table>
<table><tr><td>Site</td><td>Ever smoked cigarettes, even one or two puffs</td><td>Ever smokers who initiated smoking before age 10</td><td>Never smokers susceptible to initiate smoking in the next year</td></tr><tr><td>Huancayo, 2000</td><td>47.1 (40.9–53.5) (n = 963)</td><td>18.1 (13.6–23.6) (n = 429)</td><td>29.7 (24.8–35.1) (n = 495)</td></tr><tr><td>Lima, 2000</td><td>54.6 (49.5–59.6) (n = 1,189)</td><td>13.5 (11.1–16.4) (n = 605)</td><td>25.4 (20.6–31.0) (n = 545)</td></tr></table>
<table><tr><td>Site</td><td>Ever smoked cigarettes, even one or two puffs</td><td>Ever smokers who initiated smoking before age 10</td><td>Never smokers susceptible to initiate smoking in the next year</td></tr><tr><td>Tarapoto, 2000</td><td>42.5 (35.6–49.8) (n = 750)</td><td>10.9 (7.6–15.3) (n = 305)</td><td>19.2 (15.5–23.6) (n = 416)</td></tr><tr><td>Trujillo, 2000</td><td>46.5 (38.7–54.5) (n = 1,005)</td><td>12.3 (9.1–16.4) (n = 429)</td><td>25.5 (19.7–32.2) (n = 553)</td></tr><tr><td>Huancayo, 2003</td><td>58.6 (52.9–64.1) (n = 966)</td><td>11.6 (8.4–15.7) (n = 550)</td><td>25.8 (22.0–29.9) (n = 384)</td></tr><tr><td>Lima, 2003</td><td>59.6 (52.9–66.0) (n = 998)</td><td>13.6 (10.2–17.8) (n = 587)</td><td>30.5 (24.2–37.8) (n = 388)</td></tr><tr><td>Tarapoto, 2003</td><td>48.7 (43.5–54.0) (n = 1,082)</td><td>8.3 (5.9–11.6) (n = 505)</td><td>19.6 (15.6–24.4) (n = 554)</td></tr><tr><td>Trujillo, 2003</td><td>44.5 (39.0–50.2) (n = 1,305)</td><td>13.1 (9.6–17.7) (n = 585)</td><td>22.7 (20.8–24.7) (n = 697)</td></tr></table>
c17e4be7f9acfa1b3f15c820171fd26dc5f15eb17837d4ffbf070c9ba7d4ae26.png
complex
<table><tr><td></td><td colspan="2">Response rate</td><td colspan="2">NR</td></tr><tr><td></td><td>Prosody+</td><td>Prosody&#8722;</td><td>Prosody+</td><td>Prosody&#8722;</td></tr><tr><td>Healthy controls (CI 95%)</td><td>96 &#177; 4 (94, 98)</td><td>84 &#177; 7 (81, 87)</td><td>3 &#177; 4(2, 2)</td><td>10 &#177; 7(7, 14)</td></tr><tr><td>Patients with schizophrenia (CI 95%)</td><td>78 &#177; 16 (70, 86)</td><td>58 &#177; 19 (49, 67)</td><td>22 &#177; 17 (14, 30)</td><td>37 &#177; 20 (28, 47)</td></tr></table>
<table><tr><td></td><td colspan="2">Response rate</td><td colspan="2">NR</td></tr><tr><td></td><td>Prosody+</td><td>Prosody−</td><td>Prosody+</td><td>Prosody−</td></tr></table>
<table><tr><td>Healthy controls (CI 95%)</td><td>96 ± 4 (94, 98)</td><td>84 ± 7 (81, 87)</td><td>3 ± 4(2, 2)</td><td>10 ± 7(7, 14)</td></tr><tr><td>Patients with schizophrenia (CI 95%)</td><td>78 ± 16 (70, 86)</td><td>58 ± 19 (49, 67)</td><td>22 ± 17 (14, 30)</td><td>37 ± 20 (28, 47)</td></tr></table>
516ae0c6d76f7b9a6d5345af55af644c356dc2d99da3876cc8b4a8a3eada9544.png
simple
<table><tr><td>Clinical trials</td><td>Interventions</td><td>URL</td></tr><tr><td>124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study</td><td>Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added)</td><td>https://ClinicalTrials.gov/show/NCT01583842</td></tr><tr><td>European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses)</td><td>Drug: chemotherapy</td><td>https://ClinicalTrials.gov/show/NCT01728155</td></tr><tr><td>Phase II Study of Proton Radiation Therapy for Neuroblastoma</td><td>Radiation: proton beam radiation therapy</td><td>https://ClinicalTrials.gov/show/NCT02112617</td></tr><tr><td>Immunomonitoring of Children With Neuroblastoma</td><td>Immunological analyses</td><td>https://ClinicalTrials.gov/show/NCT01295762</td></tr><tr><td>Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral <i>&#946;</i>-glucan for High-Risk Neuroblastoma</td><td>Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH</td><td>https://ClinicalTrials.gov/show/NCT00911560</td></tr><tr><td>Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma</td><td>Laboratory biomarker analysis; cytology specimen collection procedure</td><td>https://ClinicalTrials.gov/show/NCT00904241</td></tr><tr><td>Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma</td><td>Drug: dasatinibDrug: rapamycinDrug: irinotecanDrug: temozolomideDrug: irinotecanDrug: temozolomide</td><td>https://ClinicalTrials.gov/show/NCT01467986</td></tr><tr><td>Study of DNA in Blood Samples From Patients With Neuroblastoma</td><td>Laboratory biomarker analysisGenetic: polymerase chain reactionGenetic: polyacrylamide gel electrophoresisGenetic: DNA analysis</td><td>https://ClinicalTrials.gov/show/NCT00898391</td></tr><tr><td>Monitor Response to Treatment in Neuroblastoma Using 3&amp;Apos;-Deoxy-3&amp;Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET)</td><td>Device: FLT-PET</td><td>https://ClinicalTrials.gov/show/NCT01308905</td></tr><tr><td>Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma</td><td>Drug: fenretinide Lym-X-Sorb oral powderDrug: ketoconazole</td><td>https://ClinicalTrials.gov/show/NCT02075177</td></tr><tr><td>Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma</td><td>Biological: IL-2Biological: GD2Bi-aATCBiological: GM-CSFOther: laboratory evaluations of immune responses</td><td>https://ClinicalTrials.gov/show/NCT02100930</td></tr><tr><td>Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma</td><td>Biological: anti-GD2 3F8 monoclonal antibodyDrug: GM-CSF (granulocyte-macrophage colony-stimulating factor)Drug: oral isotretinoin</td><td>https://ClinicalTrials.gov/show/NCT02100930</td></tr><tr><td>Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma</td><td>Drug: fenretinide/LXS oral powderDrug: ketoconazoleDrug: vincristine</td><td>https://ClinicalTrials.gov/show/NCT02163356</td></tr><tr><td>Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma</td><td>Biological: activated T lymphocyte</td><td>https://ClinicalTrials.gov/show/NCT01802138</td></tr><tr><td>3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN</td><td>Genetic: iC9-GD2 T-cell lymphocytes &#8211; frozen cellsGenetic: iC9-GD2 T-cell lymphocytes &#8211; fresh cellsDrug: cyclophosphamideDrug: fludarabineDrug: pembrolizumab</td><td>https://ClinicalTrials.gov/show/NCT01822652</td></tr></table>
<table><tr><td>Clinical trials</td><td>Interventions</td><td>URL</td></tr><tr><td>124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patie</td><td></td><td>https://ClinicalTrials.gov/show/NCT01583842</td></tr></table>
<table><tr><td>nts With Neuroblastoma: A Pilot Study</td><td>Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added)</td><td></td></tr><tr><td>European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses)</td><td>Drug: chemotherapy</td><td>https://ClinicalTrials.gov/show/NCT01728155</td></tr><tr><td>Phase II Study of Proton Radiation Therapy for Neuroblastoma</td><td>Radiation: proton beam radiation therapy</td><td>https://ClinicalTrials.gov/show/NCT02112617</td></tr><tr><td>Immunomonitoring of Children With Neuroblastoma</td><td>Immunological analyses</td><td>https://ClinicalTrials.gov/show/NCT01295762</td></tr><tr><td>Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma</td><td>Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH</td><td>https://ClinicalTrials.gov/show/NCT00911560</td></tr><tr><td>Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma</td><td>Laboratory biomarker analysis; cytology specimen collection procedure</td><td>https://ClinicalTrials.gov/show/NCT00904241</td></tr><tr><td>Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma</td><td>Drug: dasatinibDrug: rapamycinDrug: irinotecanDrug: temozolomideDrug: irinotecanDrug: temozolomide</td><td>https://ClinicalTrials.gov/show/NCT01467986</td></tr><tr><td>Study of DNA in Blood Samples From Patients With Neuroblastoma</td><td>Laboratory biomarker analysisGenetic: polymerase chain reactionGenetic: polyacrylamide gel electrophoresisGenetic: DNA analysis</td><td>https://ClinicalTrials.gov/show/NCT00898391</td></tr><tr><td>Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine-Positron Emission Tomography (FLT-PET)</td><td>Device: FLT-PET</td><td>https://ClinicalTrials.gov/show/NCT01308905</td></tr><tr><td>Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma</td><td>Drug: fenretinide Lym-X-Sorb oral powderDrug: ketoconazole</td><td>https://ClinicalTrials.gov/show/NCT02075177</td></tr><tr><td>Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults with Neuroblastoma and Osteosarcoma</td><td>Biological: IL-2Biological: GD2Bi-aATCBiological: GM-CSFOther: laboratory evaluations of immune responses</td><td>https://ClinicalTrials.gov/show/NCT02100930</td></tr><tr><td>Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma</td><td>Biological: anti-GD2 3F8 monoclonal antibodyDrug: GM-CSF (granulocyte-macrophage colony-stimulating factor)Drug: oral isotretinoin</td><td>https://ClinicalTrials.gov/show/NCT02100930</td></tr><tr><td>Fenretinide Lym-X-Sorb+Ketoconazole+Vincristine for Recurrent or Resistant Neuroblastoma</td><td>Drug: fenretinide/LXS oral powderDrug: ketoconazoleDrug: vincristine</td><td>https://ClinicalTrials.gov/show/NCT02163356</td></tr><tr><td>Pilot Study of Activated T-Cell Therapy for Refractory/Relapsed Neuroblastoma</td><td>Biological: activated T lymphocyte</td><td>https://ClinicalTrials.gov/show/NCT01802138</td></tr><tr><td>3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN</td><td>Genetic: iC9-GD2 T-cell lymphocytes – frozen cellsGenetic: iC9-GD2 T-cell lymphocytes – fresh cellsDrug: cyclophosphamideDrug: fludarabineDrug: pembrolizumab</td><td>https://ClinicalTrials.gov/show/NCT01822652</td></tr></table>
021dbabad68a7ad792b14d061ed0531423bd4869aade3007fa149daf2b45e637.png
complex
<table><tr><td>Capacity areas/skills for HPSR+A</td><td>Proportion of staff requiring additional training (n = 123), n (%)</td></tr><tr><td>HPSR+A technical skills and conceptual underpinnings,</td><td></td></tr><tr><td> e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching</td><td>101 (82.0)</td></tr><tr><td>HPSR+A research and writing</td><td></td></tr><tr><td> Writing research methodologies</td><td>84 (68.0)</td></tr><tr><td rowspan="2"> Writing briefing notes for politicians, policymakers, external funders and donors</td><td></td></tr><tr><td>80 (65.0)</td></tr><tr><td> Writing papers for academic journals</td><td>78 (63.0)</td></tr><tr><td>Management and administration</td><td></td></tr><tr><td> Leadership</td><td>92 (75.0)</td></tr><tr><td> Effective networking</td><td>94 (76.0)</td></tr><tr><td>Financial and information management</td><td></td></tr><tr><td> Identifying and applying for external funding sources</td><td>95 (77.0)</td></tr><tr><td> Creating and managing effective and efficient financial reporting systems</td><td>91 (74.0)</td></tr><tr><td> Creating and managing effective internal information systems</td><td>101 (82.0)</td></tr></table>
<table><tr><td>Capacity areas/skills for HPSR+A</td></tr><tr><td>HPSR+A technical skills and conceptual underpinnings,</td></tr><tr><td>e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching</td></tr><tr><td>HPSR+A research and writing</td></tr><tr><td>Writing research methodologies</td></tr><tr><td rowspan="2">Writing briefing notes for politicians, policymakers, external funders and donors</td></tr><tr></tr><tr><td>Writing papers for academic journals</td></tr><tr><td>Management and administration</td></tr><tr><td>Leadership</td></tr><tr><td>Effective networking</td></tr><tr><td>Financial and information management</td></tr><tr><td>Identifying and applying for external funding sources</td></tr><tr><td>Creating and managing effective and efficient financial reporting systems</td></tr><tr><td>Creating and managing effective internal information systems</td></tr></table>
<table><tr><td>Proportion of staff requiring additional training (n = 123), n (%)</td></tr><tr><td></td></tr><tr><td>101 (82.0)</td></tr><tr><td></td></tr><tr><td>84 (68.0)</td></tr><tr><td></td></tr><tr><td>80 (65.0)</td></tr><tr><td>78 (63.0)</td></tr><tr><td></td></tr><tr><td>92 (75.0)</td></tr><tr><td>94 (76.0)</td></tr><tr><td></td></tr><tr><td>95 (77.0)</td></tr><tr><td>91 (74.0)</td></tr><tr><td>101 (82.0)</td></tr></table>
5f878d53217ae4423cf49df0789c433e72e7fe65c36e96a96f1865433f9ec60a.png
simple
<table><tr><td>Variable</td><td>n</td><td>%</td><td>SE (<i>P</i>)</td></tr><tr><td>Sex</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>207</td><td>62.9</td><td>2.67</td></tr><tr><td> Female</td><td>121</td><td>36.8</td><td>2.66</td></tr><tr><td>Age (y)</td><td></td><td></td><td></td></tr><tr><td> &lt;40</td><td>11</td><td>3.3</td><td>0.98</td></tr><tr><td> 41&#8211;50</td><td>58</td><td>17.6</td><td>2.10</td></tr><tr><td> 51&#8211;60</td><td>72</td><td>22.8</td><td>2.31</td></tr><tr><td> &gt;60</td><td>158</td><td>56.2</td><td>2.74</td></tr><tr><td>Marital status</td><td></td><td></td><td></td></tr><tr><td> Single</td><td>14</td><td>4.3</td><td>1.12</td></tr><tr><td> Married</td><td>264</td><td>8.2</td><td>1.51</td></tr><tr><td> Other</td><td>16</td><td>4.8</td><td>1.18</td></tr><tr><td>Unknown</td><td>12</td><td>3.6</td><td>1.03</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td></tr><tr><td> Afro-Trinidadian</td><td>80</td><td>24.3</td><td>2.36</td></tr><tr><td> Indo-Trinidadian</td><td>238</td><td>72.3</td><td>2.47</td></tr><tr><td> Other (including mixed race)</td><td>11</td><td>3.3</td><td>0.98</td></tr><tr><td>Highest level of education</td><td></td><td></td><td></td></tr><tr><td> Primary</td><td>213</td><td>64.7</td><td>2.63</td></tr><tr><td> Secondary</td><td>103</td><td>31.2</td><td>2.56</td></tr><tr><td> Other</td><td>2</td><td>0.6</td><td>0.43</td></tr><tr><td>Unknown</td><td>6</td><td>1.8</td><td>0.73</td></tr><tr><td>Employment status</td><td></td><td></td><td></td></tr><tr><td> Employed</td><td>62</td><td>18.8</td><td>2.15</td></tr><tr><td> Unemployed</td><td>256</td><td>77.8</td><td>2.29</td></tr><tr><td> Unknown</td><td>11</td><td>3.3</td><td>0.98</td></tr><tr><td>Religion</td><td></td><td></td><td></td></tr><tr><td> Hindu</td><td>180</td><td>54.7</td><td>2.74</td></tr><tr><td> Islam</td><td>27</td><td>8.2</td><td>1.51</td></tr><tr><td> Christian</td><td>75</td><td>22.8</td><td>2.31</td></tr><tr><td> Other</td><td>39</td><td>11.9</td><td>1.79</td></tr><tr><td> Unknown</td><td>8</td><td>2.4</td><td>0.84</td></tr></table>
<table><tr><td>Variable</td><td>n</td><td>%</td><td>SE (P)</td></tr><tr><td>Sex</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>207</td><td>62.9</td><td>2.67</td></tr><tr><td>Female</td><td>121</td><td>36.8</td><td>2.66</td></tr><tr><td>Age (y)</td><td></td><td></td><td></td></tr><tr><td><40</td><td>11</td><td>3.3</td><td>0.98</td></tr><tr><td>41–50</td><td>58</td><td>17.6</td><td>2.10</td></tr><tr><td>51–60</td><td>72</td><td>22.8</td><td>2.31</td></tr><tr><td>>60</td><td>158</td><td>56.2</td><td>2.74</td></tr></table>
<table><tr><td>Marital status</td><td></td><td></td><td></td></tr><tr><td>Single</td><td>14</td><td>4.3</td><td>1.12</td></tr><tr><td>Married</td><td>264</td><td>8.2</td><td>1.51</td></tr><tr><td>Other</td><td>16</td><td>4.8</td><td>1.18</td></tr><tr><td>Unknown</td><td>12</td><td>3.6</td><td>1.03</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td></tr><tr><td>Afro-Trinidadian</td><td>80</td><td>24.3</td><td>2.36</td></tr><tr><td>Indo-Trinidadian</td><td>238</td><td>72.3</td><td>2.47</td></tr><tr><td>Other (including mixed race)</td><td>11</td><td>3.3</td><td>0.98</td></tr><tr><td>Highest level of education</td><td></td><td></td><td></td></tr><tr><td>Primary</td><td>213</td><td>64.7</td><td>2.63</td></tr><tr><td>Secondary</td><td>103</td><td>31.2</td><td>2.56</td></tr><tr><td>Other</td><td>2</td><td>0.6</td><td>0.43</td></tr><tr><td>Unknown</td><td>6</td><td>1.8</td><td>0.73</td></tr><tr><td>Employment status</td><td></td><td></td><td></td></tr><tr><td>Employed</td><td>62</td><td>18.8</td><td>2.15</td></tr><tr><td>Unemployed</td><td>256</td><td>77.8</td><td>2.29</td></tr><tr><td>Unknown</td><td>11</td><td>3.3</td><td>0.98</td></tr><tr><td>Religion</td><td></td><td></td><td></td></tr><tr><td>Hindu</td><td>180</td><td>54.7</td><td>2.74</td></tr><tr><td>Islam</td><td>27</td><td>8.2</td><td>1.51</td></tr><tr><td>Christian</td><td>75</td><td>22.8</td><td>2.31</td></tr><tr><td>Other</td><td>39</td><td>11.9</td><td>1.79</td></tr><tr><td>Unknown</td><td>8</td><td>2.4</td><td>0.84</td></tr></table>
4a9197a72bdd3845b64a72d3e5eabc783c3061d278531812f891899b5df9f5d0.png
complex
<table><tr><td rowspan="2">Variables</td><td>Cases</td><td>Controls</td><td>Adjusted OR ratio</td><td rowspan="2">P value</td></tr><tr><td>No. (%)</td><td>No. (%)</td><td>(95% Cl)</td></tr><tr><td>Family size (mean 95% Cl)</td><td>5.8(5.3-6.4)</td><td>4.8(4.4-5.1)</td><td>1.359(1.026-1.799)</td><td>0.032</td></tr><tr><td>Sleeping on bed</td><td>74(82.2%)</td><td>183(94.8%)</td><td>0.158(0.028-0.898)</td><td>0.037</td></tr><tr><td>Ref. ground</td><td>16(17.8%)</td><td>10(5.2%)</td><td>1</td><td></td></tr><tr><td>Cracked house wall (Yes)</td><td>60 (66.7%)</td><td>84 (44.4%)</td><td>6.368(1.585-25.580)</td><td>0.009</td></tr><tr><td>Ref. (un-cracked)</td><td>30(33.3%)</td><td>105(55.6%)</td><td>1</td><td></td></tr><tr><td>Own goats (Yes)</td><td>37(41.1%)</td><td>43(22.3%)</td><td>6.445(1.463-28.384)</td><td>0.014</td></tr><tr><td>Ref. (No)</td><td>53(58.9%)</td><td>150(77.7%)</td><td>1</td><td></td></tr><tr><td>Sleeping outside the house under bed net</td><td>16(17.8%)</td><td>118(61.1%)</td><td>0.093(0.024-0.357)</td><td>0.001</td></tr><tr><td>Ref. (without bed net)</td><td>74(82.2%)</td><td>75(38.9%)</td><td>1</td><td></td></tr><tr><td>Smoking house (Yes)</td><td>50(56.2%)</td><td>168(87.0%)</td><td>0.082(0.011-0.630)</td><td>0.016</td></tr><tr><td>Ref. (No)</td><td>39(43.8%)</td><td>25(13.0%)</td><td>1</td><td></td></tr><tr><td>Number of days stayed in the farm field (mean 95% CL)</td><td>91.3(61.7-120.9)</td><td>8(5.9-10)</td><td>1.100(1.015-1.192)</td><td>0.020</td></tr></table>
<table><tr><td rowspan="2">Variables</td><td>Cases</td><td>Controls</td><td>Adjusted OR ratio</td><td rowspan="2">P value</td></tr><tr><td>No. (%)</td><td>No. (%)</td><td>(95% Cl)</td></tr><tr><td>Family size (mean 95% Cl)</td><td>5.8(5.3-6.4)</td><td>4.8(4.4-5.1)</td><td>1.359(1.026-1.799)</td><td>0.032</td></tr><tr><td>Sleeping on bed</td><td>74(82.2%)</td><td>183(94.8%)</td><td>0.158(0.028-0.898)</td><td>0.037</td></tr><tr><td>Ref. ground</td><td>16(17.8%)</td><td>10(5.2%)</td><td>1</td><td></td></tr><tr><td>Cracked house wall (Yes)</td><td>60 (66.7%)</td><td>84 (44.4%)</td><td>6.368(1.585-25.580)</td><td>0.009</td></tr><tr><td>Ref. (un-cracked)</td><td>30(33.3%)</td><td>105(55.6%)</td><td>1</td><td></td></tr><tr><td>Own goats (Yes)</td><td>37(41.1%)</td><td>43(22.3%)</td><td>6.445(1.463-28.384)</td><td>0.014</td></tr></table>
<table><tr><td>Ref. (No)</td><td>53(58.9%)</td><td>150(77.7%)</td><td>1</td><td></td></tr><tr><td>Sleeping outside the house under bed net</td><td>16(17.8%)</td><td>118(61.1%)</td><td>0.093(0.024-0.357)</td><td>0.001</td></tr><tr><td>Ref. (without bed net)</td><td>74(82.2%)</td><td>75(38.9%)</td><td>1</td><td></td></tr><tr><td>Smoking house (Yes)</td><td>50(56.2%)</td><td>168(87.0%)</td><td>0.082(0.011-0.630)</td><td>0.016</td></tr><tr><td>Ref. (No)</td><td>39(43.8%)</td><td>25(13.0%)</td><td>1</td><td></td></tr><tr><td>Number of days stayed in the farm field (mean 95% CL)</td><td>91.3(61.7-120.9)</td><td>8(5.9-10)</td><td>1.100(1.015-1.192)</td><td>0.020</td></tr></table>
e7b94328afe7a4805b2aa03fe1a4f0ef063b12c90fda2ae99a3dbaee3c58dee9.png
complex
<table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose mg kg<sup>&#8722;1</sup></td><td>Cotton pellet granuloma</td></tr><tr><td>Weight of pellets Mean &#177; SEM</td></tr><tr><td>Control</td><td>0.3 mL</td><td>51.73 &#177; 2.35</td></tr><tr><td>Indomethacin</td><td>10</td><td>19.82 &#177; 2.52 (61.68)<sup>b</sup></td></tr><tr><td>EEDR</td><td>100</td><td>37.24 &#177; 2.00 (27.99)<sup>NS</sup></td></tr><tr><td>EEDR</td><td>200</td><td>30.85 &#177; 3.72 (40.36)<sup>b</sup></td></tr><tr><td>EEDR</td><td>400</td><td>29.77 &#177; 3.76 (42.44)<sup>a</sup></td></tr></table>
<table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose mg kg−1</td><td>Cotton pellet granuloma</td></tr><tr><td>Weight of pellets Mean ± SEM</td></tr><tr><td>Control</td><td>0.3 mL</td><td>51.73 ± 2.35</td></tr><tr><td>Indomethacin</td><td>10</td><td>19.82 ± 2.52 (61.68)b</td></tr><tr><td>EEDR</td><td>100</td><td>37.24 ± 2.00 (27.99)NS</td></tr><tr><td>EEDR</td><td>2</td><td>30.85 ± 3.72 (40.36</td></tr></table>
<table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose mg kg−1</td><td>Cotton pellet granuloma</td></tr><tr><td>Weight of pellets Mean ± SEM</td></tr><tr><td></td><td>00</td><td>)b</td></tr><tr><td>EEDR</td><td>400</td><td>29.77 ± 3.76 (42.44)a</td></tr></table>
38faa325fa1ef7142f47f0185c8d79492a36b15bce9c5663158995af6ed5bdfb.png
simple
<table><tr><td>Characteristic</td><td>All</td><td>LGE [IQR]</td><td>Non-LGE [IQR]</td><td>p value</td></tr><tr><td></td><td>(<i>n </i>= 20)</td><td>(<i>n </i>= 8)</td><td>(<i>n </i>= 12)</td><td></td></tr><tr><td>Age (years)</td><td>77 [65-82]</td><td>75 [70-80]</td><td>78 [65-84]</td><td>0.4</td></tr><tr><td>Female sex, <i>n </i>(%)</td><td>18 (90%)</td><td>8 (100%)</td><td>10 (83%)</td><td>0.5</td></tr><tr><td>Triggering factor (emotional/physical)</td><td>15 (75%)</td><td>7 (88%)</td><td>8 (67%)</td><td>0.6</td></tr><tr><td>Chest pain</td><td>18 (90%)</td><td>8 (100%)</td><td>10 (83%)</td><td>0.5</td></tr><tr><td>Cardiac event</td><td></td><td></td><td></td><td></td></tr><tr><td> CHF</td><td>3 (15%)</td><td>2 (25%)</td><td>1 (8%)</td><td>0.5</td></tr><tr><td> Cardiogenic shock</td><td>3 (15%)</td><td>3 (38%)</td><td>0 (0%)</td><td>0.049*</td></tr><tr><td>Peak creatine kinase level (IU/L)</td><td>204 [141-223]</td><td>212 [203-243]</td><td>146 [107-221]</td><td>0.09</td></tr><tr><td>Serum noradrenaline elevation</td><td>11 (55%)</td><td>4 (50%)</td><td>7 (58%)</td><td>1.0</td></tr><tr><td>ECG abnormalities</td><td>20 (100%)</td><td>8 (100%)</td><td>12 (100%)</td><td>1.0</td></tr><tr><td> ST elevation</td><td>12 (60%)</td><td>7 (88%)</td><td>5 (42%)</td><td>0.07</td></tr><tr><td> ST depression</td><td>2 (10%)</td><td>0 (0%)</td><td>2 (17%)</td><td>0.5</td></tr><tr><td> T inversion</td><td>10 (50%)</td><td>2 (25%)</td><td>8 (67%)</td><td>0.2</td></tr><tr><td>LVOT obstruction</td><td>1 (5%)</td><td>1 (13%)</td><td>0 (0%)</td><td>0.4</td></tr><tr><td>Ejection fraction (LVG) (%)</td><td>49 [45-53]</td><td>49 [44-52]</td><td>49 [47-53]</td><td>0.7</td></tr><tr><td>Typical TTC</td><td>11 (55%)</td><td>5 (63%)</td><td>6 (50%)</td><td>0.7</td></tr><tr><td>Time from symptom onset to CMR (days)</td><td>5 [3-6]</td><td>5 [3-6]</td><td>4 [3-6]</td><td>0.8</td></tr><tr><td>Ejection fraction (CMR) (%)</td><td>51 [45-54]</td><td>50 [43-53]</td><td>51 [50-58]</td><td>0.6</td></tr><tr><td>Duration to normalization (days)</td><td></td><td></td><td></td><td></td></tr><tr><td> Electrocardiography</td><td>151 [132-188]</td><td>215 [175-363]</td><td>140 [112-151]</td><td>0.005*</td></tr><tr><td> Echocardiography</td><td>10 [6-14]</td><td>15 [10-18]</td><td>7 [5-13]</td><td>0.03*</td></tr></table>
<table><tr><td>Characteristic</td><td>All</td><td>LGE [IQR]</td><td>Non-LGE [IQR]</td><td>p value</td></tr><tr><td></td><td>(n = 20)</td><td>(n = 8)</td><td>(n = 12)</td><td></td></tr><tr><td>Age (years)</td><td>77 [65-82]</td><td>75 [70-80]</td><td>78 [65-84]</td><td>0.4</td></tr><tr><td>Female sex, n (%)</td><td>18 (90%)</td><td>8 (100%)</td><td>10 (83%)</td><td>0.5</td></tr><tr><td>Triggering factor (emotional/physical)</td><td>15 (75%)</td><td>7 (88%)</td><td>8 (67%)</td><td>0.6</td></tr><tr><td>Chest pain</td><td>18 (90%)</td><td>8 (100%)</td><td>10 (83%)</td><td>0.5</td></tr><tr><td>Cardiac event</td><td></td><td></td><td></td><td></td></tr></table>
<table><tr><td>Characteristic</td><td>All</td><td>LGE [IQR]</td><td>Non-LGE [IQR]</td><td>p value</td></tr><tr><td></td><td>(n = 20)</td><td>(n = 8)</td><td>(n = 12)</td><td></td></tr><tr><td>CHF</td><td>3 (15%)</td><td>2 (25%)</td><td>1 (8%)</td><td>0.5</td></tr><tr><td>Cardiogenic shock</td><td>3 (15%)</td><td>3 (38%)</td><td>0 (0%)</td><td>0.049*</td></tr><tr><td>Peak creatine kinase level (IU/L)</td><td>204 [141-223]</td><td>212 [203-243]</td><td>146 [107-221]</td><td>0.09</td></tr><tr><td>Serum noradrenaline elevation</td><td>11 (55%)</td><td>4 (50%)</td><td>7 (58%)</td><td>1.0</td></tr><tr><td>ECG abnormalities</td><td>20 (100%)</td><td>8 (100%)</td><td>12 (100%)</td><td>1.0</td></tr><tr><td>ST elevation</td><td>12 (60%)</td><td>7 (88%)</td><td>5 (42%)</td><td>0.07</td></tr><tr><td>ST depression</td><td>2 (10%)</td><td>0 (0%)</td><td>2 (17%)</td><td>0.5</td></tr><tr><td>T inversion</td><td>10 (50%)</td><td>2 (25%)</td><td>8 (67%)</td><td>0.2</td></tr><tr><td>LVOT obstruction</td><td>1 (5%)</td><td>1 (13%)</td><td>0 (0%)</td><td>0.4</td></tr><tr><td>Ejection fraction (LVG) (%)</td><td>49 [45-53]</td><td>49 [44-52]</td><td>49 [47-53]</td><td>0.7</td></tr><tr><td>Typical TTC</td><td>11 (55%)</td><td>5 (63%)</td><td>6 (50%)</td><td>0.7</td></tr><tr><td>Time from symptom onset to CMR (days)</td><td>5 [3-6]</td><td>5 [3-6]</td><td>4 [3-6]</td><td>0.8</td></tr><tr><td>Ejection fraction (CMR) (%)</td><td>51 [45-54]</td><td>50 [43-53]</td><td>51 [50-58]</td><td>0.6</td></tr><tr><td>Duration to normalization (days)</td><td></td><td></td><td></td><td></td></tr><tr><td>Electrocardiography</td><td>151 [132-188]</td><td>215 [175-363]</td><td>140 [112-151]</td><td>0.005*</td></tr><tr><td>Echocardiography</td><td>10 [6-14]</td><td>15 [10-18]</td><td>7 [5-13]</td><td>0.03*</td></tr></table>
69f4185d1b5e258904f268af7655885a9394ac5a7843f08cf12409ac9d168424.png
simple
<table><tr><td>Successful Aging Approach</td><td>Definition</td><td>References</td></tr><tr><td>Biomedical</td><td>Absence of multi-morbidity</td><td>[6]</td></tr><tr><td>Psycho-Cognitive</td><td>Absence of depression, absence of anxiety, no cognitive impairment, regular functioning, quality of life, resilience</td><td>[3,12,14,38]</td></tr><tr><td>Lay View Approach</td><td>Presence of well-being, good self perceived health</td><td>[8,12]</td></tr><tr><td>Combined Approach</td><td>Optimal functioning</td><td>[6,12]</td></tr></table>
<table><tr><td>Successful Aging Approach</td><td>Definition</td><td>References</td></tr><tr><td>Biomedical</td><td>Absence of multi-morbidity</td><td>[6]</td></tr><tr><td>Psycho-Cognitive</td><td>Absence of depression, absence of anxiety, no cognitive impairment, regular functioning, quality of life, resilience</td><td>[3,12,14,38]</td></tr></table>
<table><tr><td>Successful Aging Approach</td><td>Definition</td><td>References</td></tr><tr><td>Lay View Approach</td><td>Presence of well-being, good self perceived health</td><td>[8,12]</td></tr><tr><td>Combined Approach</td><td>Optimal functioning</td><td>[6,12]</td></tr></table>
9fe8545e6152550dbaaa8b03f9f6ceee74e41b643f3343d6109e9e806b5cae87.png
complex
<table><tr><td>Country and Year</td><td>Criteria used for identifying asymptomatic malaria cases</td><td>Study subjects, sample size</td><td>Follow-up protocol and duration</td><td>Ref.</td></tr><tr><td colspan="5">Africa</td></tr><tr><td>Gabon, 2003</td><td>No clinical symptoms of malaria with a <i>P. falciparum </i>positive blood smear, asymptomatic for at least 5 days during follow-up.</td><td>Children6 months to 10 years, N = 60</td><td>Examined once daily for 7 days thereafter, once every 2 days</td><td>[37]</td></tr><tr><td>Tanzania, 2006</td><td>Presence of <i>P. falciparum </i>on blood smear, axillary temperature of &lt; 37.5&#176;C, and no other symptoms or signs of malaria</td><td>Children4-59 months,N = 127</td><td>No follow-up.</td><td>[33]</td></tr><tr><td colspan="5">South America</td></tr><tr><td>Brazilian Amazon, 2002</td><td>Individuals positive by microscopy, and/or positive by PCR; and individuals negative by microscopy that subsequently became positive by PCR.</td><td>All age groups,N = 172</td><td>Follow-up to day 10 and 60.</td><td>[21]</td></tr><tr><td>Colombia, 2008</td><td>Presence of microscopic asexual parasite stages of <i>P. falciparum</i>, <i>P. vivax </i>or <i>P. malariae </i>or of mixed infections in blood, which persisted for at least two weeks without causing any symptoms, or as the detection of parasite DNA by PCR on day 0 in people who remained asymptomatic during the follow-up period.</td><td>Individuals2-78 years,N = 21</td><td>Follow-up on days 14 and 28.</td><td>[19]</td></tr><tr><td colspan="5">Asia</td></tr><tr><td>Papua, 2003</td><td>No fever history or treatment for malaria within the past week, no clinical evidence of malaria or other infection, no diarrhea, and no current pregnancy but both <i>P. falciparum </i>and <i>P. vivax </i>positive individuals</td><td>Adults&gt; 16 years,N = 105</td><td>Supervised overnight at local health center. A third axillary temperature was recorded the following morning.</td><td>[38]</td></tr><tr><td>Indonesia, 2010</td><td>Presence of asexual <i>P. falciparum </i>or <i>P. vivax </i>parasitemia in the absence of fever (temperature &#8804; 37.9&#176;C) and of clinical signs or symptoms suggestive for malaria or another infectious disease.</td><td>Children5-15 years,N = 381</td><td>No follow-up.</td><td>[27]</td></tr></table>
<table><tr><td>Country</td><td>Crite</td><td>Study subject</td><td>Follow-up protocol and durati</td><td>Ref</td></tr></table>
<table><tr><td> and Year</td><td>ria used for identifying asymptomatic malaria cases</td><td>s, sample size</td><td>on</td><td>.</td></tr><tr><td colspan="5">Africa</td></tr><tr><td>Gabon, 2003</td><td>No clinical symptoms of malaria with a P. falciparum positive blood smear, asymptomatic for at least 5 days during follow-up.</td><td>Children6 months to 10 years, N = 60</td><td>Examined once daily for 7 days thereafter, once every 2 days</td><td>[37]</td></tr><tr><td>Tanzania, 2006</td><td>Presence of P. falciparum on blood smear, axillary temperature of < 37.5°C, and no other symptoms or signs of malaria</td><td>Children4-59 months,N = 127</td><td>No follow-up.</td><td>[33]</td></tr><tr><td colspan="5">South America</td></tr><tr><td>Brazilian Amazon, 2002</td><td>Individuals positive by microscopy, and/or positive by PCR; and individuals negative by microscopy that subsequently became positive by PCR.</td><td>All age groups,N = 172</td><td>Follow-up to day 10 and 60.</td><td>[21]</td></tr><tr><td>Colombia, 2008</td><td>Presence of microscopic asexual parasite stages of P. falciparum, P. vivax or P. malariae or of mixed infections in blood, which persisted for at least two weeks without causing any symptoms, or as the detection of parasite DNA by PCR on day 0 in people who remained asymptomatic during the follow-up period.</td><td>Individuals2-78 years,N = 21</td><td>Follow-up on days 14 and 28.</td><td>[19]</td></tr><tr><td colspan="5">Asia</td></tr><tr><td>Papua, 2003</td><td>No fever history or treatment for malaria within the past week, no clinical evidence of malaria or other infection, no diarrhea, and no current pregnancy but both P. falciparum and P. vivax positive individuals</td><td>Adults> 16 years,N = 105</td><td>Supervised overnight at local health center. A third axillary temperature was recorded the following morning.</td><td>[38]</td></tr><tr><td>Indonesia, 2010</td><td>Presence of asexual P. falciparum or P. vivax parasitemia in the absence of fever (temperature ≤ 37.9°C) and of clinical signs or symptoms suggestive for malaria or another infectious disease.</td><td>Children5-15 years,N = 381</td><td>No follow-up.</td><td>[27]</td></tr></table>
36f88ed582bd0bdf0254df192a761747cd5449c424e4e174da31d02879d2fe58.png
complex
<table><tr><td rowspan="2">Samples</td><td colspan="6">Inhibition zones &#177; (mm)<sup>1</sup></td></tr><tr><td><i>E. coli</i>CCMB261</td><td><i>S. aureus</i> CCMB262</td><td><i>S. aureus</i> CCMB263</td><td><i>P. aeruginosa</i>CCMB268</td><td><i>C. albicans</i>CCMB286</td><td><i>C. parapsilosis</i>CCMB288</td></tr><tr><td><i>L. alnifolia</i> leaves</td><td>R</td><td>10.2 &#177; 1.3</td><td>10 &#177; 0.5</td><td>R</td><td>R</td><td>R</td></tr><tr><td><i>L. alnifolia</i> stems</td><td>R</td><td>12.3 &#177; 1.0</td><td>13.9 &#177; 0.8</td><td>R</td><td>R</td><td>R</td></tr><tr><td><i>L. alnifolia</i> flowers</td><td>R</td><td>8.4 &#177; 0.9</td><td>R</td><td>R</td><td>R</td><td>6.9 &#177; 0.1</td></tr><tr><td><i>L. origanoides</i> leaves</td><td>R</td><td>13.0 &#177; 0.5</td><td>12.0 &#177; 0.9</td><td>R</td><td>11.7 &#177; 0.4</td><td>7.1 &#177; 0.4</td></tr><tr><td><i>L. origanoides</i> stems</td><td>R</td><td>R</td><td>R</td><td>R</td><td>R</td><td>R</td></tr><tr><td><i>L. thymoides </i> leaves</td><td>R</td><td>11.2 &#177; 1.0</td><td>9.7 &#177; 1.3</td><td>R</td><td>R</td><td>R</td></tr><tr><td><i>L. thymoides </i>stems</td><td>R</td><td>8.7 &#177; 0.6</td><td>R</td><td>R</td><td>R</td><td>R</td></tr><tr><td><i>L. thymoides </i> flowers</td><td>R</td><td>8.5 &#177; 1.5</td><td>R</td><td>R</td><td>R</td><td>R</td></tr><tr><td>Cloramphenicol<sup>2</sup></td><td>15.8 &#177; 1.7</td><td>22.6 &#177; 2.2</td><td>R</td><td>8.5 &#177; 0.9</td><td>&#8212;</td><td>&#8212;</td></tr><tr><td>Nystatin<sup>3</sup></td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>&#8212;</td><td>17.5 &#177; 0.9</td><td>16.6 &#177; 0.9</td></tr></table>
<table><tr><td rowspan="2">Samples</td><td colspan="6">Inhibition zones ± (mm)1</td></tr><tr><td>E. coliCCMB261</td><td>S. aureus CCMB262</td><td>S. aureus CCMB263</td><td>P. aeruginosaCCMB268</td><td>C. albicansCCMB286</td><td>C. parapsilosisCCMB288</td></tr><tr><td>L. alnifolia leaves</td><td>R</td><td>10.2 ± 1.3</td><td>10 ± 0.5</td><td>R</td><td>R</td><td>R</td></tr><tr><td>L. alnifolia stems</td><td>R</td><td>12.3 ± 1.0</td><td>13.9 ± 0.8</td><td>R</td><td>R</td><td>R</td></tr><tr><td>L. alnifolia flowers</td><td>R</td><td>8.4 ± 0.9</td><td>R</td><td>R</td><td>R</td><td>6.9 ± 0.1</td></tr><tr><td>L. origanoides leaves</td><td>R</td><td>13.0 ± 0.5</td><td>12.0 ± 0.9</td><td>R</td><td>11.7 ± 0.4</td><td>7.1 ± 0.4</td></tr><tr><td>L. origanoides stems</td><td>R</td><td>R</td><td>R</td><td>R</td><td>R</td><td>R</td></tr><tr><td>L. thymoides leaves</td><td>R</td><td>11.2 ± 1.0</td><td>9.7 ± 1.3</td><td>R</td><td>R</td><td>R</td></tr><tr><td>L. thymoides stems</td><td>R</td><td>8.7 ± 0.6</td><td>R</td><td>R</td><td>R</td><td>R</td></tr></table>
<table><tr><td rowspan="2">Samples</td><td colspan="6">Inhibition zones ± (mm)1</td></tr><tr><td>E. coliCCMB261</td><td>S. aureus CCMB262</td><td>S. aureus CCMB263</td><td>P. aeruginosaCCMB268</td><td>C. albicansCCMB286</td><td>C. parapsilosisCCMB288</td></tr><tr><td>L. thymoides flowers</td><td>R</td><td>8.5 ± 1.5</td><td>R</td><td>R</td><td>R</td><td>R</td></tr><tr><td>Cloramphenicol2</td><td>15.8 ± 1.7</td><td>22.6 ± 2.2</td><td>R</td><td>8.5 ± 0.9</td><td>—</td><td>—</td></tr><tr><td>Nystatin3</td><td>—</td><td>—</td><td>—</td><td>—</td><td>17.5 ± 0.9</td><td>16.6 ± 0.9</td></tr></table>
eb5e2e7f59bdde7d9732367d5a69d92602999495c2029b1eced30faab504021f.png
complex
<table><tr><td colspan="2">Characteristics</td><td>n (<i>N</i> = 157)</td><td>%</td></tr><tr><td rowspan="4">Age</td><td>&lt;19 years</td><td>3</td><td>1.9</td></tr><tr><td>20&#8211;24 years</td><td>104</td><td>66.3</td></tr><tr><td>25&#8211;29 years</td><td>47</td><td>29.9</td></tr><tr><td>&gt;30 years</td><td>3</td><td>1.9</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>67</td><td>42.7</td></tr><tr><td>Female</td><td>88</td><td>56.1</td></tr><tr><td rowspan="3">Marital status</td><td>Divorced</td><td>2</td><td>1.3</td></tr><tr><td>Not Married</td><td>151</td><td>96.2</td></tr><tr><td>Married</td><td>4</td><td>2.5</td></tr><tr><td rowspan="3">Educational level</td><td>Bachelor degree</td><td>120</td><td>76.4</td></tr><tr><td>Master degree</td><td>14</td><td>8.9</td></tr><tr><td>Doctor degree</td><td>23</td><td>14.6</td></tr><tr><td rowspan="5">Work experience in the health sector</td><td>&lt;6 months</td><td>52</td><td>33.1</td></tr><tr><td>6&#8211;12 months</td><td>53</td><td>33.8</td></tr><tr><td>12&#8211;24 months</td><td>44</td><td>28.0</td></tr><tr><td>24&#8211;36 months</td><td>3</td><td>1.9</td></tr><tr><td>&gt;36 months</td><td>5</td><td>3.2</td></tr><tr><td rowspan="5">Hours worked daily</td><td>&lt;6 h</td><td>9</td><td>5.7</td></tr><tr><td>6&#8211;8 h</td><td>86</td><td>54.8</td></tr><tr><td>8&#8211;10 h</td><td>41</td><td>26.1</td></tr><tr><td>10&#8211;12 h</td><td>18</td><td>11</td></tr><tr><td>&gt;12 h</td><td>3</td><td>1.9</td></tr><tr><td rowspan="4">Night shifts/week</td><td>&lt;1</td><td>34</td><td>21.7</td></tr><tr><td>1</td><td>71</td><td>45.2</td></tr><tr><td>&gt;1</td><td>46</td><td>29.3</td></tr><tr><td>0</td><td>6</td><td>3.8</td></tr><tr><td rowspan="5">Clinic service visits/week</td><td>&lt;5</td><td>99</td><td>63.1</td></tr><tr><td>5&#8211;9</td><td>19</td><td>12.1</td></tr><tr><td>10&#8211;14</td><td>7</td><td>4.5</td></tr><tr><td>15&#8211;19</td><td>6</td><td>3.8</td></tr><tr><td>&gt;20</td><td>26</td><td>16.6</td></tr><tr><td rowspan="5">Discharges/month</td><td>&lt;5</td><td>49</td><td>31.2</td></tr><tr><td>5&#8211;9</td><td>35</td><td>22.3</td></tr><tr><td>10&#8211;14</td><td>24</td><td>15.3</td></tr><tr><td>15&#8211;19</td><td>15</td><td>12.1</td></tr><tr><td>&gt;20</td><td>30</td><td>19.1</td></tr></table>
<table><tr><td colspan="2">Characteristics</td><td>n (N = 157)</td><td>%</td></tr><tr><td rowspan="4">Age</td><td><19 years</td><td>3</td><td>1.9</td></tr><tr><td>20–24 years</td><td>104</td><td>66.3</td></tr><tr><td>25–29 years</td><td>47</td><td>29.9</td></tr><tr><td>>30 years</td><td>3</td><td>1.9</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>67</td><td>42.7</td></tr><tr><td>Female</td><td>88</td><td>56.1</td></tr><tr><td rowspan="3">Marital status</td><td>Divorced</td><td>2</td><td>1.3</td></tr><tr><td>Not Married</td><td>151</td><td>96.2</td></tr><tr><td>Married</td><td>4</td><td>2.5</td></tr><tr><td rowspan="2">Educational level</td><td>Bachelor degree</td><td>120</td><td>76.4</td></tr><tr><td>Master degree</td><td>14</td><td>8.9</td></tr></table>
<table><tr><td>Educational level</td><td>Doctor degree</td><td>23</td><td>14.6</td></tr><tr><td rowspan="5">Work experience in the health sector</td><td><6 months</td><td>52</td><td>33.1</td></tr><tr><td>6–12 months</td><td>53</td><td>33.8</td></tr><tr><td>12–24 months</td><td>44</td><td>28.0</td></tr><tr><td>24–36 months</td><td>3</td><td>1.9</td></tr><tr><td>>36 months</td><td>5</td><td>3.2</td></tr><tr><td rowspan="5">Hours worked daily</td><td><6 h</td><td>9</td><td>5.7</td></tr><tr><td>6–8 h</td><td>86</td><td>54.8</td></tr><tr><td>8–10 h</td><td>41</td><td>26.1</td></tr><tr><td>10–12 h</td><td>18</td><td>11</td></tr><tr><td>>12 h</td><td>3</td><td>1.9</td></tr><tr><td rowspan="4">Night shifts/week</td><td><1</td><td>34</td><td>21.7</td></tr><tr><td>1</td><td>71</td><td>45.2</td></tr><tr><td>>1</td><td>46</td><td>29.3</td></tr><tr><td>0</td><td>6</td><td>3.8</td></tr><tr><td rowspan="5">Clinic service visits/week</td><td><5</td><td>99</td><td>63.1</td></tr><tr><td>5–9</td><td>19</td><td>12.1</td></tr><tr><td>10–14</td><td>7</td><td>4.5</td></tr><tr><td>15–19</td><td>6</td><td>3.8</td></tr><tr><td>>20</td><td>26</td><td>16.6</td></tr><tr><td rowspan="5">Discharges/month</td><td><5</td><td>49</td><td>31.2</td></tr><tr><td>5–9</td><td>35</td><td>22.3</td></tr><tr><td>10–14</td><td>24</td><td>15.3</td></tr><tr><td>15–19</td><td>15</td><td>12.1</td></tr><tr><td>>20</td><td>30</td><td>19.1</td></tr></table>
7218de6fc23796deb05334090941df9b8cdd00cda7544243685e57655abb886d.png
simple
<table><tr><td>Neonatal characteristic </td><td>Newborn-monotherapy dyadsMean (SE) or <i>n</i> (%)</td><td>Newborn-triple therapy dyadsMean (SE) or <i>n</i> (%)</td><td><i>p</i> value</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>45 (53%)</td><td>18 (49%)</td><td>NS</td></tr><tr><td>Gestational age (weeks)<sup><i>&#8727;</i></sup></td><td>38 (0.2)</td><td>37 (0.5)</td><td>&lt;0.01</td></tr><tr><td>Birth weight (g)<sup><i>&#8727;</i></sup></td><td>3079 (63)</td><td>2864 (96)</td><td>NS</td></tr><tr><td>Small for gestational age</td><td>18 (21%)</td><td>3 (8%)</td><td>NS</td></tr><tr><td>Toxicology screen</td><td> </td><td> </td><td> </td></tr><tr><td> Positive</td><td>10 (12%)</td><td>23 (62%)</td><td>&lt;0.05</td></tr><tr><td>NICU admission</td><td>19 (22%)</td><td>20 (54%)</td><td>&lt;0.01</td></tr><tr><td>Length of stay in hospital (days)<sup><i>&#8727;</i></sup></td><td>3 (0.5)</td><td>8 (2)</td><td>&lt;0.05</td></tr><tr><td>CPS involved</td><td>15 (18%)</td><td>26 (70%)</td><td>&lt;0.01</td></tr></table>
<table><tr><td>Neonatal characteristic</td><td>Newborn-monotherapy dyadsMean (SE) or n (%)</td><td>Newborn-triple therapy dyadsMean (SE) or n (%)</td><td>p value</td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>45 (53%)</td><td>18 (49%)</td><td>NS</td></tr><tr><td>Gestational age (weeks)∗</td><td>38 (0.2)</td><td>37 (0.5)</td><td><0.01</td></tr><tr><td>Birth weight (g)∗</td><td>3079 (63)</td><td>2864 (96)</td><td>NS</td></tr><tr><td>Small for gestational age</td><td>18 (21%)</td><td>3 (8%)</td><td>NS</td></tr><tr><td>Toxicology screen</td><td></td><td></td><td></td></tr></table>
<table><tr><td>Positive</td><td>10 (12%)</td><td>23 (62%)</td><td><0.05</td></tr><tr><td>NICU admission</td><td>19 (22%)</td><td>20 (54%)</td><td><0.01</td></tr><tr><td>Length of stay in hospital (days)∗</td><td>3 (0.5)</td><td>8 (2)</td><td><0.05</td></tr><tr><td>CPS involved</td><td>15 (18%)</td><td>26 (70%)</td><td><0.01</td></tr></table>
19012ee9c3c84b5d7b35e1a9602eb0db9b9953ee8d41169cf64f8ceb01e5ffd2.png
simple
<table><tr><td>ARV site</td><td>Total number of patients</td></tr><tr><td>Thamaga primary hospital</td><td>1646</td></tr><tr><td>Nkoyaphiri clinic</td><td>1726</td></tr><tr><td>Gabane clinic</td><td>392</td></tr><tr><td>Thamaga clinic</td><td>114</td></tr><tr><td>Mmankgodi clinic</td><td>70</td></tr><tr><td>Kopong clinic</td><td>200</td></tr><tr><td>Mmopane clinic</td><td>120</td></tr><tr><td>Total</td><td>4268</td></tr></table>
<table><tr><td>ARV site</td></tr><tr><td>Thamaga primary hospital</td></tr><tr><td>Nkoyaphiri clinic</td></tr><tr><td>Gabane clinic</td></tr><tr><td>Thamaga clinic</td></tr><tr><td>Mmankgodi clinic</td></tr><tr><td>Kopong clinic</td></tr><tr><td>Mmopane clinic</td></tr><tr><td>Total</td></tr></table>
<table><tr><td>Total number of patients</td></tr><tr><td>1646</td></tr><tr><td>1726</td></tr><tr><td>392</td></tr><tr><td>114</td></tr><tr><td>70</td></tr><tr><td>200</td></tr><tr><td>120</td></tr><tr><td>4268</td></tr></table>
cd8d3d47aea593f5fe2a9aee7ecef03759ea4d2e77f05fb28ec49adf7857e21a.png
complex
<table><tr><td rowspan="2">Group</td><td rowspan="2">No. mice</td><td colspan="2">Vaccine and administration</td><td rowspan="2">Anti&#8208;HCV Abs</td><td colspan="4">Days post&#8208;prime</td></tr><tr><td>Prime</td><td>2xboost</td><td>0</td><td>14</td><td>28</td><td>42</td></tr><tr><td></td><td></td><td></td><td></td><td>Serum IgM</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td>0</td><td>5</td><td></td><td></td><td>Serum IgG</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td></td><td></td><td>im</td><td>Feeding</td><td>Serum IgM</td><td>0/5</td><td>5/5</td><td>5/5</td><td>5/5</td></tr><tr><td>1</td><td>5</td><td>HEK293T&#8208;E1E2</td><td>Lettuce E1E2</td><td>Serum IgG</td><td>0/5</td><td>0/5</td><td>0/5</td><td>4/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/5</td><td>4/5</td><td>4/5</td><td>4/5</td></tr><tr><td></td><td></td><td>Feeding</td><td></td><td>Serum IgM</td><td>0/7</td><td>0/7</td><td>1/7</td><td>2/7</td></tr><tr><td>2</td><td>7</td><td>Lettuce&#8208;E1E2&#8710;N6</td><td></td><td>Serum IgG</td><td>0/7</td><td>0/7</td><td>0/7</td><td>0/7</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/7</td><td>3/7</td><td>3/7</td><td>3/7</td></tr><tr><td></td><td></td><td>Feeding</td><td></td><td>Serum IgM</td><td>0/5</td><td>0/5</td><td>1/5</td><td>1/5</td></tr><tr><td>3</td><td>5</td><td>Lettuce&#8208;E1E2</td><td></td><td>Serum IgG</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td>4</td><td>5</td><td>im</td><td>im</td><td>Serum IgM</td><td>0/5</td><td>ND</td><td>5/5</td><td>5/5</td></tr><tr><td></td><td></td><td>HEK293T&#8208;E1E2</td><td>HEK293T&#8208;E1E2</td><td>Serum IgG</td><td>0/5</td><td>ND</td><td>5/5</td><td>5/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>ND</td><td>ND</td><td>5/5</td><td>5/5</td></tr></table>
<table><tr><td>Group</td><td>No. mice</td><td colspan="2">Vaccine and administration</td><td>Anti‐HCV Abs</td><td colspan="4">Days post‐prime</td></tr></table>
<table><tr><td>Group</td><td>No. mice</td><td>Prime</td><td>2xboost</td><td>Anti‐HCV Abs</td><td>0</td><td>14</td><td>28</td><td>42</td></tr><tr><td></td><td></td><td></td><td></td><td>Serum IgM</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td>0</td><td>5</td><td></td><td></td><td>Serum IgG</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td></td><td></td><td>im</td><td>Feeding</td><td>Serum IgM</td><td>0/5</td><td>5/5</td><td>5/5</td><td>5/5</td></tr><tr><td>1</td><td>5</td><td>HEK293T‐E1E2</td><td>Lettuce E1E2</td><td>Serum IgG</td><td>0/5</td><td>0/5</td><td>0/5</td><td>4/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/5</td><td>4/5</td><td>4/5</td><td>4/5</td></tr><tr><td></td><td></td><td>Feeding</td><td></td><td>Serum IgM</td><td>0/7</td><td>0/7</td><td>1/7</td><td>2/7</td></tr><tr><td>2</td><td>7</td><td>Lettuce‐E1E2∆N6</td><td></td><td>Serum IgG</td><td>0/7</td><td>0/7</td><td>0/7</td><td>0/7</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/7</td><td>3/7</td><td>3/7</td><td>3/7</td></tr><tr><td></td><td></td><td>Feeding</td><td></td><td>Serum IgM</td><td>0/5</td><td>0/5</td><td>1/5</td><td>1/5</td></tr><tr><td>3</td><td>5</td><td>Lettuce‐E1E2</td><td></td><td>Serum IgG</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td>4</td><td>5</td><td>im</td><td>im</td><td>Serum IgM</td><td>0/5</td><td>ND</td><td>5/5</td><td>5/5</td></tr><tr><td></td><td></td><td>HEK293T‐E1E2</td><td>HEK293T‐E1E2</td><td>Serum IgG</td><td>0/5</td><td>ND</td><td>5/5</td><td>5/5</td></tr><tr><td></td><td></td><td></td><td></td><td>Faeces IgA</td><td>ND</td><td>ND</td><td>5/5</td><td>5/5</td></tr></table>
41a4403dd2ac23791690183e73205a590b7829791e63bf352de8d13363a6539c.png
complex
<table><tr><td>species</td><td>factors associated with chick-a-dee call variation</td><td>references</td></tr><tr><td rowspan="4">black-capped chickadee <i>Poecile atricapillus</i></td><td>species</td><td>[48,68&#8211;70]</td></tr><tr><td>flock</td><td>[71,72]</td></tr><tr><td>individual</td><td>[73]</td></tr><tr><td>predator</td><td>[74&#8211;76]</td></tr><tr><td>boreal chickadee <i>P. hudsonicus</i></td><td>individual</td><td>[77]</td></tr><tr><td>chestnut-backed chickadee <i>P. rufescens</i></td><td>individual</td><td>[78]</td></tr><tr><td rowspan="7">Carolina chickadee <i>P. carolinensis</i></td><td>species</td><td>[48]</td></tr><tr><td>local population</td><td>[79]</td></tr><tr><td>individual</td><td>[80]</td></tr><tr><td>energetic state</td><td>[81]</td></tr><tr><td>predator</td><td>[82&#8211;85]</td></tr><tr><td>food</td><td>[87,88]</td></tr><tr><td>flight</td><td>[59,82]</td></tr><tr><td>Mexican chickadee <i>P. sclateri</i></td><td>individual</td><td>[89]</td></tr><tr><td rowspan="3">mountain chickadee <i>P. gambeli</i></td><td>species</td><td>[68,69]</td></tr><tr><td>individual</td><td>[90]</td></tr><tr><td>flight</td><td>[91]</td></tr><tr><td rowspan="2">tufted titmouse <i>Baeolophus bicolor</i></td><td>individual</td><td>[92]</td></tr><tr><td>predator</td><td>[83,93,94]</td></tr><tr><td>crested tit <i>Lophophanes cristatus</i></td><td>proximity to cover</td><td>[95,96]</td></tr><tr><td>willow tit <i>Poecile montana</i></td><td>predator</td><td>[97]</td></tr></table>
<table><tr><td>species</td><td>factors associated with chick-a-dee call variation</td><td>references</td></tr><tr><td rowspan="4">black-capped chickadee Poecile atricapillus</td><td>species</td><td>[48,68–70]</td></tr><tr><td>flock</td><td>[71,72]</td></tr><tr><td>individual</td><td>[73]</td></tr><tr><td>predator</td><td>[74–76]</td></tr><tr><td>boreal chickadee P. hudsonicus</td><td>individual</td><td>[77]</td></tr><tr><td>chestnut-backed chickadee P. rufescens</td><td>individual</td><td>[78]</td></tr><tr><td rowspan="7">Carolina chickadee P. carolinensis</td><td>species</td><td>[48]</td></tr><tr><td>local population</td><td>[79]</td></tr><tr><td>individual</td><td>[80]</td></tr><tr><td>energetic state</td><td>[81]</td></tr><tr><td>predator</td><td>[82–85]</td></tr><tr><td>food</td><td>[87,88]</td></tr><tr><td>flight</td><td>[59,82]</td></tr><tr><td>Mexican chickadee P. sclateri</td><td>individual</td><td>[89]</td></tr><tr><td rowspan="2">mou</td><td>species</td><td>[68,69]</td></tr><tr><td>i</td><td>[90</td></tr></table>
<table><tr><td rowspan="2">ntain chickadee P. gambeli</td><td>ndividual</td><td>]</td></tr><tr><td>flight</td><td>[91]</td></tr><tr><td rowspan="2">tufted titmouse Baeolophus bicolor</td><td>individual</td><td>[92]</td></tr><tr><td>predator</td><td>[83,93,94]</td></tr><tr><td>crested tit Lophophanes cristatus</td><td>proximity to cover</td><td>[95,96]</td></tr><tr><td>willow tit Poecile montana</td><td>predator</td><td>[97]</td></tr></table>
9777079b89514aa189c6b34ee562784d3e726744c8a149303c9f2b3addc43f86.png
simple
<table><tr><td> </td><td>n</td><td>%*</td></tr><tr><td>Number of patients</td><td>635</td><td> </td></tr><tr><td>Median age at time of VIT-initiation (years) (range)</td><td>39</td><td>(5&#8211;77)</td></tr><tr><td>Male/female</td><td>322/313</td><td> </td></tr><tr><td>Results of allergy testing</td><td> </td><td> </td></tr><tr><td> <i>Vespula</i> (<i>vulgaris</i>/<i>germanica</i>) mono sensitization</td><td>251</td><td>39.5</td></tr><tr><td> Honey bee (<i>Apis mellifera</i>) mono sensitization</td><td>33</td><td>5.2</td></tr><tr><td> Double sensitization</td><td>351</td><td>55.3</td></tr><tr><td>Severity of anaphylaxis to pre-VIT index field sting</td><td> </td><td> </td></tr><tr><td> Large local reaction</td><td>8</td><td>1.3</td></tr><tr><td> Grade I (mild)</td><td>171</td><td>26.9</td></tr><tr><td> Grade II (moderate)</td><td>321</td><td>50.6</td></tr><tr><td> Grade III (severe)</td><td>135</td><td>21.3</td></tr><tr><td>Treatment course</td><td> </td><td> </td></tr><tr><td> Mean duration of VIT (years) (range)</td><td>3.9</td><td>(3&#8211;13)</td></tr><tr><td> Mean observation time after VIT (years) (range)</td><td>7.0</td><td>(0&#8211;17)</td></tr></table>
<table><tr><td></td></tr><tr><td>Number of patients</td></tr><tr><td>Median age at time of VIT-initiation (years) (range)</td></tr><tr><td>Male/female</td></tr><tr><td>Results of allergy testing</td></tr><tr><td>Vespula (vulgaris/germanica) mono sensitization</td></tr><tr><td>Honey bee (Apis mellifera) mono sensitization</td></tr><tr><td>Double sensitization</td></tr><tr><td>Severity of anaphylaxis to pre-VIT index field sting</td></tr><tr><td>Large local reaction</td></tr><tr><td>Grade I (mild)</td></tr><tr><td>Grade II (moderate)</td></tr><tr><td>Grade III (severe)</td></tr><tr><td>Treatment course</td></tr><tr><td>Mean duration of VIT (years) (range)</td></tr><tr><td>Mean observation time after VIT (years) (range)</td></tr></table>
<table><tr><td>n</td><td>%*</td></tr><tr><td>635</td><td></td></tr><tr><td>39</td><td>(5–77)</td></tr><tr><td>322/313</td><td></td></tr><tr><td></td><td></td></tr><tr><td>251</td><td>39.5</td></tr><tr><td>33</td><td>5.2</td></tr><tr><td>351</td><td>55.3</td></tr><tr><td></td><td></td></tr><tr><td>8</td><td>1.3</td></tr><tr><td>171</td><td>26.9</td></tr><tr><td>321</td><td>50.6</td></tr><tr><td>135</td><td>21.3</td></tr><tr><td></td><td></td></tr><tr><td>3.9</td><td>(3–13)</td></tr><tr><td>7.0</td><td>(0–17)</td></tr></table>
3d5765a99720f2f2359a28bc08895fb5fe8b3e51cce6b07f66df889ce7731228.png
simple
<table><tr><td>Disease</td><td>No. withdrawals/treated patients</td><td>Inefficacy or loss of efficacy</td><td>Adverse event</td><td>Persistent remission</td><td>On-demand treatment</td><td>Patient request</td><td>Switch to canakinumab</td></tr><tr><td>AOSD</td><td>20/35</td><td>14</td><td>3</td><td>1</td><td>0</td><td>2</td><td>2</td></tr><tr><td>Gout</td><td>18/28</td><td>0</td><td>0</td><td>17</td><td>1</td><td>0</td><td>0</td></tr><tr><td>SJIA</td><td>16/26</td><td>7</td><td>3</td><td>5</td><td>0</td><td>1</td><td>6</td></tr><tr><td>CAPS</td><td>11/21</td><td>1</td><td>1</td><td>1</td><td>0</td><td>8</td><td>3</td></tr><tr><td>MKD</td><td>7/10</td><td>2</td><td>2</td><td>0</td><td>0</td><td>3</td><td>4</td></tr><tr><td>FMF</td><td>6/13</td><td>1</td><td>3</td><td>0</td><td>1</td><td>1</td><td>3</td></tr><tr><td>SAPHO</td><td>7/9</td><td>5</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Schnitzler&#8217;s syndrome</td><td>3/7</td><td>1</td><td>2</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Spondylo arthritis</td><td>5/5</td><td>2</td><td>3</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Vasculitis</td><td>2/4</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Chondro calcinosis</td><td>2/4</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>TRAPS</td><td>1/3</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>GPP</td><td>2/3</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Polychondritis</td><td>1/3</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>NAPS12</td><td>2/2</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr></table>
<table><tr><td>Disease</td><td>No. withdrawals/treated patients</td><td>Inefficacy or loss of efficacy</td><td>Adverse event</td><td>Persistent remission</td><td>On-demand treatment</td><td>Patient request</td><td>Switch to canakinumab</td></tr><tr><td>AOSD</td><td>20/35</td><td>14</td><td>3</td><td>1</td><td>0</td><td>2</td><td>2</td></tr><tr><td>Gout</td><td>18/28</td><td>0</td><td>0</td><td>17</td><td>1</td><td>0</td><td>0</td></tr><tr><td>SJIA</td><td>16/26</td><td>7</td><td>3</td><td>5</td><td>0</td><td>1</td><td>6</td></tr><tr><td>CAPS</td><td>11/21</td><td>1</td><td>1</td><td>1</td><td>0</td><td>8</td><td>3</td></tr><tr><td>MKD</td><td>7/10</td><td>2</td><td>2</td><td>0</td><td>0</td><td>3</td><td>4</td></tr><tr><td>FMF</td><td>6/13</td><td>1</td><td>3</td><td>0</td><td>1</td><td>1</td><td>3</td></tr><tr><td>SAPHO</td><td>7/9</td><td>5</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td></tr></table>
<table><tr><td>Disease</td><td>No. withdrawals/treated patients</td><td>Inefficacy or loss of efficacy</td><td>Adverse event</td><td>Persistent remission</td><td>On-demand treatment</td><td>Patient request</td><td>Switch to canakinumab</td></tr><tr><td>Schnitzler’s syndrome</td><td>3/7</td><td>1</td><td>2</td><td>0</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Spondylo arthritis</td><td>5/5</td><td>2</td><td>3</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Vasculitis</td><td>2/4</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2</td></tr><tr><td>Chondro calcinosis</td><td>2/4</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>TRAPS</td><td>1/3</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>GPP</td><td>2/3</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Polychondritis</td><td>1/3</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>NAPS12</td><td>2/2</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr></table>
7ea05d0d83e6c02a09bc085c482e6576242d4223ea04c7645ed06d19d7128a77.png
complex
<table><tr><td></td><td colspan="2">Total</td><td colspan="2">Sham</td><td colspan="2">0.5 mA</td><td colspan="2">1.0 mA</td><td colspan="2">1.5 mA</td></tr><tr><td><i>N</i></td><td colspan="2">87</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">21</td></tr><tr><td>RT negative</td><td>1170.90</td><td>(21.73)</td><td>1135.21</td><td>(34.23)</td><td>1213.46</td><td>(42.21)</td><td>1164.88</td><td>(45.87)</td><td>1170.02</td><td>(51.81)</td></tr><tr><td>RT neutral</td><td>1151.04</td><td>(20.25)</td><td>1110.98</td><td>(34.62)</td><td>1206.59</td><td>(42.62)</td><td>1117.34</td><td>(38.04)</td><td>1170.09</td><td>(45.57)</td></tr><tr><td>AC negative</td><td>79.66</td><td>(0.76)</td><td>81.48</td><td>(1.49)</td><td>79.20</td><td>(1.61)</td><td>80.11</td><td>(1.78)</td><td>77.77</td><td>(1.02)</td></tr><tr><td>AC neutral</td><td>80.89</td><td>(0.81)</td><td>81.70</td><td>(1.74)</td><td>80.91</td><td>(1.66)</td><td>81.59</td><td>(1.43)</td><td>79.29</td><td>(1.72)</td></tr></table>
<table><tr><td></td><td colspan="2">Total</td><td colspan="2">Sham</td><td colspan="2">0.5 mA</td><td colspan="2">1.0 mA</td><td colspan="2">1.5 mA</td></tr><tr><td>N</td><td colspan="2">87</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">21</td></tr><tr><td>RT negative</td><td>1170.90</td><td>(21.73)</td><td>1135.21</td><td>(34.23)</td><td>1213.46</td><td>(42.21)</td><td>1164.88</td><td>(45.87)</td><td>1170.02</td><td>(51.81)</td></tr><tr><td>RT neutral</td><td>1151.04</td><td>(20.25)</td><td>1110.98</td><td>(34.62)</td><td>1206.59</td><td>(42.62)</td><td>1117.34</td><td>(38.04)</td><td>1170.09</td><td>(45.57)</td></tr><tr><td>AC negative</td><td>79</td><td>(0.</td><td>81.</td><td>(1</td><td>79.20</td><td>(1.61)</td><td>80.11</td><td>(1.7</td><td>7</td><td>(1.0</td></tr></table>
<table><tr><td></td><td colspan="2">Total</td><td colspan="2">Sham</td><td colspan="2">0.5 mA</td><td colspan="2">1.0 mA</td><td colspan="2">1.5 mA</td></tr><tr><td>N</td><td colspan="2">87</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">21</td></tr><tr><td></td><td>.66</td><td>76)</td><td>48</td><td>.49)</td><td></td><td></td><td></td><td>8)</td><td>7.77</td><td>2)</td></tr><tr><td>AC neutral</td><td>80.89</td><td>(0.81)</td><td>81.70</td><td>(1.74)</td><td>80.91</td><td>(1.66)</td><td>81.59</td><td>(1.43)</td><td>79.29</td><td>(1.72)</td></tr></table>
28a316edd201c7a7c77a2c2ea7e4df584d3345c46be8e67522463e66b8c9b801.png
complex
<table><tr><td></td><td></td><td colspan="2">RF</td><td colspan="2">PCVA</td></tr><tr><td></td><td></td><td>Median</td><td>95% UI</td><td>Median</td><td>95% UI</td></tr><tr><td>Adult</td><td>No HCE</td><td>0.726</td><td>(0.721, 0.730)</td><td>0.624</td><td>(0.619, 0.631)</td></tr><tr><td></td><td>HCE</td><td>0.772</td><td>(0.769, 0.776)</td><td>0.675</td><td>(0.669, 0.680)</td></tr><tr><td>Child</td><td>No HCE</td><td>0.763</td><td>(0.755, 0.769)</td><td>0.632</td><td>(0.626, 0.642)</td></tr><tr><td></td><td>HCE</td><td>0.779</td><td>(0.775, 0.785)</td><td>0.682</td><td>(0.671, 0.690)</td></tr><tr><td>Neonate</td><td>No HCE</td><td>0.720</td><td>(0.710, 0.732)</td><td>0.695</td><td>(0.682, 0.705)</td></tr><tr><td></td><td>HCE</td><td>0.726</td><td>(0.717, 0.734)</td><td>0.733</td><td>(0.719, 0.743)</td></tr></table>
<table><tr><td></td><td></td><td colspan="2">RF</td><td colspan="2">PCVA</td></tr><tr><td></td><td></td><td>Median</td><td>95% UI</td><td>Median</td><td>95% UI</td></tr><tr><td>Adult</td><td>No HCE</td><td>0.726</td><td>(0.721, 0.730)</td><td>0.624</td><td>(0.619, 0.631)</td></tr><tr><td></td><td>HCE</td><td>0.772</td><td>(0.769, 0.776)</td><td>0.675</td><td>(0.669, 0.680)</td></tr><tr><td>Child</td><td>No HCE</td><td>0.763</td><td>(0.755, 0.769)</td><td>0.632</td><td>(0.626, 0.642)</td></tr><tr><td></td><td>HCE</td><td>0.779</td><td>(0.775, 0.785)</td><td>0.682</td><td>(0.671, 0.690)</td></tr><tr><td>Neonate</td><td>No HCE</td><td>0.720</td><td>(0.710, 0.732)</td><td>0.695</td><td>(0.682, 0.705)</td></tr></table>
<table><tr><td></td><td colspan="2">RF</td><td colspan="2">PCVA</td></tr><tr><td></td><td>Median</td><td>95% UI</td><td>Median</td><td>95% UI</td></tr><tr><td>HCE</td><td>0.726</td><td>(0.717, 0.734)</td><td>0.733</td><td>(0.719, 0.743)</td></tr></table>
acf975ad1fdf4552d8e866485a621850385bd0728be5f4c8dd610e35e9e9ee3f.png
complex
<table><tr><td> </td><td colspan="2">5-HT</td><td colspan="2">Motilin</td><td colspan="2">VIP</td><td colspan="2">Somatostatin</td></tr><tr><td>TDCA</td><td>&#8722;0.07</td><td>0.76</td><td>0.11</td><td>0.65</td><td>0.23</td><td>0.32</td><td>0.19</td><td>0.43</td></tr><tr><td>TCA</td><td>&#8722;0.33</td><td>0.15</td><td>&#8722;0.02</td><td>0.93</td><td>0.01</td><td>0.96</td><td>0.09</td><td>0.71</td></tr><tr><td>TLCA</td><td>&#8722;0.06</td><td>0.81</td><td>&#8722;0.10</td><td>0.69</td><td>0.06</td><td>0.80</td><td>&#8722;0.17</td><td>0.48</td></tr></table>
<table><tr><td></td><td colspan="2">5-HT</td><td colspan="2">Motilin</td><td colspan="2">VIP</td><td colspan="2">Somatostatin</td></tr><tr><td>TDCA</td><td>−0.07</td><td>0.76</td><td>0.11</td><td>0.65</td><td>0.23</td><td>0.32</td><td>0.19</td><td>0.43</td></tr><tr><td>TCA</td><td>−0.33</td><td>0.15</td><td>−0.02</td><td>0.93</td><td>0.01</td><td>0.96</td><td>0.09</td><td>0.71</td></tr></table>
<table><tr><td>TLCA</td><td>−0.06</td><td>0.81</td><td>−0.10</td><td>0.69</td><td>0.06</td><td>0.80</td><td>−0.17</td><td>0.48</td></tr></table>
48f30b687315d295c78ee3ac06aa071a6572227342e5fb2de4afc334919f27bd.png
simple
<table><tr><td>Variable</td><td>Elderly</td><td>Middle aged</td><td>Young</td><td>P value</td></tr><tr><td>TChol</td><td>79(44%)</td><td>161 (42%)</td><td>11(31%)</td><td>0.3</td></tr><tr><td>HDL-C</td><td>98(54%)</td><td>205(53%)</td><td>15(41%)</td><td>0.3</td></tr><tr><td>LDL-C</td><td>129 (71%)</td><td>286(74%)</td><td>26 (72%)</td><td>0.7</td></tr><tr><td>TG</td><td>18 (10%)</td><td>56(15%)</td><td>1(2%)</td><td>0.05</td></tr></table>
<table><tr><td>Variable</td><td>Elderly</td><td>Middle aged</td><td>Young</td><td>P value</td></tr><tr><td>TChol</td><td>79(44%)</td><td>161 (42%)</td><td>11(31%)</td><td>0.3</td></tr><tr><td>HDL-C</td><td>98(54%)</td><td>205(53%)</td><td>15(41%)</td><td>0.3</td></tr><tr><td>LDL-C</td><td>129 (71%)</td><td>286(74%)</td><td>26 (72%)</td><td>0.7</td></tr></table>
<table><tr><td>TG</td><td>18 (10%)</td><td>56(15%)</td><td>1(2%)</td><td>0.05</td></tr></table>
28c0fc02095e218ad072c52998949988ba8ed70f0416544dd8beaa516ed6c82f.png
simple
<table><tr><td>Patients</td><td>NMO/NMOSD</td><td>MS</td></tr><tr><td>Number</td><td>20</td><td>8</td></tr><tr><td>Age</td><td>49.4 &#177; 3.9</td><td>43.0 &#177; 4.8</td></tr><tr><td>Male:Female</td><td>4:16</td><td>4:4</td></tr><tr><td>Disease duration</td><td>8.1 &#177; 2.0</td><td>9.9 &#177; 3.7</td></tr><tr><td>Relapses in the last 2 years</td><td>1.2 &#177; 0.3</td><td>2.3 &#177; 0.5</td></tr><tr><td>EDSS<sup><i>&#8727;</i></sup> score in disease remission</td><td>3.3 &#177; 0.5</td><td>4.1 &#177; 1.0</td></tr></table>
<table><tr><td>Patients</td><td>NMO/NMOSD</td><td>MS</td></tr><tr><td>Number</td><td>20</td><td>8</td></tr></table>
<table><tr><td>Patients</td><td>NMO/NMOSD</td><td>MS</td></tr><tr><td>Age</td><td>49.4 ± 3.9</td><td>43.0 ± 4.8</td></tr><tr><td>Male:Female</td><td>4:16</td><td>4:4</td></tr><tr><td>Disease duration</td><td>8.1 ± 2.0</td><td>9.9 ± 3.7</td></tr><tr><td>Relapses in the last 2 years</td><td>1.2 ± 0.3</td><td>2.3 ± 0.5</td></tr><tr><td>EDSS∗ score in disease remission</td><td>3.3 ± 0.5</td><td>4.1 ± 1.0</td></tr></table>
b7dd328c83bb11b7a92052517ea63c053e8cd0c65d401134a2c05c2117f45829.png
complex
<table><tr><td colspan="2">% Change in relative probability of delivery with a 5-min increase in travel time<sup>a</sup></td></tr><tr><td>Delivery at any facility</td><td>&#8722;30.0</td></tr><tr><td>Public facility delivery</td><td>&#8722;28.2</td></tr><tr><td>Private facility delivery</td><td>&#8722;32.9</td></tr><tr><td>NGO facility delivery</td><td>&#8722;28.6</td></tr></table>
<table><tr><td>% Change in relative probability of delivery with a 5-min increase in travel timea</td></tr><tr><td>Delivery at any facility</td></tr><tr><td>Public facility delivery</td></tr><tr><td>Private facility delivery</td></tr><tr><td>NGO facility delivery</td></tr></table>
<table><tr><td>% Change in relative probability of delivery with a 5-min increase in travel timea</td></tr><tr><td>−30.0</td></tr><tr><td>−28.2</td></tr><tr><td>−32.9</td></tr><tr><td>−28.6</td></tr></table>
b6da2883ffba25126555130e59bd35e0c11c1afb0e58749b9bfe9a128a6e18c9.png
complex
<table><tr><td>Cell Types</td><td>Species/Cell Lines</td><td colspan="2">Melotonin Effects</td><td>Receptor Types</td><td>Melatonin Concentrations</td><td>References</td></tr><tr><td>Leydig cell</td><td>mouse</td><td>Inhibition of steroid production</td><td>Inhibition of <i>StAR</i> protein expression </td><td><i>Mt1 and/or Mt2</i></td><td>10 nM to 1 &#956;M</td><td>[21]</td></tr><tr><td></td><td>MA-10</td><td></td><td>Inhibition of progesterone production</td><td><i>Mt1 and/or Mt2</i></td><td>10 nM to 1 &#956;M</td><td>[21]</td></tr><tr><td></td><td>Rat</td><td>Inhibition of steroid production</td><td>Inhibition of androgen production </td><td>-</td><td>4 pM to 4 &#956;M</td><td>[40]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of GnRH-dependent intracellular Ca<sup>2+</sup>release </td><td>-</td><td>0.2 pM</td><td>[46]</td></tr><tr><td></td><td>Hamster</td><td>Inhibition of steroid production</td><td>Stimulation of CRH production</td><td><i>Mt1</i></td><td>1 and 10 &#956;M</td><td>[12,54]</td></tr><tr><td></td><td></td><td></td><td>Stimulation of tyrosine phosphatases activity</td><td><i>Mt1</i></td><td>1 and 10 &#956;M</td><td>[54]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of erk and jnk phosphorylation</td><td><i>Mt1</i></td><td>1 and 10 &#956;M</td><td>[54]</td></tr><tr><td></td><td></td><td></td><td>Downregulation of c-fos and c-jun expression</td><td><i>Mt1</i></td><td>1 and 10 &#956;M</td><td>[54]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of <i>StAR</i>, <i>Hsd3b</i> and <i>Hsd17b</i>3 expression</td><td><i>Mt1</i></td><td>1 and 10 &#956;M</td><td>[12,54]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of cAMP generation </td><td><i>Mt1</i></td><td>1 &#956;M</td><td>[12]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of androgen production</td><td><i>Mt1</i></td><td>100 pM to 1 &#956;M</td><td>[12,54]</td></tr><tr><td>Sertoli cell</td><td>Rat</td><td>Regulation of energy metabolism</td><td>Inhibition of basal lactate production</td><td><i>Mt1 and Mt2</i></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Upregulation of the insulin-stimulated lactate generation</td><td><i>Mt1 and Mt2</i></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Stimulation of GLUT1 protein expression and glucose consumption</td><td></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of LDH protein expression and activity</td><td><i>Mt1 and Mt2</i></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Stimulation of acetate production</td><td></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td>Prevention of testicular damage</td><td>Regulation of intracellular redox state</td><td><i>Mt1 and Mt2</i></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td>Hamster</td><td>Prevention of testicular damage</td><td>Stimulation of the responsiveness to FSH during testicular development</td><td>-</td><td>25 &#956;g daily injection (1 to 15 wk)</td><td>[24]</td></tr><tr><td></td><td>Bovine</td><td>Stimulation of cell growth/proliferation</td><td>Downregulation of mRNA <i>P21</i> expression</td><td><i>Mt1 and Mt2</i></td><td>0.3 to 1 nM</td><td>[59]</td></tr><tr><td></td><td></td><td>Regulation of spermatogenesis</td><td>Upregulation of <i>Cyclin D1</i>, <i>Cyclin E</i>, <i>Pdgfa</i>, <i>Dhh</i>, <i>Ocludin</i> and <i>Claudin</i> expression</td><td><i>Mt1 and Mt2</i></td><td>0.3 to 1 nM</td><td>[59]</td></tr><tr><td></td><td>Goat</td><td>Stimulation of SSCs proliferation</td><td>Stimulation of GDNF production</td><td><i>Mt1 and Mt2</i></td><td>1 nM and 1 &#956;M</td><td>[73]</td></tr></table>
<table><tr><td>Cell Types</td><td>Species/Cell Lines</td><td colspan="2">Melotonin Effects</td><td>Receptor Types</td><td>Melatonin Concentrations</td><td>References</td></tr><tr><td>Leydig cell</td><td>mouse</td><td>Inhibition of steroid production</td><td>Inhibition of StAR protein expression</td><td>Mt1 and/or Mt2</td><td>10 nM to 1 μM</td><td>[21]</td></tr><tr><td></td><td>MA-10</td><td></td><td>Inhibition of progesterone production</td><td>Mt1 and/or Mt2</td><td>10 nM to 1 μM</td><td>[21]</td></tr><tr><td></td><td>Rat</td><td>Inhibition of steroid production</td><td>Inhibition of androgen production</td><td>-</td><td>4 pM to 4 μM</td><td>[40]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of GnRH-dependent intracellular Ca2+release</td><td>-</td><td>0.2 pM</td><td>[46]</td></tr><tr><td></td><td>Hamster</td><td>Inhibition of steroid production</td><td>Stimulation of CRH production</td><td>Mt1</td><td>1 and 10 μM</td><td>[12,54]</td></tr><tr><td></td><td></td><td></td><td>Stimulation of tyrosine phosphatases activity</td><td>Mt1</td><td>1 and 10 μM</td><td>[54]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of erk and jnk phosphorylation</td><td>Mt1</td><td>1 and 10 μM</td><td>[54]</td></tr><tr><td></td><td></td><td></td><td>Downregulation of c-fos and c-jun expression</td><td>Mt1</td><td>1 and 10 μM</td><td>[54]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of StAR, Hsd3b and Hsd17b3 expression</td><td>Mt1</td><td>1 and 10 μM</td><td>[12,54]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of cAMP generation</td><td>Mt1</td><td>1 μM</td><td>[12]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of androgen production</td><td>Mt1</td><td>100 pM to 1 μM</td><td>[12,54]</td></tr><tr><td>Sertoli cell</td><td>Rat</td><td>Regulation of energy metabolism</td><td>Inhibition of basal lactate production</td><td>Mt1 and Mt2</td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Upregulation of the i</td><td>Mt1 and Mt2</td><td></td><td></td></tr></table>
<table><tr><td></td><td></td><td></td><td>nsulin-stimulated lactate generation</td><td></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Stimulation of GLUT1 protein expression and glucose consumption</td><td></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of LDH protein expression and activity</td><td>Mt1 and Mt2</td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Stimulation of acetate production</td><td></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td>Prevention of testicular damage</td><td>Regulation of intracellular redox state</td><td>Mt1 and Mt2</td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td>Hamster</td><td>Prevention of testicular damage</td><td>Stimulation of the responsiveness to FSH during testicular development</td><td>-</td><td>25 μg daily injection (1 to 15 wk)</td><td>[24]</td></tr><tr><td></td><td>Bovine</td><td>Stimulation of cell growth/proliferation</td><td>Downregulation of mRNA P21 expression</td><td>Mt1 and Mt2</td><td>0.3 to 1 nM</td><td>[59]</td></tr><tr><td></td><td></td><td>Regulation of spermatogenesis</td><td>Upregulation of Cyclin D1, Cyclin E, Pdgfa, Dhh, Ocludin and Claudin expression</td><td>Mt1 and Mt2</td><td>0.3 to 1 nM</td><td>[59]</td></tr><tr><td></td><td>Goat</td><td>Stimulation of SSCs proliferation</td><td>Stimulation of GDNF production</td><td>Mt1 and Mt2</td><td>1 nM and 1 μM</td><td>[73]</td></tr></table>
d898a7fdbeed8809f38d13d3b062e1f00622831fc16a569b31278c92ebc5e57b.png
simple
<table><tr><td>Demographics</td><td> </td></tr><tr><td>Mean age, years (range)</td><td>32 (11&#8211;55)</td></tr><tr><td>Male : female</td><td>43 : 8 </td></tr><tr><td>Transfusion requirements, units (range)</td><td>7 (3&#8211;12) </td></tr></table>
<table><tr><td>Demographics</td><td></td></tr><tr><td>Mean age, years (range)</td><td>32 (11–55)</td></tr><tr><td>Male : female</td><td>43 : 8</td></tr></table>
<table><tr><td>Demographics</td><td></td></tr><tr><td>Transfusion requirements, units (range)</td><td>7 (3–12)</td></tr></table>
5679396b595d8489393511235bd725ada18e046a2cdaecc9e3c15ee35a8babca.png
complex
<table><tr><td rowspan="2"></td><td colspan="3">Intervention group</td><td colspan="3">Control group</td><td rowspan="2"><i>P</i> Value<sup>*</sup></td></tr><tr><td>T1<sup>a</sup></td><td>T2<sup>a</sup></td><td>T3<sup>a</sup></td><td>T1<sup>a</sup></td><td>T2<sup>a</sup></td><td>T3<sup>a</sup></td></tr><tr><td>Rural (n = 1539)</td><td>0.11 &#177; 0.20</td><td>0.15 &#177; 0.23</td><td>0.15 &#177; 0.24</td><td>0.11 &#177; 0.20</td><td>0.16 &#177; 0.23</td><td>0.18 &#177; 0.24</td><td>&lt; 0.001</td></tr><tr><td>Urban (n = 1512)</td><td>0.12 &#177; 0.21</td><td>0.16 &#177; 0.23</td><td>0.16 &#177; 0.23</td><td>0.12 &#177; 0.24</td><td>0.17 &#177; 0.27</td><td>0.19 &#177; 0.29</td><td>&lt; 0.001</td></tr><tr><td>Elementary school (n = 2451)</td><td>0.09 &#177; 0.18</td><td>0.12 &#177; 0.21</td><td>0.13 &#177; 0.22</td><td>0.08 &#177; 0.18</td><td>0.12 &#177; 0.22</td><td>0.14 &#177; 0.22</td><td>&lt; 0.001</td></tr><tr><td>Secondary school (n = 600)</td><td>0.23 &#177; 0.26</td><td>0.29 &#177; 0.28</td><td>0.27 &#177; 0.28</td><td>0.26 &#177; 0.29</td><td>0.32 &#177; 0.30</td><td>0.36 &#177; 0.34</td><td>&lt; 0.001</td></tr><tr><td>Suspected myopia (n = 997)</td><td>0.34 &#177; 0.20</td><td>0.39 &#177; 0.24</td><td>0.39 &#177; 0.24</td><td>0.36 &#177; 0.24</td><td>0.44 &#177; 0.27</td><td>0.48 &#177; 0.29</td><td>&lt; 0.001</td></tr><tr><td>Non-suspected myopia (n = 2054)</td><td>0.005 &#177; 0.05</td><td>0.03 &#177; 0.09</td><td>0.03 &#177; 0.09</td><td>0.004 &#177; 0.04</td><td>0.039 &#177; 0.09</td><td>0.06 &#177; 0.10</td><td>&lt; 0.001</td></tr><tr><td>Combined (n = 3051)</td><td>0.12 &#177; 0.20</td><td>0.15 &#177; 0.23</td><td>0.16 &#177; 0.24</td><td>0.12 &#177; 0.22</td><td>0.16 &#177; 0.25</td><td>0.19 &#177; 0.27</td><td>&lt; 0.001</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="3">Intervention group</td><td colspan="3">Control group</td><td rowspan="2">P Value*</td></tr><tr><td>T1a</td><td>T2a</td><td>T3a</td><td>T1a</td><td>T2a</td><td>T3a</td></tr><tr><td>Rural (n = 1539)</td><td>0.11 ± 0.20</td><td>0.15 ± 0.23</td><td>0.15 ± 0.24</td><td>0.11 ± 0.20</td><td>0.16 ± 0.23</td><td>0.18 ± 0.24</td><td>< 0.001</td></tr><tr><td>Urban (n = </td><td>0.12 ± 0.21</td><td>0.16 ± 0.</td><td>0.1</td><td>0.12 ± 0.24</td><td></td><td>0.19 ± 0</td><td>< 0.0</td></tr></table>
<table><tr><td>1512)</td><td></td><td>23</td><td>6 ± 0.23</td><td></td><td>0.17 ± 0.27</td><td>.29</td><td>01</td></tr><tr><td>Elementary school (n = 2451)</td><td>0.09 ± 0.18</td><td>0.12 ± 0.21</td><td>0.13 ± 0.22</td><td>0.08 ± 0.18</td><td>0.12 ± 0.22</td><td>0.14 ± 0.22</td><td>< 0.001</td></tr><tr><td>Secondary school (n = 600)</td><td>0.23 ± 0.26</td><td>0.29 ± 0.28</td><td>0.27 ± 0.28</td><td>0.26 ± 0.29</td><td>0.32 ± 0.30</td><td>0.36 ± 0.34</td><td>< 0.001</td></tr><tr><td>Suspected myopia (n = 997)</td><td>0.34 ± 0.20</td><td>0.39 ± 0.24</td><td>0.39 ± 0.24</td><td>0.36 ± 0.24</td><td>0.44 ± 0.27</td><td>0.48 ± 0.29</td><td>< 0.001</td></tr><tr><td>Non-suspected myopia (n = 2054)</td><td>0.005 ± 0.05</td><td>0.03 ± 0.09</td><td>0.03 ± 0.09</td><td>0.004 ± 0.04</td><td>0.039 ± 0.09</td><td>0.06 ± 0.10</td><td>< 0.001</td></tr><tr><td>Combined (n = 3051)</td><td>0.12 ± 0.20</td><td>0.15 ± 0.23</td><td>0.16 ± 0.24</td><td>0.12 ± 0.22</td><td>0.16 ± 0.25</td><td>0.19 ± 0.27</td><td>< 0.001</td></tr></table>
0d9589ae9fe73710df5ce3f85b78b913668722358bb1226043fcdb482e4281ce.png
complex
<table><tr><td rowspan="2">Item</td><td colspan="2">Component</td></tr><tr><td>1</td><td>2</td></tr><tr><td>Pain</td><td>0.555</td><td>&#8722;0.162</td></tr><tr><td>Shortness of breath</td><td>0.497</td><td>&#8722;0.318</td></tr><tr><td>Weakness or lack of energy</td><td>0.547</td><td>&#8722;0.379</td></tr><tr><td>Nausea</td><td>0.251</td><td>&#8722;0.779</td></tr><tr><td>Vomiting</td><td>0.196</td><td>&#8722;0.694</td></tr><tr><td>Poor appetite</td><td>0.398</td><td>&#8722;0.236</td></tr><tr><td>Constipation</td><td>0.305</td><td>&#8722;0.001</td></tr><tr><td>Mouth problems</td><td>0.558</td><td>&#8722;0.305</td></tr><tr><td>Drowsiness</td><td>0.433</td><td>&#8722;0.320</td></tr><tr><td>Poor mobility</td><td>0.672</td><td>&#8722;0.050</td></tr><tr><td>Itching</td><td>0.361</td><td>&#8722;0.317</td></tr><tr><td>Difficulty sleeping</td><td>0.506</td><td>&#8722;0.386</td></tr><tr><td>Restless legs</td><td>0.150</td><td>&#8722;0.223</td></tr><tr><td>Feeling anxious</td><td>0.537</td><td>&#8722;0.303</td></tr><tr><td>Feeling depressed</td><td>0.586</td><td>&#8722;0.218</td></tr><tr><td>Changes in skin</td><td>0.329</td><td>&#8722;0.345</td></tr><tr><td>Diarrhoea</td><td>0.187</td><td>&#8722;0.486</td></tr><tr><td>Muscle cramps</td><td>0.229</td><td>&#8722;0.358</td></tr></table>
<table><tr><td rowspan="2">Item</td><td colspan="2">Component</td></tr><tr><td>1</td><td>2</td></tr><tr><td>Pain</td><td>0.555</td><td>−0.162</td></tr><tr><td>Shortness of breath</td><td>0.497</td><td>−0.318</td></tr><tr><td>Weakness or lack of energy</td><td>0.547</td><td>−0.379</td></tr><tr><td>Nausea</td><td>0.251</td><td>−0.779</td></tr><tr><td>Vomiting</td><td>0.196</td><td>−0.694</td></tr></table>
<table><tr><td rowspan="2">Item</td><td colspan="2">Component</td></tr><tr><td>1</td><td>2</td></tr><tr><td>Poor appetite</td><td>0.398</td><td>−0.236</td></tr><tr><td>Constipation</td><td>0.305</td><td>−0.001</td></tr><tr><td>Mouth problems</td><td>0.558</td><td>−0.305</td></tr><tr><td>Drowsiness</td><td>0.433</td><td>−0.320</td></tr><tr><td>Poor mobility</td><td>0.672</td><td>−0.050</td></tr><tr><td>Itching</td><td>0.361</td><td>−0.317</td></tr><tr><td>Difficulty sleeping</td><td>0.506</td><td>−0.386</td></tr><tr><td>Restless legs</td><td>0.150</td><td>−0.223</td></tr><tr><td>Feeling anxious</td><td>0.537</td><td>−0.303</td></tr><tr><td>Feeling depressed</td><td>0.586</td><td>−0.218</td></tr><tr><td>Changes in skin</td><td>0.329</td><td>−0.345</td></tr><tr><td>Diarrhoea</td><td>0.187</td><td>−0.486</td></tr><tr><td>Muscle cramps</td><td>0.229</td><td>−0.358</td></tr></table>
fc67abf3f14a53b7422e1b62d224a36bce741327aea2ccd9af1c7877836a32dd.png
simple
<table><tr><td>Variable</td><td>Current contraceptive use n (%)</td><td>Unadjusted RR (95% CI)</td><td>Adjusted RR (95% CI)</td></tr><tr><td>Age (completed years)</td><td></td><td><i>p</i> = 0.45</td><td></td></tr><tr><td> 13&#8211;19</td><td>9 (36.0)</td><td>1</td><td>&#8722;</td></tr><tr><td> 20&#8211;29</td><td>154 (50.8)</td><td>1.41 (0.83, 2.41)</td><td>&#8722;</td></tr><tr><td> 30+</td><td>131 (50.6)</td><td>1.40 (0.82, 2.40)</td><td>&#8722;</td></tr><tr><td>Level of education</td><td></td><td><i>p</i> = 0.001;p trend &lt; 0.001</td><td><i>p</i> = 0.02;p trend = 0.03</td></tr><tr><td> No formal education</td><td>16 (38.1)</td><td>1</td><td>1</td></tr><tr><td> &#8804; Basic education</td><td>123 (44.6)</td><td>1.17 (0.78, 1.76)</td><td>0.90 (0.64, 1.25)</td></tr><tr><td> &gt; Basic education</td><td>154 (59.0)</td><td>1.55 (1.04, 2.31)</td><td>1.13 (0.82, 1.58)</td></tr><tr><td>Marital Status</td><td></td><td><i>p</i> = 0.33</td><td></td></tr><tr><td> Single</td><td>24 (43.6)</td><td>1</td><td>&#8722;</td></tr><tr><td> Married</td><td>270 (50.0)</td><td>1.17 (0.86, 1.60)</td><td>&#8722;</td></tr><tr><td>Occupation</td><td></td><td><i>p</i> = 0.01</td><td><i>p</i> = 0.11</td></tr><tr><td> Unemployed</td><td>46 (39.6)</td><td>1</td><td>1</td></tr><tr><td> Semi-skilled employment</td><td>172 (50.4)</td><td>1.27 (0.99, 1.63)</td><td>1.29 (1.01, 1.66)</td></tr><tr><td> Skilled employment</td><td>75 (59.5)</td><td>1.50 (1.15, 1.96)</td><td>1.20 (0.92, 1.56)</td></tr><tr><td>Number of living children</td><td></td><td><i>p</i> = 0.32</td><td></td></tr><tr><td> 1&#8211;2</td><td>196 (48.6)</td><td>1</td><td>&#8722;</td></tr><tr><td> 3+</td><td>97 (53.0)</td><td>1.09 (0.92, 1.29)</td><td>&#8722;</td></tr><tr><td>Number of ANC visits</td><td></td><td><i>p</i> = 0.06</td><td><i>p</i> = 0.24</td></tr><tr><td> &lt; 7</td><td>109 (46.2)</td><td>1</td><td>1</td></tr><tr><td> 7+</td><td>184 (54.3)</td><td>1.18 (0.99, 1.39)</td><td>1.10 (0.94, 1.29)</td></tr><tr><td>FP discussed during ANC</td><td></td><td><i>p</i> = 0.01</td><td><i>p</i> = 0.001</td></tr><tr><td> No</td><td>71 (41.8)</td><td>1</td><td>1</td></tr><tr><td> Yes</td><td>208 (58.9)</td><td>1.41 (1.16, 1.72)</td><td>1.28 (1.07, 1.53)</td></tr><tr><td>FP discussed during PNC</td><td></td><td><i>p</i> = 0.33</td><td></td></tr><tr><td> No</td><td>12 (46.0)</td><td>1</td><td>&#8722;</td></tr><tr><td> Yes</td><td>283 (51.5)</td><td>1.24 (0.80, 1.93)</td><td>&#8722;</td></tr><tr><td>FP discussed during CWC</td><td></td><td><i>p</i> = 0.56</td><td></td></tr><tr><td> No</td><td>17 (51.4)</td><td>1</td><td>&#8722;</td></tr><tr><td> Yes</td><td>271 (51.1)</td><td>1.11 (0.78, 1.59)</td><td>&#8722;</td></tr><tr><td>Discusses FP with partner</td><td></td><td><i>p</i> &lt; 0.001</td><td><i>p</i> = 0.03</td></tr><tr><td> No</td><td>74 (37.0)</td><td>1</td><td>1</td></tr><tr><td> Yes</td><td>217 (60.6)</td><td>1.64 (1.34, 2.00)</td><td>1.22 (1.01, 1.47)</td></tr><tr><td>Desire to space children</td><td></td><td><i>p</i> &lt; 0.001</td><td><i>p</i> = 0.14</td></tr><tr><td> No</td><td>54 (36.2)</td><td>1</td><td>1</td></tr><tr><td> Yes</td><td>242 (54.9)</td><td>1.51 (1.20, 1.90)</td><td>1.16 (0.95, 1.41)</td></tr><tr><td>Resumed sexual intercourse</td><td></td><td><i>p</i> = 0.01</td><td><i>p</i> = 0.70</td></tr><tr><td> No</td><td>192 (46.8)</td><td>1</td><td>1</td></tr><tr><td> Yes</td><td>104 (57.8)</td><td>1.23 (1.05, 1.45)</td><td>1.03 (0.89, 1.19)</td></tr><tr><td>Resumed menses</td><td></td><td><i>p</i> = 0.61</td><td></td></tr><tr><td> No</td><td>215 (49.5)</td><td>1.05 (0.88, 1.25)</td><td>&#8722;</td></tr><tr><td> Yes</td><td>81 (52.9)</td><td>1</td><td>&#8722;</td></tr><tr><td>Previous contraceptive use</td><td></td><td><i>p</i> &lt; 0.001</td><td><i>p</i> &lt; 0.001</td></tr><tr><td> No</td><td>82 (28.5)</td><td>1</td><td>1</td></tr><tr><td> Yes</td><td>214 (70.9)</td><td>2.45 (2.04, 3.03)</td><td>1.91 (1.56, 2.33)</td></tr></table>
<table><tr><td>Variable</td><td>Current contraceptive use n (%)</td><td>Unadjusted RR (95% CI)</td><td>Adjusted RR (95% CI)</td></tr><tr><td>Age (completed years)</td><td></td><td>p = 0.45</td><td></td></tr><tr><td>13–19</td><td>9 (36.0)</td><td>1</td><td>−</td></tr><tr><td>20–29</td><td>154 (50.8)</td><td>1.41 (0.83, 2.41)</td><td>−</td></tr><tr><td>30+</td><td>131 (50.6)</td><td>1.40 (0.82, 2.40)</td><td>−</td></tr><tr><td>Level of education</td><td></td><td>p = 0.001;p trend < 0.001</td><td>p = 0.02;p trend = 0.03</td></tr><tr><td>No formal education</td><td>16 (38.1)</td><td>1</td><td>1</td></tr><tr><td>≤ Basic education</td><td>123 (44.6)</td><td>1.17 (0.78, 1.76)</td><td>0.90 (0.64, 1.25)</td></tr><tr><td>> Basic education</td><td>154 (59.0)</td><td>1.55 (1.04, 2.31)</td><td>1.13 (0.82, 1.58)</td></tr><tr><td>Marital Status</td><td></td><td>p = 0.33</td><td></td></tr><tr><td>Single</td><td>24 (43.6)</td><td>1</td><td>−</td></tr><tr><td>Married</td><td>270 (50.0)</td><td>1.17 (0.86, 1.60)</td><td>−</td></tr><tr><td>Occupation</td><td></td><td>p = 0.01</td><td>p = 0.11</td></tr><tr><td>Unemployed</td><td>46 (39.6)</td><td>1</td><td>1</td></tr><tr><td>Semi-skilled employment</td><td>172 (50.4)</td><td>1.27 (0.99, 1.63)</td><td>1.29 (1.01, 1.66)</td></tr><tr><td>Skilled employment</td><td>75 (59.5)</td><td>1.50 (1.15, 1.96)</td><td>1.20 (0.92, 1.56)</td></tr><tr><td>Number of living children</td><td></td><td>p = 0.32</td><td></td></tr><tr><td>1–2</td><td>196 (48.6)</td><td>1</td><td>−</td></tr><tr><td>3+</td><td>97 (53.0)</td><td>1.09 (0.92, 1.29)</td><td>−</td></tr><tr><td>Number of ANC visits</td><td></td><td>p = 0.06</td><td>p = 0.24</td></tr><tr><td>< 7</td><td>109 (46.2)</td><td>1</td><td>1</td></tr><tr><td>7+</td><td>184 (54.3)</td><td>1.18 (0.99, 1.39)</td><td>1.10 (0.94, 1.29)</td></tr><tr><td>FP discussed during ANC</td><td></td><td>p = 0.01</td><td>p = 0.001</td></tr><tr><td>No</td><td>71 (41.8)</td><td>1</td><td>1</td></tr><tr><td>Yes</td><td>208 (58.9)</td><td>1.41 (1.16, 1.72)</td><td>1.28 (1.07, 1.53)</td></tr><tr><td>FP discussed during PNC</td><td></td><td>p = 0.33</td><td></td></tr><tr><td>No</td><td>12 (46.0)</td><td>1</td><td>−</td></tr><tr><td>Yes</td><td>283 (51.5)</td><td>1.24 (0.80, 1.93)</td><td>−</td></tr><tr><td>FP discussed during CWC</td><td></td><td>p = 0.56</td><td></td></tr><tr><td>No</td><td>17 (51.4)</td><td>1</td><td>−</td></tr><tr><td>Yes</td><td>271 (51.1)</td><td>1.11 (0.78, 1.59)</td><td>−</td></tr><tr><td>Discusses FP with partner</td><td></td><td>p < 0.001</td><td>p = 0.03</td></tr><tr><td>No</td><td>74 (37.0)</td><td>1</td><td>1</td></tr><tr><td>Yes</td><td>217 (60.6)</td><td>1.64 (1.34, 2.00)</td><td>1.22 (1.01, 1.47)</td></tr><tr><td>Desire to space children</td><td></td><td>p < 0.001</td><td>p = 0.14</td></tr><tr><td>No</td><td>54 (36.2)</td><td>1</td><td>1</td></tr><tr><td>Yes</td><td>242 (54.9)</td><td>1.51 (1.20, 1.90)</td><td>1.16 (0.95, 1.41)</td></tr><tr><td>Resumed sexual intercourse</td><td></td><td>p = 0.01</td><td>p = 0.70</td></tr><tr><td>No</td><td>192 (46.8)</td><td>1</td><td>1</td></tr><tr><td>Yes</td><td>104 (57.8)</td><td>1.23 (1.05, 1.45)</td><td>1.03 (0.89, 1.19)</td></tr><tr><td>Resumed menses</td><td></td><td>p = 0.61</td><td></td></tr><tr><td>No</td><td>215 (49.5)</td><td>1.05 (0.88, 1.25)</td><td>−</td></tr><tr><td>Yes</td><td>81 (52.9)</td><td>1</td><td>−</td></tr><tr><td>Previous contraceptive use</td><td></td><td>p < 0.001</td><td>p < 0.001</td></tr><tr><td>No</td><td>82 (28.5)</td><td>1</td><td>1</td></tr></table>
<table><tr><td>Yes</td><td>214 (70.9)</td><td>2.45 (2.04, 3.03)</td><td>1.91 (1.56, 2.33)</td></tr></table>
1bc20d0031951ef0fda30b66a68626db9ed1b77bfa0eade7046ae6aad2daa7ec.png
complex
<table><tr><td colspan="3">Measurement</td><td colspan="2">Location</td><td>Data points</td><td>Sampling rate</td></tr><tr><td>Parameter</td><td>Method</td><td>Performed by</td><td>Laboratory</td><td>Office</td><td>d<sup>-1</sup> (overall)</td><td>s<sup>-1</sup></td></tr><tr><td colspan="7"><i>Physiological</i></td></tr><tr><td> Sitting time</td><td>IPAQ-long</td><td>questionnaire - interview</td><td>x</td><td></td><td>1 (4)</td><td>n.a.<sup>d</sup></td></tr><tr><td> Physical activity</td><td>IPAQ-long</td><td>questionnaire - interview</td><td>x</td><td></td><td>1 (4)</td><td>n.a.<sup>d</sup></td></tr><tr><td> Mental workload</td><td>NASA-TLX</td><td>questionnaire</td><td>x</td><td></td><td>1 (4)</td><td>n.a.<sup>d</sup></td></tr><tr><td> Salivary cortisol</td><td>saliva collection</td><td>Salivette + cortisol ELISA</td><td>x<sup>a</sup></td><td></td><td>8 (32)</td><td>n.a.<sup>d</sup></td></tr><tr><td> Heart-rate</td><td>ECG</td><td>ECG recorder</td><td>x<sup>b</sup></td><td></td><td>n.a.<sup>c</sup></td><td>250</td></tr><tr><td> Body movements</td><td>acceleration</td><td>ECG recorder</td><td>x<sup>b</sup></td><td></td><td>n.a.<sup>c</sup></td><td>250</td></tr><tr><td colspan="7"><i>Cognitive</i></td></tr><tr><td> Working speed</td><td>text editing task</td><td>computer software (matlab)</td><td>x</td><td></td><td>5 (20)</td><td>&gt;1000</td></tr><tr><td> Reaction time</td><td>Stroop-test</td><td>computer software (matlab)</td><td>x</td><td></td><td>5 (20)</td><td>&gt;1000</td></tr><tr><td> Attention</td><td>d2R-test</td><td>test sheet</td><td>x</td><td></td><td>5 (20)</td><td>n.a.<sup>d</sup></td></tr><tr><td colspan="7"><i>Office based</i></td></tr><tr><td> Body postures</td><td>logging tool</td><td>computer software (C#)</td><td></td><td>x</td><td>n.a.<sup>c</sup></td><td>&gt;1000</td></tr><tr><td> Postural changes</td><td>logging tool</td><td>computer software (C#)</td><td></td><td>x</td><td>n.a.<sup>c</sup></td><td>&gt;1000</td></tr></table>
<table><tr><td colspan="3">Measurement</td><td colspan="2">Location</td><td>Data points</td><td>Sampling rate</td></tr><tr><td>Parameter</td><td>Method</td><td>Performed by</td><td>Laboratory</td><td>Office</td><td>d-1 (overall)</td><td>s-1</td></tr><tr><td colspan="7">Physiological</td></tr></table>
<table><tr><td>Sitting time</td><td>IPAQ-long</td><td>questionnaire - interview</td><td>x</td><td></td><td>1 (4)</td><td>n.a.d</td></tr><tr><td>Physical activity</td><td>IPAQ-long</td><td>questionnaire - interview</td><td>x</td><td></td><td>1 (4)</td><td>n.a.d</td></tr><tr><td>Mental workload</td><td>NASA-TLX</td><td>questionnaire</td><td>x</td><td></td><td>1 (4)</td><td>n.a.d</td></tr><tr><td>Salivary cortisol</td><td>saliva collection</td><td>Salivette + cortisol ELISA</td><td>xa</td><td></td><td>8 (32)</td><td>n.a.d</td></tr><tr><td>Heart-rate</td><td>ECG</td><td>ECG recorder</td><td>xb</td><td></td><td>n.a.c</td><td>250</td></tr><tr><td>Body movements</td><td>acceleration</td><td>ECG recorder</td><td>xb</td><td></td><td>n.a.c</td><td>250</td></tr><tr><td colspan="7">Cognitive</td></tr><tr><td>Working speed</td><td>text editing task</td><td>computer software (matlab)</td><td>x</td><td></td><td>5 (20)</td><td>>1000</td></tr><tr><td>Reaction time</td><td>Stroop-test</td><td>computer software (matlab)</td><td>x</td><td></td><td>5 (20)</td><td>>1000</td></tr><tr><td>Attention</td><td>d2R-test</td><td>test sheet</td><td>x</td><td></td><td>5 (20)</td><td>n.a.d</td></tr><tr><td colspan="7">Office based</td></tr><tr><td>Body postures</td><td>logging tool</td><td>computer software (C#)</td><td></td><td>x</td><td>n.a.c</td><td>>1000</td></tr><tr><td>Postural changes</td><td>logging tool</td><td>computer software (C#)</td><td></td><td>x</td><td>n.a.c</td><td>>1000</td></tr></table>
ee6abc8a1f2d293c061321c6ff7fe9ce45cd866f8aa82ea96f66c308e4a2595f.png
simple
<table><tr><td>Patient type</td><td>RCTs n (%)</td></tr><tr><td>Medical/Surgical</td><td>106 (43)</td></tr><tr><td>Medical only</td><td>56 (23)</td></tr><tr><td> Bronchiolitis</td><td>16 (6)</td></tr><tr><td> Sepsis/Shock</td><td>13 (5)</td></tr><tr><td> Asthma</td><td>8 (3)</td></tr><tr><td> Other medical</td><td>19 (8)</td></tr><tr><td>Surgical only</td><td>60 (24)</td></tr><tr><td>Cardiac surgery</td><td>46 (19)</td></tr><tr><td>Noncardiac surgery</td><td>14 (6)</td></tr><tr><td>Trauma/Burns only</td><td>26 (10)</td></tr><tr><td> Traumatic brain Injury</td><td>13 (5)</td></tr><tr><td> Burns</td><td>13 (5)</td></tr></table>
<table><tr><td>Patient type</td><td>RCTs n (%)</td></tr><tr><td>Medical/Surgical</td><td>106 (43)</td></tr><tr><td>Medical only</td><td>56 (23)</td></tr><tr><td>Bronchiolitis</td><td>16 (6)</td></tr><tr><td>Sepsis/Shock</td><td>13 (5)</td></tr><tr><td>Asthma</td><td>8 (3)</td></tr><tr><td>Other medical</td><td>19 (8)</td></tr><tr><td>Surgical only</td><td>60 (24)</td></tr><tr><td>Cardiac surgery</td><td>46 (19)</td></tr><tr><td>Noncardiac surgery</td><td>14 (6)</td></tr></table>
<table><tr><td>Trauma/Burns only</td><td>26 (10)</td></tr><tr><td>Traumatic brain Injury</td><td>13 (5)</td></tr><tr><td>Burns</td><td>13 (5)</td></tr></table>
ff0b45f13cd4381fb7232694c99357353fd58f7da8b6f9651e671860f73c4f82.png
simple
<table><tr><td></td><td>Neoadjuvant (<i>n</i> = 80)</td><td>Adjuvant (<i>n</i> = 90)</td><td><i>P</i></td></tr><tr><td>PHS (days)</td><td>11 (7&#8211;33)</td><td>11 (5&#8211;51)</td><td>0.920<sup>a</sup></td></tr><tr><td>PHS with complications (days)</td><td>15</td><td>17</td><td>0.503<sup>b</sup></td></tr><tr><td>PHS without complications (days)</td><td>11</td><td>11</td><td>0.972<sup>a</sup></td></tr><tr><td>Patients with complications</td><td>15 (18.8%)</td><td>20 (22.2%)</td><td>0.704</td></tr><tr><td>Non-surgical complications</td><td></td><td></td><td></td></tr><tr><td>Pneumonia</td><td>1 (1.3%)</td><td>3 (3.3%)</td><td>0.623</td></tr><tr><td>Pleural effusion</td><td>0 (0.0%)</td><td>2 (2.2%)</td><td>0.499</td></tr><tr><td>Gastrointestinal motility disorders</td><td>3 (3.8%)</td><td>3 (3.3%)</td><td>1.000</td></tr><tr><td>Thrombosis</td><td>1 (1.3%)</td><td>1 (1.1%)</td><td>1.000</td></tr><tr><td>Renal dysfunction</td><td>1 (1.3%)</td><td>1 (1.1%)</td><td>1.000</td></tr><tr><td>Catheter-related sepsis</td><td>1 (1.3%)</td><td>0 (0.0%)</td><td>0.471</td></tr><tr><td>Other (urinary, thrombocytopenia)</td><td>1 (1.3%)</td><td>4 (4.4%)</td><td>0.372</td></tr><tr><td>Surgical complications</td><td></td><td></td><td></td></tr><tr><td>Anastomotic leakage</td><td>0 (0.0%)</td><td>2 (2.2%)</td><td>0.499</td></tr><tr><td>Surgical site infection</td><td>5 (6.2%)</td><td>6 (6.7%)</td><td>1.000</td></tr><tr><td>Postoperative hemorrhage</td><td>3 (3.8%)</td><td>1 (1.1%)</td><td>0.343</td></tr><tr><td>Wound dehiscence</td><td>0 (0.0%)</td><td>2 (2.2%)</td><td>0.499</td></tr><tr><td>Lymphorrhea</td><td>2 (2.5%)</td><td>1 (1.1%)</td><td>0.602</td></tr><tr><td>Ileus</td><td>0 (0.0%)</td><td>1 (1.1%)</td><td>1.000</td></tr><tr><td>Biliary fistula</td><td>1 (1.3%)</td><td>0 (0.0%)</td><td>0.471</td></tr></table>
<table><tr><td></td><td>Neoadjuvant (n = 80)</td><td>Adjuvant (n = 90)</td><td>P</td></tr><tr><td>PHS (days)</td><td>11 (7–33)</td><td>11 (5–51)</td><td>0.920a</td></tr><tr><td>PHS with complications (days)</td><td>15</td><td>17</td><td>0.503b</td></tr><tr><td>PHS without complications (days)</td><td>11</td><td>11</td><td>0.972a</td></tr></table>
<table><tr><td>Patients with complications</td><td>15 (18.8%)</td><td>20 (22.2%)</td><td>0.704</td></tr><tr><td>Non-surgical complications</td><td></td><td></td><td></td></tr><tr><td>Pneumonia</td><td>1 (1.3%)</td><td>3 (3.3%)</td><td>0.623</td></tr><tr><td>Pleural effusion</td><td>0 (0.0%)</td><td>2 (2.2%)</td><td>0.499</td></tr><tr><td>Gastrointestinal motility disorders</td><td>3 (3.8%)</td><td>3 (3.3%)</td><td>1.000</td></tr><tr><td>Thrombosis</td><td>1 (1.3%)</td><td>1 (1.1%)</td><td>1.000</td></tr><tr><td>Renal dysfunction</td><td>1 (1.3%)</td><td>1 (1.1%)</td><td>1.000</td></tr><tr><td>Catheter-related sepsis</td><td>1 (1.3%)</td><td>0 (0.0%)</td><td>0.471</td></tr><tr><td>Other (urinary, thrombocytopenia)</td><td>1 (1.3%)</td><td>4 (4.4%)</td><td>0.372</td></tr><tr><td>Surgical complications</td><td></td><td></td><td></td></tr><tr><td>Anastomotic leakage</td><td>0 (0.0%)</td><td>2 (2.2%)</td><td>0.499</td></tr><tr><td>Surgical site infection</td><td>5 (6.2%)</td><td>6 (6.7%)</td><td>1.000</td></tr><tr><td>Postoperative hemorrhage</td><td>3 (3.8%)</td><td>1 (1.1%)</td><td>0.343</td></tr><tr><td>Wound dehiscence</td><td>0 (0.0%)</td><td>2 (2.2%)</td><td>0.499</td></tr><tr><td>Lymphorrhea</td><td>2 (2.5%)</td><td>1 (1.1%)</td><td>0.602</td></tr><tr><td>Ileus</td><td>0 (0.0%)</td><td>1 (1.1%)</td><td>1.000</td></tr><tr><td>Biliary fistula</td><td>1 (1.3%)</td><td>0 (0.0%)</td><td>0.471</td></tr></table>
8b98dd7edbd44c04f4a4a2f01e3eec938ea13e87e73b46e87b456a6c7d9757ba.png
complex
<table><tr><td> </td><td colspan="3">Pre-supplementation</td><td colspan="3">Post-supplementation</td></tr><tr><td>Measure</td><td>Subjects reporting GIT symptoms post-supplement (mean)</td><td>Subjects GIT symptom free post-supplement (mean)</td><td><i>P </i>value</td><td>Subjects reporting GIT symptoms post- supplement (mean)</td><td>Subjects GIT symptom free post-supplement (mean)</td><td><i>P </i>value</td></tr><tr><td>General health indices</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Neurological index</td><td>1.3</td><td>0.5</td><td>&lt; 0.004</td><td>1.0</td><td>0.4</td><td><i>ns</i></td></tr><tr><td>Chalder fatigue scale</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Total fatigue scores</td><td>14.2</td><td>11.8</td><td><i>ns</i></td><td>12.6</td><td>8.9</td><td><i>ns</i></td></tr><tr><td>Amino acids</td><td rowspan="2"> </td><td rowspan="2"> </td><td rowspan="2"> </td><td rowspan="2"> </td><td rowspan="2"> </td><td rowspan="2"> </td></tr><tr><td> (Relative % abundance)</td></tr><tr><td> Asparagine</td><td>6.60%</td><td>4.78%</td><td>&lt; 0.03</td><td>6.11%</td><td>4.89%</td><td><i>ns</i></td></tr><tr><td> Hydroxylysine</td><td>1.62%</td><td>1.15%</td><td>&lt; 0.05</td><td>1.72%</td><td>1.32%</td><td><i>ns</i></td></tr><tr><td> Hydroxyproline</td><td>0.58%</td><td>0.34%</td><td>&lt; 0.04</td><td>0.65%</td><td>0.52%</td><td><i>ns</i></td></tr></table>
<table><tr><td></td><td colspan="3">Pre-supplementation</td><td colspan="3">Post-supplementation</td></tr><tr><td>Measure</td><td>Subjects reporting GIT symptoms post-supplement (mean)</td><td>Subjects GIT symptom free post-supplement (mean)</td><td>P value</td><td>Subjects reporting GIT symptoms post- supplement (mean)</td><td>Subjects GIT symptom free post-supplement (mean)</td><td>P value</td></tr><tr><td>General health indices</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Neurological index</td><td>1.3</td><td>0.5</td><td>< 0.004</td><td>1.0</td><td>0.4</td><td>ns</td></tr></table>
<table><tr><td>Chalder fatigue scale</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total fatigue scores</td><td>14.2</td><td>11.8</td><td>ns</td><td>12.6</td><td>8.9</td><td>ns</td></tr><tr><td>Amino acids</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td></tr><tr><td>(Relative % abundance)</td></tr><tr><td>Asparagine</td><td>6.60%</td><td>4.78%</td><td>< 0.03</td><td>6.11%</td><td>4.89%</td><td>ns</td></tr><tr><td>Hydroxylysine</td><td>1.62%</td><td>1.15%</td><td>< 0.05</td><td>1.72%</td><td>1.32%</td><td>ns</td></tr><tr><td>Hydroxyproline</td><td>0.58%</td><td>0.34%</td><td>< 0.04</td><td>0.65%</td><td>0.52%</td><td>ns</td></tr></table>
076a53d15ab6e74e8d04cd4a6802d4df7f10973e4d102359f6ea94419f09a38f.png
complex
<table><tr><td rowspan="2">Variable</td><td>Glaucoma group <i>n</i> = 8777</td><td>Control group <i>n</i> = 35,108</td><td rowspan="2"><i>p-</i>value</td></tr><tr><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td>Age, year, (mean&#177;SD)</td><td>59.4&#177;13.6</td><td>59.4&#177;13.6</td><td>1.000</td></tr><tr><td>Age, categorical</td><td></td><td></td><td>1.000</td></tr><tr><td> 30&#8211;50</td><td>2228 (25.4)</td><td>8912 (25.4)</td><td></td></tr><tr><td> 50&#8211;60</td><td>2012 (22.9)</td><td>8048 (22.9)</td><td></td></tr><tr><td> 60&#8211;70</td><td>2239 (25.5)</td><td>8956 (25.5)</td><td></td></tr><tr><td>&#8805; 70</td><td>2298 (26.2)</td><td>9192 (26.2)</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td>1.000</td></tr><tr><td> Male</td><td>4376 (49.9)</td><td>17,504 (49.9)</td><td></td></tr><tr><td> Female</td><td>4401 (50.1)</td><td>17,604 (50.1)</td><td></td></tr><tr><td>Charlson comorbidity index</td><td></td><td></td><td>&lt; 0.0001</td></tr><tr><td>&lt; 3</td><td>7463 (85.0)</td><td>309,339 (88.1)</td><td></td></tr><tr><td> &#8805;3</td><td>1314 (15.0)</td><td>4169 (11.9)</td><td></td></tr><tr><td>Insurance cost</td><td></td><td></td><td>&lt; 0.0001</td></tr><tr><td>&lt; 40,000 NTD</td><td>7618 (86.8)</td><td>31,052 (88.4)</td><td></td></tr><tr><td> &#8805;40,000 NTD</td><td>1159 (13.2)</td><td>4056 (11.6)</td><td></td></tr><tr><td>Urbanization level</td><td></td><td></td><td>&lt; 0.0001</td></tr><tr><td> Urban</td><td>6761 (77.0)</td><td>25,464 (72.5)</td><td></td></tr><tr><td> Rural</td><td>2016 (23.0)</td><td>9644 (27.5)</td><td></td></tr><tr><td>Living alone</td><td></td><td></td><td>0.62</td></tr><tr><td> No</td><td>7973 (90.8)</td><td>32,830 (90.7)</td><td></td></tr><tr><td> Yes</td><td>804 (9.2)</td><td>3278 (9.3)</td><td></td></tr><tr><td colspan="4">Substance abuse</td></tr><tr><td> No</td><td>8704 (99.2)</td><td>34,786 (99.1)</td><td>0.49</td></tr><tr><td> Yes</td><td>73 (0.8)</td><td>322 (0.9)</td><td></td></tr><tr><td>Depression during the follow-up period</td><td>515 (5.9)</td><td>1282 (3.7)</td><td>&lt; 0.0001</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td>Glaucoma group n = 8777</td><td>Control group n = 35,108</td><td rowspan="2">p-value</td></tr><tr><td>n (%)</td><td>n (%)</td></tr><tr><td>Age, year, (mean±SD)</td><td>59.4±13.6</td><td>59.4±13.6</td><td>1.000</td></tr><tr><td>Age, categorical</td><td></td><td></td><td>1.000</td></tr><tr><td>30–50</td><td>2228 (25.4)</td><td>8912 (25.4)</td><td></td></tr><tr><td>50–60</td><td>2012 (22.9)</td><td>8048 (22.9)</td><td></td></tr><tr><td>60–70</td><td>2239 (25.5)</td><td>8956 (25.5)</td><td></td></tr><tr><td>≥ 70</td><td>2298 (26.2)</td><td>9192 (26.2)</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td>1.000</td></tr><tr><td>Male</td><td>4376 (49.9)</td><td>17,504 (49.9)</td><td></td></tr><tr><td>Female</td><td>4401 (50.1)</td><td>17,604 (50.1)</td><td></td></tr><tr><td>Charlson comorbidity index</td><td></td><td></td><td>< 0.0001</td></tr><tr><td>< 3</td><td>7463 (85.0)</td><td>309,339 (88.1)</td><td></td></tr><tr><td>≥3</td><td>1314 (15.0)</td><td>4169 (11.9)</td><td></td></tr><tr><td>Insurance cost</td><td></td><td></td><td>< 0.0001</td></tr><tr><td>< 40,000 NTD</td><td>7618 (86.8)</td><td>31,052 (88.4)</td><td></td></tr><tr><td>≥40,000 NTD</td><td>1159 (13.2)</td><td>4056 (11.6)</td><td></td></tr><tr><td>Urbanization level</td><td></td><td></td><td>< 0.0001</td></tr><tr><td>Urban</td><td>6761 (77.0)</td><td>25,464 (72.5)</td><td></td></tr><tr><td>Rural</td><td>2016 (23.0)</td><td>9644 (27.5)</td><td></td></tr><tr><td>Living alone</td><td></td><td></td><td>0.62</td></tr></table>
<table><tr><td rowspan="2">Variable</td><td>Glaucoma group n = 8777</td><td>Control group n = 35,108</td><td rowspan="2">p-value</td></tr><tr><td>n (%)</td><td>n (%)</td></tr><tr><td>No</td><td>7973 (90.8)</td><td>32,830 (90.7)</td><td></td></tr><tr><td>Yes</td><td>804 (9.2)</td><td>3278 (9.3)</td><td></td></tr><tr><td colspan="4">Substance abuse</td></tr><tr><td>No</td><td>8704 (99.2)</td><td>34,786 (99.1)</td><td>0.49</td></tr><tr><td>Yes</td><td>73 (0.8)</td><td>322 (0.9)</td><td></td></tr><tr><td>Depression during the follow-up period</td><td>515 (5.9)</td><td>1282 (3.7)</td><td>< 0.0001</td></tr></table>
ee7ab18aa0d46dbd66e44866d4ec76e061650bbe6b418b03d3722216acb3e4b3.png
simple
<table><tr><td>Municipality</td><td>% Speaking indigenous language</td><td>% Speaking Zapotec monolingual</td><td>% Speaking Zapotec monolingual</td><td>% Of 15 year-old or older who read and write in Spanish</td><td>Average number of years in school</td><td>% Of the population engaged in primary production activities</td></tr><tr><td> </td><td>Year 2000</td><td>Year 2000</td><td>Year 1950</td><td>Year 2000</td><td>Year 2000</td><td>Year 2000</td></tr><tr><td>Juchita&#769;n de Zaragoza</td><td>70.01</td><td>8.81</td><td>27.26</td><td>52.11</td><td>6.26</td><td>13.89</td></tr><tr><td>San Blas Atempa</td><td>92.76</td><td>24.87</td><td>72.08</td><td>39.95</td><td>3.56</td><td>33.79</td></tr><tr><td>Santa Mari&#769;a Xadani</td><td>97.71</td><td>34.07</td><td>83.33</td><td>32.05</td><td>3.36</td><td>35.01</td></tr></table>
<table><tr><td>Municipality</td><td>% Speaking indigenous language</td><td>% Speaking Zapotec monolingual</td><td>% Speaking Zapotec monolingual</td><td>% Of 15 year-old or older who read and write in Spanish</td><td>Average number of years in school</td><td>% Of the population engaged in primary production activities</td></tr><tr><td></td><td>Year 2000</td><td>Year 2000</td><td>Year 1950</td><td>Year 2000</td><td>Year 2000</td><td>Year 2000</td></tr><tr><td>Juchitán de Za</td><td>7</td><td>8.</td><td>2</td><td>52.</td><td></td><td></td></tr></table>
<table><tr><td>Municipality</td><td>% Speaking indigenous language</td><td>% Speaking Zapotec monolingual</td><td>% Speaking Zapotec monolingual</td><td>% Of 15 year-old or older who read and write in Spanish</td><td>Average number of years in school</td><td>% Of the population engaged in primary production activities</td></tr><tr><td></td><td>Year 2000</td><td>Year 2000</td><td>Year 1950</td><td>Year 2000</td><td>Year 2000</td><td>Year 2000</td></tr><tr><td>ragoza</td><td>0.01</td><td>81</td><td>7.26</td><td>11</td><td>6.26</td><td>13.89</td></tr><tr><td>San Blas Atempa</td><td>92.76</td><td>24.87</td><td>72.08</td><td>39.95</td><td>3.56</td><td>33.79</td></tr><tr><td>Santa María Xadani</td><td>97.71</td><td>34.07</td><td>83.33</td><td>32.05</td><td>3.36</td><td>35.01</td></tr></table>
cadb50118ef6e62d94cf84a57b110c778301194bebfbfdee9c24400682796c15.png
complex
<table><tr><td></td><td>Total cohort</td><td>&lt;70 years</td><td>&#8805;70 years</td></tr><tr><td colspan="4">Demographics</td></tr><tr><td> N (%)</td><td>2280</td><td>1497 (65.7)</td><td>783 (34.3)</td></tr><tr><td> Age, mean (SD) [1]</td><td>61.1 (17.0)</td><td>52.2 (13.6)</td><td>78.2 (6.2)</td></tr><tr><td> Gender (male), n (%) [1]</td><td>1315 (57.7)</td><td>821 (54.8)</td><td>494 (63.1)</td></tr><tr><td> Included at University Medical Centre, n (%)</td><td>1860 (81.6)</td><td>1271 (84.9)</td><td>589 (75.2)</td></tr><tr><td colspan="4">Co-morbidities, n (%)</td></tr><tr><td> COPD [2]</td><td>349 (15.3)</td><td>158 (10.6)</td><td>191 (24.4)</td></tr><tr><td> Heart failure [1]</td><td>329 (14.4)</td><td>133 (8.9)</td><td>196 (25.0)</td></tr><tr><td> Liver disease [1]</td><td>113 (5.0)</td><td>94 (6.3)</td><td>19 (2.4)</td></tr><tr><td> Renal disease [1]</td><td>416 (18.2)</td><td>261 (17.4)</td><td>155 (19.8)</td></tr><tr><td> Nursing home [2]</td><td>138 (6.1)</td><td>46 (3.1)</td><td>92 (11.7)</td></tr><tr><td> Immune-compromised [2]</td><td>951 (41.7)</td><td>720 (48.1)</td><td>231 (29.5)</td></tr><tr><td> Malignancy &#8211; [1]</td><td>253 (11.1)</td><td>155 (10.4)</td><td>98 (12.5)</td></tr><tr><td> Malignancy + [3]</td><td>345 (15.1)</td><td>244 (16.3)</td><td>101 (12.9)</td></tr><tr><td> DNR status (%) (6)</td><td>478 (21.0)</td><td>185 (12.4)</td><td>293 (37.4)</td></tr><tr><td colspan="4">Suspected source of infection, n (%)</td></tr><tr><td> Pulmonary</td><td>1059 (46.4)</td><td>620 (41.4)</td><td>439 (56.1)</td></tr><tr><td> Urogenital</td><td>675 (29.6)</td><td>397 (26.5)</td><td>278 (35.5)</td></tr><tr><td> Abdominal</td><td>396 (17.4)</td><td>273 (18.2)</td><td>123 (15.7)</td></tr><tr><td> Skin</td><td>198 (8.7)</td><td>145 (9.7)</td><td>53 (6.8)</td></tr><tr><td> Neurological</td><td>48 (2.1)</td><td>35 (2.3)</td><td>13 (1.7)</td></tr><tr><td> other</td><td>396 (17.4)</td><td>301 (20.1)</td><td>95 (12.1)</td></tr><tr><td colspan="4">Vital signs on admission</td></tr><tr><td> Systolic blood pressure, mean (SD) (241)</td><td>131.9 (25.9)</td><td>129.8 (23.5)</td><td>135.7 (29.3)</td></tr><tr><td> Heart rate, mean (SD) (45)</td><td>108.0 (20.3)</td><td>110.2 (19.7)</td><td>103.8 (20.9)</td></tr><tr><td> Respiratory rate, mean (SD) (558)</td><td>24.0 (7.2)</td><td>22.83 (6.9)</td><td>25.73 (7.5)</td></tr><tr><td> Oxygen saturation, mean (SD) (71)</td><td>95.2 (4.8)</td><td>95.8 (4.6)</td><td>94.1 (5.2)</td></tr><tr><td> Temperature (&#176;C), mean (SD) (94)</td><td>38.72 (1.11)</td><td>38.74 (1.06)</td><td>38.69 (1.20)</td></tr><tr><td> Altered mental status n (%) (420)</td><td>370 (16.2)</td><td>161 (10.8)</td><td>209 (26.7)</td></tr><tr><td colspan="4">Laboratory analysis on admission</td></tr><tr><td> Lactate (mmol/l), median (IQR) (293)</td><td>1.9 (1.4&#8211;2.6)</td><td>1.8 (1.4&#8211;2.6)</td><td>2.0 (1.5&#8211;2.8)</td></tr><tr><td> Platelets (&#215;10<sup>9</sup>/l), median (IQR) (41)</td><td>209 (151&#8211;280)</td><td>207 (148&#8211;279)</td><td>213.5 (156&#8211;286)</td></tr><tr><td> INR median (IQR), (702)</td><td>1.1 (1&#8211;1.4)</td><td>1.1 (1.0&#8211;1.29)</td><td>1.2 (1.0&#8211;2.4)</td></tr><tr><td> Creatinine (&#956;g/l), median (IQR) [16]</td><td>87 (67&#8211;120)</td><td>83 (64&#8211;110)</td><td>95 (74&#8211;134)</td></tr><tr><td> Urea (mmol/l), median (IQR) (40)</td><td>7.0 (5.1&#8211;10.2)</td><td>6.2 (4.6&#8211;8.8)</td><td>8.8 (6.6&#8211;12.5)</td></tr><tr><td> Band cells &gt;5%, n (%)</td><td>179 (7.9)</td><td>103 (6.9)</td><td>76 (9.7)</td></tr><tr><td> Bilirubin (&#956;mol/l), median (IQR) (349)</td><td>12 (8&#8211;19)</td><td>12 (8&#8211;18)</td><td>12 (9&#8211;20)</td></tr><tr><td colspan="4">Treatment variables</td></tr><tr><td> Time to antibiotics (min), median (IQR) [23]</td><td>103 (58&#8211;167)</td><td>109 (63&#8211;174)</td><td>91 (51&#8211;152)</td></tr><tr><td> Fluid resuscitation (L during ED stay), median (IQR)</td><td>1 (0.5&#8211;1.5)</td><td>1 (0.5&#8211;1.5)</td><td>1 (0.5&#8211;1.5)</td></tr><tr><td> Supplementary oxygen (L/min), median (IQR) (85)</td><td>3 (0&#8211;5)</td><td>2 (0&#8211;5)</td><td>3 (2&#8211;6)</td></tr></table>
<table><tr><td></td><td>Total cohort</td></tr><tr><td colspan="2">Demographics</td></tr><tr><td>N (%)</td><td>2280</td></tr><tr><td>Age, mean (SD) [1]</td><td>61.1 (17.0)</td></tr><tr><td>Gender (male), n (%) [1]</td><td>1315 (57.7)</td></tr><tr><td>Included at University Medical Centre, n (%)</td><td>1860 (81.6)</td></tr><tr><td colspan="2">Co-morbidities, n (%)</td></tr><tr><td>COPD [2]</td><td>349 (15.3)</td></tr><tr><td>Heart failure [1]</td><td>329 (14.4)</td></tr><tr><td>Liver disease [1]</td><td>113 (5.0)</td></tr><tr><td>Renal disease [1]</td><td>416 (18.2)</td></tr><tr><td>Nursing home [2]</td><td>138 (6.1)</td></tr><tr><td>Immune-compromised [2]</td><td>951 (41.7)</td></tr><tr><td>Malignancy – [1]</td><td>253 (11.1)</td></tr><tr><td>Malignancy + [3]</td><td>345 (15.1)</td></tr><tr><td>DNR status (%) (6)</td><td>478 (21.0)</td></tr><tr><td colspan="2">Suspected source of infection, n (%)</td></tr><tr><td>Pulmonary</td><td>1059 (46.4)</td></tr><tr><td>Urogenital</td><td>675 (29.6)</td></tr><tr><td>Abdominal</td><td>396 (17.4)</td></tr><tr><td>Skin</td><td>198 (8.7)</td></tr><tr><td>Neurological</td><td>48 (2.1)</td></tr><tr><td>other</td><td>396 (17.4)</td></tr><tr><td colspan="2">Vital signs on admission</td></tr><tr><td>Systolic blood pressure, mean (SD) (241)</td><td>131.9 (25.9)</td></tr><tr><td>Heart rate, mean (SD) (45)</td><td>108.0 (20.3)</td></tr><tr><td>Respiratory rate, mean (SD) (558)</td><td>24.0 (7.2)</td></tr><tr><td>Oxygen saturation, mean (SD) (71)</td><td>95.2 (4.8)</td></tr><tr><td>Temperature (°C), mean (SD) (94)</td><td>38.72 (1.11)</td></tr><tr><td>Altered mental status n (%) (420)</td><td>370 (16.2)</td></tr><tr><td colspan="2">Laboratory analysis on admission</td></tr><tr><td>Lactate (mmol/l), median (IQR) (293)</td><td>1.9 (1.4–2.6)</td></tr><tr><td>Platelets (×109/l), median (IQR) (41)</td><td>209 (151–280)</td></tr><tr><td>INR median (IQR), (702)</td><td>1.1 (1–1.4)</td></tr><tr><td>Creatinine (μg/l), median (IQR) [16]</td><td>87 (67–120)</td></tr><tr><td>Urea (mmol/l), median (IQR) (40)</td><td>7.0 (5.1–10.2)</td></tr><tr><td>Band cells >5%, n (%)</td><td>179 (7.9)</td></tr><tr><td>Bilirubin (μmol/l), median (IQR) (349)</td><td>12 (8–19)</td></tr><tr><td colspan="2">Treatment variables</td></tr><tr><td>Time to antibiotics (min), median (IQR) [23]</td><td>103 (58–167)</td></tr><tr><td>Fluid resuscitation (L during ED stay), median (IQR)</td><td>1 (0.5–1.5)</td></tr><tr><td>Supplementary oxygen (L/min), median (IQR) (85)</td><td>3 (0–5)</td></tr></table>
<table><tr><td><70 years</td><td>≥70 years</td></tr><tr><td colspan="2">Demographics</td></tr><tr><td>1497 (65.7)</td><td>783 (34.3)</td></tr><tr><td>52.2 (13.6)</td><td>78.2 (6.2)</td></tr><tr><td>821 (54.8)</td><td>494 (63.1)</td></tr><tr><td>1271 (84.9)</td><td>589 (75.2)</td></tr><tr><td colspan="2">Co-morbidities, n (%)</td></tr><tr><td>158 (10.6)</td><td>191 (24.4)</td></tr><tr><td>133 (8.9)</td><td>196 (25.0)</td></tr><tr><td>94 (6.3)</td><td>19 (2.4)</td></tr><tr><td>261 (17.4)</td><td>155 (19.8)</td></tr><tr><td>46 (3.1)</td><td>92 (11.7)</td></tr><tr><td>720 (48.1)</td><td>231 (29.5)</td></tr><tr><td>155 (10.4)</td><td>98 (12.5)</td></tr><tr><td>244 (16.3)</td><td>101 (12.9)</td></tr><tr><td>185 (12.4)</td><td>293 (37.4)</td></tr><tr><td colspan="2">Suspected source of infection, n (%)</td></tr><tr><td>620 (41.4)</td><td>439 (56.1)</td></tr><tr><td>397 (26.5)</td><td>278 (35.5)</td></tr><tr><td>273 (18.2)</td><td>123 (15.7)</td></tr><tr><td>145 (9.7)</td><td>53 (6.8)</td></tr><tr><td>35 (2.3)</td><td>13 (1.7)</td></tr><tr><td>301 (20.1)</td><td>95 (12.1)</td></tr><tr><td colspan="2">Vital signs on admission</td></tr><tr><td>129.8 (23.5)</td><td>135.7 (29.3)</td></tr><tr><td>110.2 (19.7)</td><td>103.8 (20.9)</td></tr><tr><td>22.83 (6.9)</td><td>25.73 (7.5)</td></tr><tr><td>95.8 (4.6)</td><td>94.1 (5.2)</td></tr><tr><td>38.74 (1.06)</td><td>38.69 (1.20)</td></tr><tr><td>161 (10.8)</td><td>209 (26.7)</td></tr><tr><td colspan="2">Laboratory analysis on admission</td></tr><tr><td>1.8 (1.4–2.6)</td><td>2.0 (1.5–2.8)</td></tr><tr><td>207 (148–279)</td><td>213.5 (156–286)</td></tr><tr><td>1.1 (1.0–1.29)</td><td>1.2 (1.0–2.4)</td></tr><tr><td>83 (64–110)</td><td>95 (74–134)</td></tr><tr><td>6.2 (4.6–8.8)</td><td>8.8 (6.6–12.5)</td></tr><tr><td>103 (6.9)</td><td>76 (9.7)</td></tr><tr><td>12 (8–18)</td><td>12 (9–20)</td></tr><tr><td colspan="2">Treatment variables</td></tr><tr><td>109 (63–174)</td><td>91 (51–152)</td></tr><tr><td>1 (0.5–1.5)</td><td>1 (0.5–1.5)</td></tr><tr><td>2 (0–5)</td><td>3 (2–6)</td></tr></table>
71dc2b1b555fd1ad01091f7f12c500533dbf19d3fbc664c92385f53db4be5df4.png
simple
<table><tr><td> </td><td>Before</td><td>After</td></tr><tr><td><i>N</i></td><td>39249</td><td>39249</td></tr><tr><td>Analgesics (<i>N</i>, %)</td><td> </td><td> </td></tr><tr><td> Represcribed pregabalin use</td><td>&#8212;</td><td>4009 (10.2)</td></tr><tr><td> 1-2-line drugs</td><td>5416 (13.8)</td><td>3213 (8.2)</td></tr><tr><td>Continued use</td><td>&#8212;</td><td>1761 (4.5)</td></tr><tr><td>New use</td><td>&#8212;</td><td>1348 (3.4)</td></tr><tr><td>Changed/added drugs</td><td>&#8212;</td><td>104 (0.3)</td></tr><tr><td> TCAs</td><td>837 (2.1)</td><td>448 (1.1)</td></tr><tr><td> Gabapentin</td><td>355 (0.9)</td><td>197 (0.5)</td></tr><tr><td> Neurotropin</td><td>3775 (9.6)</td><td>2106 (5.4)</td></tr><tr><td> Duloxetine</td><td>501 (1.3)</td><td>455 (1.2)</td></tr><tr><td> Mexiletine</td><td>310 (0.8)</td><td>221 (0.6)</td></tr><tr><td> Opioids</td><td>8171 (20.8)</td><td>5954 (15.2)</td></tr><tr><td>Continued use</td><td>&#8212;</td><td>1580 (4.0)</td></tr><tr><td>New use</td><td>&#8212;</td><td>2894 (7.4)</td></tr><tr><td>Changed/additions of drugs/route</td><td>&#8212;</td><td>1480 (3.8)</td></tr><tr><td> Oral opioids</td><td>5008 (12.8)</td><td>3350 (8.5)</td></tr><tr><td>Continued use</td><td>&#8212;</td><td>1358 (3.5)</td></tr><tr><td>New use</td><td>&#8212;</td><td>1649 (4.2)</td></tr><tr><td>Changed/added drugs</td><td>&#8212;</td><td>160 (0.4)</td></tr><tr><td>Changed/additions of route</td><td>&#8212;</td><td>183 (0.5)</td></tr><tr><td> Nonoral opioids</td><td>4737 (12.1)</td><td>3368 (8.6)</td></tr><tr><td>Continued use</td><td>&#8212;</td><td>702 (1.8)</td></tr><tr><td>New use</td><td>&#8212;</td><td>1465 (3.7)</td></tr><tr><td>Changed/added drugs</td><td>&#8212;</td><td>527 (1.3)</td></tr><tr><td>Changed/additions of route</td><td>&#8212;</td><td>674 (1.7)</td></tr><tr><td> Weak opioids</td><td>3238 (8.2)</td><td>2377 (6.1)</td></tr><tr><td>Continued use</td><td>&#8212;</td><td>710 (1.8)</td></tr><tr><td>New use</td><td>&#8212;</td><td>1444 (3.7)</td></tr><tr><td>Changed/added drugs</td><td>&#8212;</td><td>76 (0.2)</td></tr><tr><td>Changed/additions of the strength</td><td>&#8212;</td><td>147 (0.4)</td></tr><tr><td> Strong opioids</td><td>5928 (15.1)</td><td>3963 (10.1)</td></tr><tr><td>Continued use</td><td>&#8212;</td><td>1010 (2.6)</td></tr><tr><td>New use</td><td>&#8212;</td><td>1644 (4.2)</td></tr><tr><td>Changed/added drugs</td><td>&#8212;</td><td>1062 (2.7)</td></tr><tr><td>Changed/additions of the strength</td><td>&#8212;</td><td>247 (0.6)</td></tr></table>
<table><tr><td></td><td>Before</td><td>After</td></tr><tr><td>N</td><td>39249</td><td>39249</td></tr><tr><td>Analgesics (N, %)</td><td></td><td></td></tr><tr><td>Represcribed pregabalin use</td><td>—</td><td>4009 (10.2)</td></tr><tr><td>1-2-line drugs</td><td>5416 (13.8)</td><td>3213 (8.2)</td></tr><tr><td>Continued use</td><td>—</td><td>1761 (4.5)</td></tr><tr><td>New use</td><td>—</td><td>1348 (3.4)</td></tr><tr><td>Changed/added drugs</td><td>—</td><td>104 (0.3)</td></tr><tr><td>TCAs</td><td>837 (2.1)</td><td>448 (1.1)</td></tr><tr><td>Gabapentin</td><td>355 (0.9)</td><td>197 (0.5)</td></tr><tr><td>Neurotropin</td><td>3775 (9.6)</td><td>2106 (5.4)</td></tr><tr><td>Duloxetine</td><td>501 (1.3)</td><td>455 (1.2)</td></tr><tr><td>Mexiletine</td><td>310 (0.8)</td><td>221 (0.6)</td></tr><tr><td>Opioids</td><td>8171 (20.8)</td><td>5954 (15.2)</td></tr><tr><td>Continued use</td><td>—</td><td>1580 (4.0)</td></tr><tr><td>New use</td><td>—</td><td>2894 (7.4)</td></tr><tr><td>Changed/additions of drugs/route</td><td>—</td><td>1480 (3.8)</td></tr><tr><td>Oral opioids</td><td>5008 (12.8)</td><td>3350 (8.5)</td></tr><tr><td>Continued use</td><td>—</td><td>1358 (3.5)</td></tr><tr><td>New use</td><td>—</td><td>1649 (4.2)</td></tr><tr><td>Changed/added drugs</td><td>—</td><td>160 (0.4)</td></tr><tr><td>Changed/additions of route</td><td>—</td><td>183 (0.5)</td></tr><tr><td>No</td><td>4737 (1</td><td>3368 </td></tr></table>
<table><tr><td>noral opioids</td><td>2.1)</td><td>(8.6)</td></tr><tr><td>Continued use</td><td>—</td><td>702 (1.8)</td></tr><tr><td>New use</td><td>—</td><td>1465 (3.7)</td></tr><tr><td>Changed/added drugs</td><td>—</td><td>527 (1.3)</td></tr><tr><td>Changed/additions of route</td><td>—</td><td>674 (1.7)</td></tr><tr><td>Weak opioids</td><td>3238 (8.2)</td><td>2377 (6.1)</td></tr><tr><td>Continued use</td><td>—</td><td>710 (1.8)</td></tr><tr><td>New use</td><td>—</td><td>1444 (3.7)</td></tr><tr><td>Changed/added drugs</td><td>—</td><td>76 (0.2)</td></tr><tr><td>Changed/additions of the strength</td><td>—</td><td>147 (0.4)</td></tr><tr><td>Strong opioids</td><td>5928 (15.1)</td><td>3963 (10.1)</td></tr><tr><td>Continued use</td><td>—</td><td>1010 (2.6)</td></tr><tr><td>New use</td><td>—</td><td>1644 (4.2)</td></tr><tr><td>Changed/added drugs</td><td>—</td><td>1062 (2.7)</td></tr><tr><td>Changed/additions of the strength</td><td>—</td><td>247 (0.6)</td></tr></table>
02efd969449fda1133900ffa9cc1ae791ee732a8c42afcc6610a3c5fef6c0ddd.png
complex
<table><tr><td rowspan="2">Characteristic</td><td colspan="2">No. of wells (column %)</td><td rowspan="2"><i>p</i></td></tr><tr><td>Normoxic (<i>n</i> = 196)</td><td>Low O<sub>2</sub> (<i>n</i> = 57)</td></tr><tr><td colspan="4">Pipe type</td></tr><tr><td> No pipe</td><td>14 (7.1)</td><td>4 (7.0)</td><td>0.018&#8727;</td></tr><tr><td> Iron</td><td>155 (79.1)</td><td>36 (63.2)</td><td></td></tr><tr><td> PVC</td><td>27 (13.8)</td><td>17 (29.8)</td><td></td></tr><tr><td>Iron ladder</td><td>58 (29.6)</td><td>21 (36.8)</td><td>0.380&#8727;</td></tr><tr><td>Cement casing</td><td>172 (87.8)</td><td>48 (84.2)</td><td>0.634&#8727;</td></tr><tr><td>Leakage of water</td><td>89 (45.4)</td><td>23 (40.4)</td><td>0.600&#8727;</td></tr><tr><td colspan="4">Rust occurrence</td></tr><tr><td> On ladder</td><td>31 (15.8)</td><td>17 (29.8)</td><td>0.029&#8727;</td></tr><tr><td> On pipe</td><td>73 (37.2)</td><td>17 (29.8)</td><td>0.383&#8727;</td></tr><tr><td> On leaked water</td><td>16 (8.2)</td><td>2 (3.5)</td><td>0.379&#8224;</td></tr><tr><td colspan="4">Surroundings</td></tr><tr><td> Large tree (&gt;2 m)</td><td>131 (66.8)</td><td>36 (63.2)</td><td>0.721&#8727;</td></tr><tr><td> Small tree (&lt;2 m)</td><td>75 (38.3)</td><td>24 (42.1)</td><td>0.712&#8727;</td></tr><tr><td> Hut</td><td>61 (31.1)</td><td>19 (33.3)</td><td>0.877&#8727;</td></tr><tr><td> Rubbish, oil</td><td>18 (9.2)</td><td>4 (7.0)</td><td>0.791&#8224;</td></tr><tr><td> Roof</td><td>8 (4.1)</td><td>1 (1.7)</td><td>0.688&#8224;</td></tr><tr><td> Cover (&gt;80%)</td><td>9 (4.6)</td><td>10 (17.5)</td><td>0.003&#8224;</td></tr><tr><td colspan="4">Soil type</td></tr><tr><td> Loam</td><td>168 (85.7)</td><td>36 (63.2)</td><td>&lt;0.001&#8224;</td></tr><tr><td> Sandy loam</td><td>16 (8.2)</td><td>15 (26.3)</td><td></td></tr><tr><td> Sandy</td><td>3 (1.5)</td><td>5 (8.8)</td><td></td></tr><tr><td> Sandy clay</td><td>6 (3.1)</td><td>0 (0)</td><td></td></tr><tr><td> Clay</td><td>1 (0.5)</td><td>1 (1.8)</td><td></td></tr><tr><td> Clay loam</td><td>2 (1)</td><td>0 (0)</td><td></td></tr><tr><td colspan="4">Period since last rain (d)</td></tr><tr><td> 0</td><td>57 (29.1)</td><td>11 (19.3)</td><td>&lt;0.001&#8727;</td></tr><tr><td> 1</td><td>131 (66.8)</td><td>31 (54.4)</td><td></td></tr><tr><td> 2</td><td>8 (4.1)</td><td>15 (26.3)</td><td></td></tr><tr><td colspan="4">Water&#8225;</td></tr><tr><td> Color&#8212;not clear</td><td>25 (13.2)</td><td>7 (12.5)</td><td>0.887&#8727;</td></tr><tr><td> Odor&#8212;not fresh</td><td>39 (20.6)</td><td>19 (33.9)</td><td>0.040&#8727;</td></tr></table>
<table><tr><td rowspan="2">Characteristic</td><td colspan="2">No. of wells (column %)</td><td rowspan="2">p</td></tr><tr><td>Normoxic (n = 196)</td><td>Low O2 (n = 57)</td></tr><tr><td colspan="4">Pipe type</td></tr><tr><td>No pipe</td><td>14 (7.1)</td><td>4 (7.0)</td><td>0.018∗</td></tr><tr><td>Iron</td><td>155 (79.1)</td><td>36 (63.2)</td><td></td></tr><tr><td>PVC</td><td>27 (13.8)</td><td>17 (29.8)</td><td></td></tr><tr><td>Iron ladder</td><td>58 (29.6)</td><td>21 (36.8)</td><td>0.380∗</td></tr><tr><td>Cement casing</td><td>172 (87.8)</td><td>48 (84.2)</td><td>0.634∗</td></tr><tr><td>Leakage of water</td><td>89 (45.4)</td><td>23 (40.4)</td><td>0.600∗</td></tr><tr><td colspan="4">Rust occurrence</td></tr><tr><td>On ladder</td><td>31 (15.8)</td><td>17 (29.8)</td><td>0.029∗</td></tr><tr><td>On pipe</td><td>73 (37.2)</td><td>17 (29.8)</td><td>0.383∗</td></tr><tr><td>On leaked water</td><td>16 (8.2)</td><td>2 (3.5)</td><td>0.379†</td></tr><tr><td colspan="4">Surroundings</td></tr><tr><td>Large tree (>2 m)</td><td>131 (66.8)</td><td>36 (63.2)</td><td>0.721∗</td></tr></table>
<table><tr><td rowspan="2">Characteristic</td><td colspan="2">No. of wells (column %)</td><td rowspan="2">p</td></tr><tr><td>Normoxic (n = 196)</td><td>Low O2 (n = 57)</td></tr><tr><td>Small tree (<2 m)</td><td>75 (38.3)</td><td>24 (42.1)</td><td>0.712∗</td></tr><tr><td>Hut</td><td>61 (31.1)</td><td>19 (33.3)</td><td>0.877∗</td></tr><tr><td>Rubbish, oil</td><td>18 (9.2)</td><td>4 (7.0)</td><td>0.791†</td></tr><tr><td>Roof</td><td>8 (4.1)</td><td>1 (1.7)</td><td>0.688†</td></tr><tr><td>Cover (>80%)</td><td>9 (4.6)</td><td>10 (17.5)</td><td>0.003†</td></tr><tr><td colspan="4">Soil type</td></tr><tr><td>Loam</td><td>168 (85.7)</td><td>36 (63.2)</td><td><0.001†</td></tr><tr><td>Sandy loam</td><td>16 (8.2)</td><td>15 (26.3)</td><td></td></tr><tr><td>Sandy</td><td>3 (1.5)</td><td>5 (8.8)</td><td></td></tr><tr><td>Sandy clay</td><td>6 (3.1)</td><td>0 (0)</td><td></td></tr><tr><td>Clay</td><td>1 (0.5)</td><td>1 (1.8)</td><td></td></tr><tr><td>Clay loam</td><td>2 (1)</td><td>0 (0)</td><td></td></tr><tr><td colspan="4">Period since last rain (d)</td></tr><tr><td>0</td><td>57 (29.1)</td><td>11 (19.3)</td><td><0.001∗</td></tr><tr><td>1</td><td>131 (66.8)</td><td>31 (54.4)</td><td></td></tr><tr><td>2</td><td>8 (4.1)</td><td>15 (26.3)</td><td></td></tr><tr><td colspan="4">Water‡</td></tr><tr><td>Color—not clear</td><td>25 (13.2)</td><td>7 (12.5)</td><td>0.887∗</td></tr><tr><td>Odor—not fresh</td><td>39 (20.6)</td><td>19 (33.9)</td><td>0.040∗</td></tr></table>
03ece78a398e326f5ff6c96a87482441506bed89f3a2884c25381c5ba30e3ead.png
complex
<table><tr><td>Characteristic</td><td><i>n</i> = 133</td></tr><tr><td>Age (years)<sup>a</sup></td><td>67.2 &#177; 9.4</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>77</td></tr><tr><td> Female</td><td>56</td></tr><tr><td colspan="2">Diagnosis</td></tr><tr><td> Pancreatic carcinoma</td><td>49</td></tr><tr><td> Cholangiocarcinoma</td><td>49</td></tr><tr><td> Ampullary carcinoma</td><td>13</td></tr><tr><td> Intraductal papillary mucinous neoplasm</td><td>6</td></tr><tr><td> Neuroendocrine tumor</td><td>5</td></tr><tr><td> Others</td><td>11</td></tr><tr><td>Total bilirubin (mg/dL)<sup>a</sup></td><td>4.9 &#177; 5.5</td></tr><tr><td colspan="2">Preoperative biliary drainage</td></tr><tr><td> Yes</td><td>93</td></tr><tr><td> No</td><td>40</td></tr><tr><td colspan="2">Operation</td></tr><tr><td> PD</td><td>20</td></tr><tr><td> SSPPD</td><td>41</td></tr><tr><td> PPPD</td><td>72</td></tr><tr><td>Operation time (min)<sup>a</sup></td><td>454.3 &#177; 99.8</td></tr><tr><td>Blood loss (mL)<sup>a</sup></td><td>990.6 &#177; 701.3</td></tr><tr><td colspan="2">Transfusion</td></tr><tr><td> Yes</td><td>33</td></tr><tr><td> No</td><td>100</td></tr></table>
<table><tr><td>Characteristic</td><td>n = 133</td></tr><tr><td>Age (years)a</td><td>67.2 ± 9.4</td></tr><tr><td colspan="2">Sex</td></tr><tr><td>Male</td><td>77</td></tr><tr><td>Female</td><td>56</td></tr><tr><td colspan="2">Diagnosis</td></tr><tr><td>Pancreatic carcinoma</td><td>49</td></tr><tr><td>Cholangiocarcinoma</td><td>49</td></tr><tr><td>Ampullary carcinoma</td><td>13</td></tr><tr><td>Intraductal papillary mucinous neoplasm</td><td>6</td></tr><tr><td>Neuroendocrine tumor</td><td>5</td></tr><tr><td>Others</td><td>11</td></tr><tr><td>Total bilirubin (mg/dL)a</td><td>4.9 ± 5.5</td></tr><tr><td colspan="2">Preoperative biliary drainage</td></tr></table>
<table><tr><td>Characteristic</td><td>n = 133</td></tr><tr><td>Yes</td><td>93</td></tr><tr><td>No</td><td>40</td></tr><tr><td colspan="2">Operation</td></tr><tr><td>PD</td><td>20</td></tr><tr><td>SSPPD</td><td>41</td></tr><tr><td>PPPD</td><td>72</td></tr><tr><td>Operation time (min)a</td><td>454.3 ± 99.8</td></tr><tr><td>Blood loss (mL)a</td><td>990.6 ± 701.3</td></tr><tr><td colspan="2">Transfusion</td></tr><tr><td>Yes</td><td>33</td></tr><tr><td>No</td><td>100</td></tr></table>
61a9b8109563f5c3a7b5bb74b87c1d956736a6e2b62420b0d7e738dce5df48a2.png
complex
<table><tr><td rowspan="2"></td><td colspan="2">Baseline</td><td colspan="2">10% O<sub>2</sub></td><td colspan="2">Recovery</td></tr><tr><td>GFP (<i>n</i> = 4)</td><td>Cre (<i>n</i> = 6)</td><td>GFP (<i>n</i> = 4)</td><td>Cre (<i>n</i> = 6)</td><td>GFP (<i>n</i> = 4)</td><td>Cre (<i>n</i> = 6)</td></tr><tr><td colspan="7">Heart rate (BPM)</td></tr><tr><td>Pre</td><td>527 &#177; 13</td><td>504 &#177; 26</td><td>665 &#177; 11</td><td>656 &#177; 10</td><td>559 &#177; 20</td><td>560 &#177; 26</td></tr><tr><td>Post</td><td>495 &#177; 28</td><td>579 &#177; 10*</td><td>665 &#177; 16</td><td>721 &#177; 7***</td><td>524 &#177; 30</td><td>633 &#177; 14*</td></tr><tr><td colspan="7">Systolic blood pressure (mmHg)</td></tr><tr><td>Pre</td><td>129 &#177; 6</td><td>128 &#177; 5</td><td>124 &#177; 3</td><td>132 &#177; 3</td><td>129 &#177; 4</td><td>124 &#177; 6</td></tr><tr><td>Post</td><td>135 &#177; 5</td><td>152 &#177; 7*</td><td>126 &#177; 6</td><td>129 &#177; 5</td><td>128 &#177; 7</td><td>126 &#177; 6</td></tr><tr><td colspan="7">Diastolic blood pressure (mmHg)</td></tr><tr><td>Pre</td><td>62 &#177; 7</td><td>68 &#177; 6</td><td>62 &#177; 5</td><td>69 &#177; 5</td><td>62 &#177; 6</td><td>66 &#177; 6</td></tr><tr><td>Post</td><td>68 &#177; 6</td><td>81 &#177; 8*</td><td>65 &#177; 6</td><td>64 &#177; 4</td><td>63 &#177; 5</td><td>61 &#177; 7</td></tr><tr><td colspan="7">Respiratory rate (min<sup>&#8722;1</sup>)</td></tr><tr><td>Pre</td><td>185 &#177; 5</td><td>199 &#177; 7</td><td>280 &#177; 6</td><td>263 &#177; 7</td><td>145 &#177; 11</td><td>167 &#177; 10</td></tr><tr><td>Post</td><td>191 &#177; 3</td><td>199 &#177; 8</td><td>271 &#177; 3</td><td>266 &#177; 6</td><td>153 &#177; 9</td><td>155 &#177; 9</td></tr><tr><td colspan="7">Minute volume (au g<sup>&#8722;1</sup> min<sup>&#8722;1</sup>)</td></tr><tr><td>Pre</td><td>1.0 &#177; 0.1</td><td>1.0 &#177; 0.1</td><td>3.4 &#177; 0.1</td><td>3.3 &#177; 0.2</td><td>1.1 &#177; 0.1</td><td>1.2 &#177; 0.1</td></tr><tr><td>Post</td><td>1.0 &#177; 0.1</td><td>1.1 &#177; 0.1</td><td>3.2 &#177; 0.2</td><td>3.5 &#177; 0.2</td><td>1.1 &#177; 0.1</td><td>1.4 &#177; 0.1</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="2">Baseline</td></tr><tr><td>GFP (n = 4)</td><td>Cre (n = 6)</td></tr><tr><td colspan="3">Heart rate (BPM)</td></tr><tr><td>Pre</td><td>527 ± 13</td><td>504 ± 26</td></tr><tr><td>Post</td><td>495 ± 28</td><td>579 ± 10*</td></tr><tr><td colspan="3">Systolic blood pressure (mmHg)</td></tr><tr><td>Pre</td><td>129 ± 6</td><td>128 ± 5</td></tr><tr><td>Post</td><td>135 ± 5</td><td>152 ± 7*</td></tr><tr><td colspan="3">Diastolic blood pressure (mmHg)</td></tr><tr><td>Pre</td><td>62 ± 7</td><td>68 ± 6</td></tr><tr><td>Post</td><td>68 ± 6</td><td>81 ± 8*</td></tr><tr><td colspan="3">Respiratory rate (min−1)</td></tr><tr><td>Pre</td><td>185 ± 5</td><td>199 ± 7</td></tr><tr><td>Post</td><td>191 ± 3</td><td>199 ± 8</td></tr><tr><td colspan="3">Minute volume (au g−1 min−1)</td></tr><tr><td>Pre</td><td>1.0 ± 0.1</td><td>1.0 ± 0.1</td></tr><tr><td>Post</td><td>1.0 ± 0.1</td><td>1.1 ± 0.1</td></tr></table>
<table><tr><td colspan="2">10% O2</td><td colspan="2">Recovery</td></tr><tr><td>GFP (n = 4)</td><td>Cre (n = 6)</td><td>GFP (n = 4)</td><td>Cre (n = 6)</td></tr><tr><td colspan="4">Heart rate (BPM)</td></tr><tr><td>665 ± 11</td><td>656 ± 10</td><td>559 ± 20</td><td>560 ± 26</td></tr><tr><td>665 ± 16</td><td>721 ± 7***</td><td>524 ± 30</td><td>633 ± 14*</td></tr><tr><td colspan="4">Systolic blood pressure (mmHg)</td></tr><tr><td>124 ± 3</td><td>132 ± 3</td><td>129 ± 4</td><td>124 ± 6</td></tr><tr><td>126 ± 6</td><td>129 ± 5</td><td>128 ± 7</td><td>126 ± 6</td></tr><tr><td colspan="4">Diastolic blood pressure (mmHg)</td></tr><tr><td>62 ± 5</td><td>69 ± 5</td><td>62 ± 6</td><td>66 ± 6</td></tr><tr><td>65 ± 6</td><td>64 ± 4</td><td>63 ± 5</td><td>61 ± 7</td></tr><tr><td colspan="4">Respiratory rate (min−1)</td></tr><tr><td>280 ± 6</td><td>263 ± 7</td><td>145 ± 11</td><td>167 ± 10</td></tr><tr><td>271 ± 3</td><td>266 ± 6</td><td>153 ± 9</td><td>155 ± 9</td></tr><tr><td colspan="4">Minute volume (au g−1 min−1)</td></tr><tr><td>3.4 ± 0.1</td><td>3.3 ± 0.2</td><td>1.1 ± 0.1</td><td>1.2 ± 0.1</td></tr><tr><td>3.2 ± 0.2</td><td>3.5 ± 0.2</td><td>1.1 ± 0.1</td><td>1.4 ± 0.1</td></tr></table>
98279206d68c15446545e0d2fbb410b166486853c21f2294ee5aba10f16f67cb.png
simple
<table><tr><td>Markers</td><td>ADHLSC</td><td>BM-MSC [14, 15]</td><td>ASC [15]</td></tr><tr><td>CD73</td><td>98.3% (95.0&#8211;99.7)</td><td>&#8805;95% (guideline)</td><td>&#8805;95%</td></tr><tr><td>CD90</td><td>91.5% (86.9&#8211;95.0)</td><td>&#8805;95% (guideline)</td><td>&#8805;95%</td></tr><tr><td>CD105</td><td>96.7% (93.8&#8211;99.6)</td><td>&#8805;95% (guideline)</td><td>&#8805;95%</td></tr><tr><td>CD11b</td><td>0.7% (0.0&#8211;2.0)</td><td>&#8804;2% (guideline)</td><td>&#8804;2%</td></tr><tr><td>CD14</td><td>2.0% (0.0&#8211;3.26)</td><td>&#8804;2% (guideline)</td><td>&#8804;2%</td></tr><tr><td>CD19</td><td>0.5% (0.0&#8211;2.0)</td><td>&#8804;2% (guideline)</td><td>&#8804;2%</td></tr><tr><td>CD45</td><td>1.1% (0.0&#8211;2.8)</td><td>&#8804;2% (guideline)</td><td>&#8804;2%</td></tr><tr><td>HLA-DR</td><td>0.8%&#177; 0.5</td><td>&#8804;2% (guideline)</td><td>&#8804;2%</td></tr><tr><td>CD34</td><td>1.3% (0.1&#8211;2.6)</td><td>0.1% (0.0&#8722;0.1)</td><td>9.0% (5.1&#8211;30.1)</td></tr><tr><td>CD36</td><td>3.5% (0.0&#8211;12.0)</td><td>0.1% (0.0&#8722;0.2)</td><td>11.5% (4.8&#8211;13.4)</td></tr><tr><td>CD91</td><td>0.7% (0.0&#8722;1.7)</td><td>N.D.</td><td>47.6% (12.7&#8211;87.4)</td></tr><tr><td>CD140b</td><td>93.8% (99.4&#8211;78.6)</td><td>54.3% (45.9&#8211;87.5)</td><td>79.9% (49.2&#8211;87.5)</td></tr><tr><td>CD141</td><td>7.2% (4.2&#8211;12.8)</td><td>N.D.</td><td>&#8805;95%</td></tr><tr><td>CD201</td><td>53.3% (0.17&#8211;81.1)</td><td>2.0% (1.8&#8211;4.8)</td><td>13.6% (9.5&#8211;25.6)</td></tr></table>
<table><tr><td>Markers</td><td>ADHLSC</td><td>BM-MSC [14, 15]</td><td>ASC [15]</td></tr><tr><td>CD73</td><td>98.3% (95.0–99.7)</td><td>≥95% (guideline)</td><td>≥95%</td></tr><tr><td>CD90</td><td>91.5% (86.9–95.0)</td><td>≥95% (guideline)</td><td>≥95%</td></tr><tr><td>CD105</td><td>96.7% (93.8–99.6)</td><td>≥95% (guideline)</td><td>≥95%</td></tr><tr><td>CD11b</td><td>0.7% (0.0–2.0)</td><td>≤2% (guideline)</td><td>≤2%</td></tr><tr><td>CD14</td><td>2.0% (0.0–3.26)</td><td>≤2% (guideline)</td><td>≤2%</td></tr><tr><td>CD19</td><td>0.5% (0.0–2.0)</td><td>≤2% (guideline)</td><td>≤2%</td></tr><tr><td>CD45</td><td>1.1% (0.0–2.8)</td><td>≤2% (guideline)</td><td>≤2%</td></tr><tr><td>HLA-DR</td><td>0.8%± 0.5</td><td>≤2% (guideline)</td><td>≤2%</td></tr><tr><td>CD34</td><td>1.3% (0.1–2.6)</td><td>0.1% (0.0−0.1)</td><td>9.0% (5.1–30.1)</td></tr></table>
<table><tr><td>CD36</td><td>3.5% (0.0–12.0)</td><td>0.1% (0.0−0.2)</td><td>11.5% (4.8–13.4)</td></tr><tr><td>CD91</td><td>0.7% (0.0−1.7)</td><td>N.D.</td><td>47.6% (12.7–87.4)</td></tr><tr><td>CD140b</td><td>93.8% (99.4–78.6)</td><td>54.3% (45.9–87.5)</td><td>79.9% (49.2–87.5)</td></tr><tr><td>CD141</td><td>7.2% (4.2–12.8)</td><td>N.D.</td><td>≥95%</td></tr><tr><td>CD201</td><td>53.3% (0.17–81.1)</td><td>2.0% (1.8–4.8)</td><td>13.6% (9.5–25.6)</td></tr></table>
5145d9384f6aa67cda1b6ad0db21f57d0a63d040c6ae58bea23311dc3fb32d9b.png
simple
<table><tr><td>Measure</td><td>DF</td><td><i>F</i></td><td><i>P</i></td></tr><tr><td>DASS-depression</td><td>1.61</td><td>.24</td><td>.79</td></tr><tr><td>DASS-anxiety</td><td>1.60</td><td>1.72</td><td>.19</td></tr><tr><td>DASS-stress</td><td>1.61</td><td>2.05</td><td>.14</td></tr><tr><td>DASS-total</td><td>1.60</td><td>1.39</td><td>.26</td></tr><tr><td>FS (Wellbeing)</td><td>1.45</td><td>.57</td><td>.57</td></tr></table>
<table><tr><td>Measure</td><td>DF</td><td>F</td><td>P</td></tr><tr><td>DASS-depression</td><td>1.61</td><td>.24</td><td>.79</td></tr><tr><td>DASS-anxiety</td><td>1.60</td><td>1.72</td><td>.19</td></tr><tr><td>DASS-stress</td><td>1.61</td><td>2.05</td><td>.14</td></tr></table>
<table><tr><td>DASS-total</td><td>1.60</td><td>1.39</td><td>.26</td></tr><tr><td>FS (Wellbeing)</td><td>1.45</td><td>.57</td><td>.57</td></tr></table>
df1891314c7a4dd4e3368aa870163c276b00d2751a02c4b1b69a48deb2bac6d9.png
simple
<table><tr><td>Comparison</td><td>P-value</td><td>Comparison</td><td>P-value</td></tr><tr><td>Breast/Colon</td><td>0.0001</td><td>Colon/SCC</td><td>0.135</td></tr><tr><td>Breast/SCC</td><td>0.114</td><td>Colon/KA</td><td>0.027</td></tr><tr><td>Breast/KA</td><td>0.0001</td><td>KA/SCC</td><td>0.0001</td></tr><tr><td>Breast (T)/Breast (M)</td><td>0.723</td><td>MSI-High/MSI-Low</td><td>0.443</td></tr></table>
<table><tr><td>Comparison</td><td>P-value</td><td>Comparison</td><td>P-value</td></tr><tr><td>Breast/Colon</td><td>0.0001</td><td>Colon/SCC</td><td>0.135</td></tr><tr><td>Breast/SCC</td><td>0.114</td><td>Colon/KA</td><td>0.027</td></tr><tr><td>Brea</td><td>0.0</td><td>KA/</td><td>0.000</td></tr></table>
<table><tr><td>st/KA</td><td>001</td><td>SCC</td><td>1</td></tr><tr><td>Breast (T)/Breast (M)</td><td>0.723</td><td>MSI-High/MSI-Low</td><td>0.443</td></tr></table>
e98ff0af418732d61fcc861f2306b9feb3c471cb9cab1f015bac02e2e68c2059.png
simple
<table><tr><td></td><td>DL-CNN vs RS1</td><td>AI-CALS vs RS1</td><td>DL-CNN vs RS2</td><td>AI-CALS vs RS2</td></tr><tr><td>Average minimum distance <i>AVDIST</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Pre-treatment</td><td>4.8 &#177; 1.8mm</td><td>5.3 &#177; 2.7mm</td><td>4.9 &#177; 3.4mm</td><td>4.5 &#177; 1.9mm</td></tr><tr><td> Post-treatment</td><td>4.3 &#177; 1.7mm</td><td>4.4 &#177; 1.8mm</td><td>4.7 &#177; 3.1mm</td><td>4.9 &#177; 3.7mm</td></tr><tr><td> Both</td><td>4.6 &#177; 1.8mm</td><td>4.8 &#177; 2.3mm</td><td>4.8 &#177; 3.2mm</td><td>4.7 &#177; 2.9mm</td></tr><tr><td>Jaccard index <i>JACCARD</i><sup>3D</sup></td><td></td><td></td><td></td><td></td></tr><tr><td> Pre-treatment</td><td>45.3 &#177; 8.5%</td><td>42.5 &#177; 14.1%</td><td>46.8 &#177; 9.3%</td><td>42.8 &#177; 12.5%</td></tr><tr><td> Post-treatment</td><td>29.8 &#177; 17.7%</td><td>32.9 &#177; 14.8%</td><td>28.8 &#177; 19.7%</td><td>28.6 &#177; 18.2%</td></tr><tr><td> Both</td><td>37.5 &#177; 15.8%</td><td>37.7 &#177; 15.2%</td><td>37.8 &#177; 17.8%</td><td>35.7 &#177; 17.1%</td></tr></table>
<table><tr><td></td><td>DL-CNN vs RS1</td><td>AI-CALS vs RS1</td><td>DL-CNN vs RS2</td><td>AI-CALS vs RS2</td></tr><tr><td>Average minimum distance AVDIST</td><td></td><td></td><td></td><td></td></tr><tr><td>Pre-treat</td><td>4.8 </td><td>5.3 ± 2</td><td>4.9 ± 3.</td><td>4.5 ± 1.</td></tr></table>
<table><tr><td>ment</td><td>± 1.8mm</td><td>.7mm</td><td>4mm</td><td>9mm</td></tr><tr><td>Post-treatment</td><td>4.3 ± 1.7mm</td><td>4.4 ± 1.8mm</td><td>4.7 ± 3.1mm</td><td>4.9 ± 3.7mm</td></tr><tr><td>Both</td><td>4.6 ± 1.8mm</td><td>4.8 ± 2.3mm</td><td>4.8 ± 3.2mm</td><td>4.7 ± 2.9mm</td></tr><tr><td>Jaccard index JACCARD3D</td><td></td><td></td><td></td><td></td></tr><tr><td>Pre-treatment</td><td>45.3 ± 8.5%</td><td>42.5 ± 14.1%</td><td>46.8 ± 9.3%</td><td>42.8 ± 12.5%</td></tr><tr><td>Post-treatment</td><td>29.8 ± 17.7%</td><td>32.9 ± 14.8%</td><td>28.8 ± 19.7%</td><td>28.6 ± 18.2%</td></tr><tr><td>Both</td><td>37.5 ± 15.8%</td><td>37.7 ± 15.2%</td><td>37.8 ± 17.8%</td><td>35.7 ± 17.1%</td></tr></table>
096d7922908e0c35c1bc02398a4b3f083e2fe475b7d977c0ec3d93ca29e731e7.png
complex
<table><tr><td>Targets</td><td colspan="3">MLC leaf width</td></tr><tr><td></td><td>10 mm</td><td>4 mm</td><td><i>p </i>value</td></tr><tr><td>Pgtv</td><td></td><td></td><td></td></tr><tr><td> Dmax</td><td>7056.1 &#177; 127.2</td><td>6996.3 &#177; 88.9</td><td>0.24</td></tr><tr><td> Dmin</td><td>6035.5 &#177; 113.7</td><td>6132.2 &#177; 107.4</td><td>0.06</td></tr><tr><td> Dmean</td><td>6495.2 &#177; 39.0</td><td>6491.1 &#177; 30.4</td><td>0.44</td></tr><tr><td>PTV</td><td></td><td></td><td></td></tr><tr><td> Dmean</td><td>5478.5 &#177; 78.4</td><td>5489.2 &#177; 64.3</td><td>0.74</td></tr></table>
<table><tr><td>Targets</td><td colspan="3">MLC leaf width</td></tr><tr><td></td><td>10 mm</td><td>4 mm</td><td>p value</td></tr><tr><td>Pgtv</td><td></td><td></td><td></td></tr><tr><td>Dmax</td><td>7056.1 ± 127.2</td><td>6996.3 ± 88.9</td><td>0.24</td></tr><tr><td>Dmin</td><td>6035.5 ± 113.7</td><td>6132.2 ± 107.4</td><td>0.06</td></tr><tr><td>Dmean</td><td>6495.2 ± 39.0</td><td>6491.1 ± 30.4</td><td>0.44</td></tr><tr><td>PTV</td><td></td><td></td><td></td></tr></table>
<table><tr><td>Dmean</td><td>5478.5 ± 78.4</td><td>5489.2 ± 64.3</td><td>0.74</td></tr></table>
b311723db2e831a2b1e5d1f8a6b3f1dd2bc06dc5819f293ce53998c9b9038f4b.png
simple
<table><tr><td>Location</td><td>N</td><td>A</td><td>SD</td><td>Ho</td><td>SD</td><td>He</td><td>SD</td></tr><tr><td>Bolungarvik</td><td>11</td><td>2.08</td><td>0.79</td><td>0.24</td><td>0.21</td><td>0.29</td><td>0.25</td></tr><tr><td>Grafarvogur, Reykjavik</td><td>12</td><td>2.33</td><td>0.65</td><td>0.43</td><td>0.26</td><td>0.42</td><td>0.18</td></tr><tr><td>Storhofdi Lighthouse</td><td>15</td><td>2.83</td><td>1.03</td><td>0.32</td><td>0.23</td><td>0.39</td><td>0.22</td></tr><tr><td>Kalfafell</td><td>7</td><td>1.25</td><td>0.45</td><td>0.14</td><td>0.30</td><td>0.12</td><td>0.22</td></tr><tr><td>Reydarfjordur</td><td>16</td><td>2.17</td><td>0.94</td><td>0.25</td><td>0.26</td><td>0.26</td><td>0.23</td></tr><tr><td>Asbrandsstadir</td><td>12</td><td>2.67</td><td>0.78</td><td>0.24</td><td>0.18</td><td>0.34</td><td>0.16</td></tr><tr><td>Sveinbjarnargerdi</td><td>8</td><td>3.50</td><td>1.17</td><td>0.36</td><td>0.18</td><td>0.47</td><td>0.15</td></tr><tr><td><i>Total/mean</i></td><td><i>81</i></td><td><i>2.40</i></td><td><i>0.83</i></td><td><i>0.28</i></td><td><i>0.23</i></td><td><i>0.33</i></td><td><i>0.20</i></td></tr></table>
<table><tr><td>Location</td><td>N</td><td>A</td><td>SD</td><td>Ho</td><td>SD</td><td>He</td><td>SD</td></tr><tr><td>Bolungarvik</td><td>11</td><td>2.08</td><td>0.79</td><td>0.24</td><td>0.21</td><td>0.29</td><td>0.25</td></tr><tr><td>Grafarvogur, Reykjavik</td><td>12</td><td>2.33</td><td>0.65</td><td>0.43</td><td>0.26</td><td>0.42</td><td>0.18</td></tr><tr><td>Storhofdi Lighthouse</td><td>15</td><td>2.83</td><td>1.03</td><td>0.32</td><td>0.23</td><td>0.39</td><td>0.22</td></tr><tr><td>Kalfafell</td><td>7</td><td>1.25</td><td>0.45</td><td>0.14</td><td>0.30</td><td>0.12</td><td>0.22</td></tr><tr><td>Reydarfjordur</td><td>16</td><td>2.17</td><td>0.94</td><td>0.25</td><td>0.26</td><td>0.26</td><td>0.23</td></tr><tr><td>Asbrandsstadir</td><td>12</td><td>2.67</td><td>0.78</td><td>0.24</td><td>0.18</td><td>0.34</td><td>0.16</td></tr></table>
<table><tr><td>Location</td><td>N</td><td>A</td><td>SD</td><td>Ho</td><td>SD</td><td>He</td><td>SD</td></tr><tr><td>Sveinbjarnargerdi</td><td>8</td><td>3.50</td><td>1.17</td><td>0.36</td><td>0.18</td><td>0.47</td><td>0.15</td></tr><tr><td>Total/mean</td><td>81</td><td>2.40</td><td>0.83</td><td>0.28</td><td>0.23</td><td>0.33</td><td>0.20</td></tr></table>
b99faf885af8fe999155fbceb4bc65ecf39173d1834e8e6c43708a10e95ce429.png
complex
<table><tr><td></td><td colspan="2">Females</td><td colspan="2">Males</td><td>Unadjusted OR (95 % CI)</td><td>Adjusted OR<sup>a</sup> (95 % CI)</td></tr><tr><td></td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td></td><td></td></tr><tr><td>Total<sup>b</sup></td><td>3750</td><td></td><td>326</td><td></td><td></td><td></td></tr><tr><td colspan="7">Morphology</td></tr><tr><td> Ductal carcinoma</td><td>2693</td><td>83.6</td><td>253</td><td>95.1</td><td>Reference</td><td>Reference</td></tr><tr><td> Lobular carcinoma</td><td>276</td><td>8.6</td><td>4</td><td>1.5</td><td>0.15 (0.06&#8211;0.41)</td><td>0.14 (0.05&#8211;0.43)</td></tr><tr><td> Medullary carcinoma</td><td>60</td><td>1.9</td><td>2</td><td>0.8</td><td>0.35 (0.09&#8211;1.46)</td><td>0.46 (0.10&#8211;2.11)</td></tr><tr><td> Other</td><td>193</td><td>6.0</td><td>7</td><td>2.6</td><td>0.39 (0.18&#8211;0.83)</td><td>0.54 (0.24&#8211;1.23)</td></tr><tr><td colspan="7">TNM stage</td></tr><tr><td> 0&#8211;1</td><td>560</td><td>40.2</td><td>44</td><td>29.5</td><td>Reference</td><td>Reference</td></tr><tr><td> 2</td><td>629</td><td>45.1</td><td>70</td><td>47.0</td><td>1.42 (0.95&#8211;2.10)</td><td>1.97 (1.20&#8211;3.23)</td></tr><tr><td> 3&#8211;4</td><td>205</td><td>14.7</td><td>35</td><td>23.5</td><td>2.17 (1.37&#8211;3.44)</td><td>3.55 (1.96&#8211;6.44)</td></tr><tr><td colspan="7">Histologic grade</td></tr><tr><td> Grade 1</td><td>149</td><td>5.9</td><td>8</td><td>3.5</td><td>Reference</td><td>Reference</td></tr><tr><td> Grade 2</td><td>1057</td><td>41.7</td><td>92</td><td>39.8</td><td>1.62 (0.77&#8211;3.41)</td><td>1.88 (0.76&#8211;4.67)</td></tr><tr><td> Grade 3</td><td>1329</td><td>52.4</td><td>131</td><td>56.7</td><td>1.84 (0.88&#8211;3.83</td><td>2.66 (1.08&#8211;6.55)</td></tr><tr><td colspan="7">Lymph node status</td></tr><tr><td> Negative</td><td>1398</td><td>52.4</td><td>123</td><td>50.2</td><td>Reference</td><td>Reference</td></tr><tr><td> Positive</td><td>1270</td><td>47.6</td><td>122</td><td>49.8</td><td>1.09 (0.84&#8211;1.43)</td><td>1.55 (1.12&#8211;2.14)</td></tr><tr><td colspan="7">ER status</td></tr><tr><td> Negative</td><td>650</td><td>22.7</td><td>8</td><td>3.3</td><td>Reference</td><td>Reference</td></tr><tr><td> Positive</td><td>2211</td><td>77.3</td><td>236</td><td>96.7</td><td>8.67 (4.26&#8211;17.66)</td><td>10.59 (5.15&#8211;21.80)</td></tr><tr><td colspan="7">PR status</td></tr><tr><td> Negative</td><td>892</td><td>35.0</td><td>30</td><td>13.2</td><td>Reference</td><td>Reference</td></tr><tr><td> Positive</td><td>1654</td><td>65.0</td><td>198</td><td>86.8</td><td>3.56 (2.41&#8211;5.26)</td><td>5.04 (3.17&#8211;8.04)</td></tr><tr><td colspan="7">HER2 status</td></tr><tr><td> Negative</td><td>1404</td><td>85.9</td><td>126</td><td>83.4</td><td>Reference</td><td>Reference</td></tr><tr><td> Positive</td><td>230</td><td>14.1</td><td>25</td><td>16.6</td><td>1.21 (0.77&#8211;1.90)</td><td>1.22 (0.70&#8211;2.11)</td></tr><tr><td colspan="7">Subtypes</td></tr><tr><td> ER+ and/or PR+, HER2&#8722;</td><td>1112</td><td>69.8</td><td>118</td><td>81.9</td><td>Reference</td><td>Reference</td></tr><tr><td> ER+ and/or PR+, HER2+</td><td>182</td><td>11.4</td><td>22</td><td>15.3</td><td>1.14 (0.70&#8211;1.84)</td><td>1.18 (0.65&#8211;2.13)</td></tr><tr><td> ER&#8722;, PR&#8722;, HER2+</td><td>40</td><td>2.5</td><td>2</td><td>1.4</td><td>0.47 (0.11&#8211;1.98)</td><td>0.42 (0.09&#8211;1.98)</td></tr><tr><td> Triple-negative (ER&#8722;, PR&#8722;, HER2&#8722;)</td><td>260</td><td>16.3</td><td>2</td><td>1.4</td><td>0.07 (0.02&#8211;0.30)</td><td>0.05 (0.01&#8211;0.22)</td></tr><tr><td> ER+ and/or PR+, HER2&#8722; vs. others</td><td></td><td></td><td></td><td></td><td>0.51 (0.33&#8211;0.79)</td><td>0.42 (0.25&#8211;0.70)</td></tr></table>
<table><tr><td></td><td colspan="2">Females</td><td colspan="2">Males</td><td>Unadjusted OR (95 % CI)</td><td>Adjusted ORa (95 % CI)</td></tr><tr><td></td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td></td><td></td></tr><tr><td>Totalb</td><td>3750</td><td></td><td>326</td><td></td><td></td><td></td></tr><tr><td colspan="7">Morphology</td></tr><tr><td>Ductal carcinoma</td><td>2693</td><td>83.6</td><td>253</td><td>95.1</td><td>Reference</td><td>Reference</td></tr><tr><td>Lobular carcinoma</td><td>276</td><td>8.6</td><td>4</td><td>1.5</td><td>0.15 (0.06–0.41)</td><td>0.14 (0.05–0.43)</td></tr><tr><td>Medullary carcinoma</td><td>60</td><td>1.9</td><td>2</td><td>0.8</td><td>0.35 (0.09–1.46)</td><td>0.46 (0.10–2.11)</td></tr><tr><td>Other</td><td>193</td><td>6.0</td><td>7</td><td>2.6</td><td>0.39 (0.18–0.83)</td><td>0.54 (0.24–1.23)</td></tr><tr><td colspan="7">TNM stage</td></tr><tr><td>0–1</td><td>560</td><td>40.2</td><td>44</td><td>29.5</td><td>Reference</td><td>Reference</td></tr><tr><td>2</td><td>629</td><td>45.1</td><td>70</td><td>47.0</td><td>1.42 (0.95–2.10)</td><td>1.97 (1.20–3.23)</td></tr><tr><td>3–4</td><td>205</td><td>14.7</td><td>35</td><td>23.5</td><td>2.17 (1.37–3.44)</td><td>3.55 (1.96–6.44)</td></tr><tr><td colspan="7">Histologic grade</td></tr><tr><td>Grade 1</td><td>149</td><td>5.9</td><td>8</td><td>3.5</td><td>Reference</td><td>Reference</td></tr><tr><td>Grade 2</td><td>1057</td><td>41.7</td><td>92</td><td>39.8</td><td>1.62 (0.77–3.41)</td><td>1.88 (0.76–4.67)</td></tr><tr><td>Grade 3</td><td>1329</td><td>52.4</td><td>131</td><td>56.7</td><td>1.84 (0.88–3.83</td><td>2.66 (1.08–6.55)</td></tr><tr><td colspan="7">Lymph node status</td></tr><tr><td>Negative</td><td>1398</td><td>52.4</td><td>123</td><td>50.2</td><td>Reference</td><td>Reference</td></tr><tr><td>Positive</td><td>1270</td><td>47.6</td><td>122</td><td>49.8</td><td>1.09 (0.84–1.43)</td><td>1.55 (1.12–2.14)</td></tr><tr><td colspan="7">ER status</td></tr><tr><td>Negative</td><td>650</td><td>22.7</td><td>8</td><td>3.3</td><td>Reference</td><td>Reference</td></tr></table>
<table><tr><td></td><td colspan="2">Females</td><td colspan="2">Males</td><td>Unadjusted OR (95 % CI)</td><td>Adjusted ORa (95 % CI)</td></tr><tr><td></td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td></td><td></td></tr><tr><td>Positive</td><td>2211</td><td>77.3</td><td>236</td><td>96.7</td><td>8.67 (4.26–17.66)</td><td>10.59 (5.15–21.80)</td></tr><tr><td colspan="7">PR status</td></tr><tr><td>Negative</td><td>892</td><td>35.0</td><td>30</td><td>13.2</td><td>Reference</td><td>Reference</td></tr><tr><td>Positive</td><td>1654</td><td>65.0</td><td>198</td><td>86.8</td><td>3.56 (2.41–5.26)</td><td>5.04 (3.17–8.04)</td></tr><tr><td colspan="7">HER2 status</td></tr><tr><td>Negative</td><td>1404</td><td>85.9</td><td>126</td><td>83.4</td><td>Reference</td><td>Reference</td></tr><tr><td>Positive</td><td>230</td><td>14.1</td><td>25</td><td>16.6</td><td>1.21 (0.77–1.90)</td><td>1.22 (0.70–2.11)</td></tr><tr><td colspan="7">Subtypes</td></tr><tr><td>ER+ and/or PR+, HER2−</td><td>1112</td><td>69.8</td><td>118</td><td>81.9</td><td>Reference</td><td>Reference</td></tr><tr><td>ER+ and/or PR+, HER2+</td><td>182</td><td>11.4</td><td>22</td><td>15.3</td><td>1.14 (0.70–1.84)</td><td>1.18 (0.65–2.13)</td></tr><tr><td>ER−, PR−, HER2+</td><td>40</td><td>2.5</td><td>2</td><td>1.4</td><td>0.47 (0.11–1.98)</td><td>0.42 (0.09–1.98)</td></tr><tr><td>Triple-negative (ER−, PR−, HER2−)</td><td>260</td><td>16.3</td><td>2</td><td>1.4</td><td>0.07 (0.02–0.30)</td><td>0.05 (0.01–0.22)</td></tr><tr><td>ER+ and/or PR+, HER2− vs. others</td><td></td><td></td><td></td><td></td><td>0.51 (0.33–0.79)</td><td>0.42 (0.25–0.70)</td></tr></table>
5a6b6d6848733a37ef5cacc39e4bd5344cdbbfd0977aabb9b6e87b0dab0a175d.png
simple
<table><tr><td></td><td>Daily Cannabis Users</td><td>Cannabis Non-Users</td></tr><tr><td>Sample Size (N)</td><td>243</td><td>244</td></tr><tr><td>Gender</td><td>81% male; 19% female</td><td>51% male; 49% female</td></tr><tr><td>Average Age*</td><td><i>M </i>= 37.8, <i>SD </i>= 13.3</td><td>M = 28.2, <i>SD </i>= 11.0</td></tr><tr><td>Maximum Income Bracket**</td><td>M = $44,431, <i>SD </i>= $23,027</td><td>M = $39,640, <i>SD </i>= $24,159</td></tr></table>
<table><tr><td></td></tr><tr><td>Sample Size (N)</td></tr><tr><td>Gender</td></tr><tr><td>Average Age*</td></tr><tr><td>Maximum Income Bracket**</td></tr></table>
<table><tr><td>Daily Cannabis Users</td><td>Cannabis Non-Users</td></tr><tr><td>243</td><td>244</td></tr><tr><td>81% male; 19% female</td><td>51% male; 49% female</td></tr><tr><td>M = 37.8, SD = 13.3</td><td>M = 28.2, SD = 11.0</td></tr><tr><td>M = $44,431, SD = $23,027</td><td>M = $39,640, SD = $24,159</td></tr></table>
4057718aeafec0824e6a03fa0033e9aac608b4e4ddc5ce6ccbca7f24157bb182.png
simple
<table><tr><td>Causative factors</td><td>Numbers</td></tr><tr><td>Antenatal</td><td>38 (11.7 %)</td></tr><tr><td>Intrapartum</td><td>220 (67.9 %)</td></tr><tr><td> Placental abruption</td><td>87</td></tr><tr><td> Cord prolapse</td><td>16</td></tr><tr><td> Uterine rupture</td><td>15</td></tr><tr><td> Maternal hypoxic event</td><td>8</td></tr><tr><td> Fetal exsanguination</td><td>8</td></tr><tr><td> Clinical CAM (Group I )</td><td>19</td></tr><tr><td> Non clinical CAM (Group II)</td><td>67</td></tr><tr><td>Perinatal</td><td>8 (2.5 %)</td></tr><tr><td> Fetal central nervous system or systemic infection</td><td>8</td></tr><tr><td>Miscellaneous</td><td>58 (17.9 %)</td></tr><tr><td> Suspected CAM</td><td>54</td></tr><tr><td> Unknown causes</td><td>4</td></tr><tr><td>Total</td><td>324</td></tr></table>
<table><tr><td>Causative factors</td><td>Numbers</td></tr><tr><td>Antenatal</td><td>38 (11.7 %)</td></tr><tr><td>Intrapartum</td><td>220 (67.9 %)</td></tr><tr><td>Placental abruption</td><td>87</td></tr><tr><td>Cord prolapse</td><td>16</td></tr><tr><td>Uterine rupture</td><td>15</td></tr><tr><td>Maternal hypoxic event</td><td>8</td></tr><tr><td>Fetal exsanguination</td><td>8</td></tr><tr><td>Clinical CAM (Group I )</td><td>19</td></tr><tr><td>Non clinical CAM (Group II)</td><td>67</td></tr><tr><td>Perinatal</td><td>8 (2.5 %)</td></tr><tr><td>Fetal central nervous system or systemic infection</td><td>8</td></tr><tr><td>Miscellaneous</td><td>58 (17.9 %)</td></tr><tr><td>Suspected CAM</td><td>54</td></tr></table>
<table><tr><td>Unknown causes</td><td>4</td></tr><tr><td>Total</td><td>324</td></tr></table>